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ABSTRACT
Over the recent years, the incidence of diabetes has significantly increased. Use
of preventive services and treatment with oral antidiabetic drugs (OAD) has
remained cornerstone in the management of type 2 diabetes (T2DM). Despite strong
evidence that treating diabetes using these disease management strategies
decreases morbidity, mortality and complications, glycemic control as well as other
diabetes related outcomes remain unsatisfactory. The prevalence of diabetes in the
United States has grown vastly in proportion over the last few years with the
American Diabets Association estimating that 9.3% of the population suffered from
diabetes in the year 2012. These estimates are expected to increase in the future
with the World Health Organization (WHO) estimating that 366 billion people (4.4%)
will have diabetes. Diabetes places a greater clinical as well as economic burden on
the patients as well as the health care system.
The presence of comorbid depression is frequent in people suffering from
diabetes and can cause health outcomes in patients with diabetes. Poor adherence
and persistence to diabetic medications resulting from the occurrence of adverse
events is a cause of poor health as well as economic outcomes. There is a continuing
need to evaluate the associations between comorbidities as well as common
complications of medication treatment in persons with diabetes and examine how
they influence health behavior. Evidence regarding differences in the utilization of
preventive care services in diabetic patients with and without comorbid depression is
scant. Similarly, the factors that predispose an individual to hypoglycemia as well as

the association between hypoglycemic episodes and persistence to OAD therapy,
specifically sulfonylureas, has rarely been quantified retrospectively. This dissertation
utilizes the manuscript format and has four fold objectives:
1. To review the current literature regarding the role of hypoglycemia and
comorbid depression in the diabetes and examine their impact on clinical
and economic aspects of diabetes management;
2. To quantify the effect of comorbid depression on the rates of preventive
care service use in a nationally representative population of US adults;
3. To identify significant predictors and estimate the costs associated with the
occurrence of hypoglycemia in the inpatient and outpatient settings.
4. To evaluate the association between the development of hypoglycemia and
persistence to oral sulfonylurea therapy in patients newly initiated on this
class of OAD medications.
In order to review the literature regarding the effect of hypoglycemia and comorbid
depression and diabetes, we utilized various biomedical and psychological databases.
We analyzed the effect of comorbid depression as a principal risk factor associated
with use of ADA recommended preventive services in patients with diabetes using
the Medical Expenditure Panels Survey Data. A logistic regression was performed to
achieve this objective and all the relevant confounders were controlled for in order
to achieve the results. Claims data provided by the Blue Cross and Blue Shield of
Rhode Island was utilized to assess the relationship between hypoglycemia and
persistence to sulfonylurea medication as well as outline the predictors and costs of

hypoglycemia. A time-varying Cox proportional hazards regression model was utilized
to compare the hazard rate of medication discontinuation in diabetic patients that
were exposed to hypoglycemic events, compared to those that were unexposed. A
predictive modelling approach was utilized to highlight the factors associated with
hypoglycemia.
While the impact of comorbid depression and diabetes was significant both clinically
and economically, it was seen that the extent of preventive care service use was
comparable for diabetic patients with and without comorbid depression but
suboptimal in general thus indicating major gaps in the implementation of ADA
recommended preventive care practices. While depression was not significantly
associated with increased use of the recommended diabetes preventive care
services, other sociodemographic factors were seen to contribute. Moreover, though
no significant association between events of hypoglycemia and subsequent
discontinuation sulfonylurea medication was illustrated, we demonstrated several
clinical factors to have a profound impact on the risk of developing hypoglycemic
episodes.
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PREFACE
To the reader: This dissertation utilizes the manuscript format, and is composed
of four chapters relating to the evaluation of the role of hypoglycemia & comorbid
illness on diabetes management behaviors
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1.1 Diabetes
Diabetes is a chronic metabolic disorder of characterized by different pathways. It
results in hyperglycemia with an abnormality in the body’s capability to convert
glucose (sugar) to energy. Type 2 diabetes (T2DM) is the most frequent subtype of
diabetes since it accounts for up to 90% of all cases of diabetes worldwide.1 Diabetes
is the seventh leading cause of death in the United States.2,3 Diabetes is the most
significant cause of macrovascular and microvascular complications.4,5 Patients with
diabetes have a lower quality of life as compared to people of the same age group
without diabetes and it is even lower in cases of diabetes complications and disease
progression.6-8
Recent estimates put the prevalence of diabetes for individuals aged 20 to 74
worldwide at 6.4% in 2010, and it is estimated that the prevalence would increase to
7.7% (439 million patients) by the year 2030.9 It is one of the most prevalent,
debilitating, and costly chronic conditions, both nationally as well as globally,
resulting in substantial mortality, morbidity, and economic burden.4,5,10 During the
last 20 years, the prevalence of diabetes has increased dramatically in many parts of
the world and the disease is now a worldwide public health problem. The World
Health Organization estimates that the total number of people with diabetes is
projected to rise from 171 million in 2000 to 366 million in 2030.11 According to the
American Diabetes Association (ADA), the prevalence of diabetes in the United States
was about 9.3% in the year 2012 with 29.1 million people diagnosed with this
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disorder according to the Centers for Disease Control (CDC), which was significantly
higher than the 25.8 million (8.3%)reported in previous years.12,13 In addition to this,
another 7 million people are estimated to be suffering from undiagnosed diabetes
and 86 million are estimated to suffer from prediabetes.14 The CDC estimates that
among U.S. residents aged 65 years and older, 10.9 million, or 26.9%, had diabetes in
2010.15 This number is projected to rise rapidly with the ageing of the population and
the corresponding increase in the prevalence of chronic conditions.2,16,17 Danaei et al.
in a study to estimate the undiagnosed diabetes prevalence as a function of a set of
health system and sociodemographic variables, found that prevalence of diabetes in
the U.S. was 13.7% among men and 11.7% among women ≥ 30 years.18 Previous
studies have noted major cultural and racial variations in the prevalence of
T2DM.13,19,20 According to the ADA, 12.6% non-Hispanic blacks have T2DM compared
to 7.1% non-Hispanic whites in the United States, with the highest prevalence of
diabetes found in the southern states.13,21
In a recent study by the ADA to estimate the total economic cost of diabetes for the
United States, it was demonstrated that in the year 2007 the economic burden was
estimated to be $174, approximately 1 of 8 dollars spent on medical care, as
compared with $98 billion in 1997.10,22,23 In the same year, the approximate total
cost for treating diabetes was $232 billion. Moreover, the total costs of diabetes had
increased to $245 billion with $176 billion attributable to direct medical costs and
$69 billion to lost productivity.10 After adjusting for population age and sex
differences, average medical expenditures among people with diagnosed diabetes
3

were 2.3 times higher than those in the absence of diabetes.10 Literature suggests
that a high degree of health care resource use can be attributed to diabetes namely
hospital inpatient days (25.7%), nursing/residential facility days (33.3%), prescription
medications, and visits to the physician, emergency room, hospital outpatient etc.
Previous research suggests that these estimates are higher in cases of uncontrolled
diabetes and diabetes with complications.10
The increasing prevalence of the disease and thereby its economic as well as social
impact emphasizes the importance of effective diabetes prevention and care.

4

1.2 Use of Preventive Services in Diabetes
Apart from being a major cause of heart disease and stroke, diabetes poses an
increased risk of cardiovascular, peripheral arterial and cerebrovascular diseases.24-26
Previous studies also note a much higher proportion of non-traumatic lower limb
amputations, kidney failure and blindness in diabetic patients.26 A number of studies
have concluded that timely utilization of medical and preventive care is an ideal
practice for the management of diabetes.27,28 These services can be vital in the
incidence and progression of any diabetes specific complications.29 Controlling blood
glucose, blood pressure, and LDL cholesterol levels can reduce the microvascular
complications like eye, kidney, and nerve diseases as well as macrovascular
complications like heart attack, stroke, and lower-extremity amputations. For
example, Litzeman et al. in a blinded, randomized, controlled trial of patients in an
academic general medicine practice setting found that better foot care in patients
with diabetes were likely to have reduced prevalence of lower extremity clinical
disease.28 One of the principal preventive services in patients with diabetes is the
testing the A1C which might demonstrate the patient’s blood glucose levels.
Similarly, routine eye exams diagnose symptoms of diabetes related eye disease and
this early detection is usually instrumental in preventing the progression this disease.
Comprehensive foot care programs include assessment and treatment of feet of the
diabetes patient and can help reduce amputation rates. Other preventive tests
include timely immunization against pneumococcal disease and influenza as well as
regular blood pressure and medical checks.
5

1.3 Depression
Major depressive disorder (MDD) is a grave and recurrent condition affecting around
121 million people worldwide. The World Health Organization (WHO) recognizes
depression as the fourth leading cause of disease burden associated with non-fatal
health outcomes and a leading cause of disability around the world.30 It has been
widely reported in the literature that depression is often underdiagnosed and under
treated.30,31 Even though the scenario with respect to treatment rates has been
positively changing in the past decade, many patients still suffer from symptoms of
depression.32 Gonzalez et al. in a study of a large national sample found that majority
of the people suffering from depression did not get the guideline recommended
degree of care and large disparities existed based on various factors like race and
ethnicity.33
Kessler et al. in a study using the National Comorbidity Survey Replication (NCSR)
suggested that in the United States, the lifetime prevalence of depression was 16.2%
and the 12-month prevalence was 6.6%.32 Bromet and colleagues, in a study
conducted in in over 18 countries reported that the average lifetime prevalence of
depression was 14.6% in high-income countries and 11.1% in middle to low income
countries.34 Mathers et al. in a study projecting mortality and burden of disease by
cause to year 2030 found that depression was predicted to hold the second position
among diseases contributing to the global burden of diseases by 2030 , and there has
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been a 37% increase in disability-adjusted life years of depression from the year
1990 to 2010.35
Evidence from studies suggests apart from being a major cause of morbidity,
mortality and disability, MDD is responsible for higher economic costs by means of
health care resource use as well as indirect costs including workplace absenteeism,
diminished, or lost work productivity and increased use of healthcare resources.6,36-38
This economic burden of depression has been evaluated in several studies nationally
as well as worldwide. For example, Greenberg et al. estimated the burden of
depression in the United States to be $104 billion divided as $33 billion (31%) in
medical care; $6 billion (7%) in mortality due to suicide; and $65 billion (62%) in
workplace productivity losses.39 It has also been noted that the costs of depression
increased from $77.4 billion in the year 2000 to $83.1 billion in the year 2010.40
Similarly, Luppa et al. in a systematic review of cost of illness studies of depression
estimated that the average annual costs per case ranged from $1000 to $2500 for
direct costs, from $2000 to $3700 for morbidity costs and from $200 to $400 for
mortality costs.41 Working people with depression have a lower degree of
productivity in terms of higher rates of absenteeism and reduced on-the-job output
and can lead to disability.42-44 Greenberg et al. noted that lost productivity accounted
for more than 60% of the total social economic burden of depression in the US in
2000, which was estimated at $52.9 billion.39 Stewart et al. in a study of employed
individuals, who participated in the American Productivity Audit, reported that
people with depression lost 5.6 hours of productive work every week.45 Pratt et al.
7

examined data from Data from the National Health and Nutrition Examination Survey
(NHANES) and concluded that 80% of people with depression reported some level of
functional impairment because of their depression, and 27% reported serious
difficulties in work and home life.44
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1.4 Comorbidity of Diabetes and Depression
A large body of literature has highlighted the association between diabetes and
depression.46-48 The essential finding in the aforementioned analyses has been that
that diabetes and depression co-occur frequently with the presence of once
condition significantly increasing the likelihood of patient suffering from the
other.48,49 A systematic review by Roy and colleagues suggested that prognosis of
comorbid depression in patients with diabetes, in terms of its clinical and societal
implications, is worse for either condition in comparison to when they occur
individually.50
1.4.1 A Bi-Directional Relationship between Diabetes and Depression
In a review of literature Egede et al. noted that previous research indicated a
complex relationship between diabetes and depression because the temporality of
this association is not clear.6 There is a growing body of evidence, which suggests
that there exists a bidirectional relationship between these two chronic disorders.51
Moreover, several physiological and behavioral mechanisms have been studied to
explain this possible link between diabetes and depression. Mezuk et al. in a metaanalysis of studies from 1950 to 2007 of diabetes and depression, established that
people with depression had a 60% increased risk of developing diabetes compared to
non-depressed patients while people with diabetes had a 15% increased risk of
developing depression compared to non-diabetics.52 Pan et al. studied women over a
10 year period and found that the relative risk for T2DM in women with depressed
9

mood was higher as compared to those who were non depressed (OR 1.17; 95% CI
1.05–1.30).53 Studies have found incidence of depression as a modifiable
independent risk factor in the onset of diabetes.54-56 Golden et al. performed a
longitudinal study depressive symptoms at baseline were associated with an
increased incidence of T2DM at follow-up over a 3-year period; an increased risk for
developing depressive symptoms over the 3-year period was associated with treated
T2DM, but conversely baseline impaired fasting glucose and untreated T2DM were
associated with reduced risk for depression.51 The increased risk of developing
diabetes might be due to the negative physiologic effects of depression on glucose
metabolism as well as neuroendocrine and autonomic nervous systems.54 Similarly,
diabetes can also act as a precursor to depression through various clinical and
psychological mechanisms.50 Poor metabolic control and increasing complications as
a result of diabetes may result in or further worsen depression and lessen response
to antidepressant treatment.6,50 For example In a study of 1,586 older adults from
the Rancho Bernardo study, Palinkas et al. reported that there was a 3.7- fold
increase in odds of depression in those with a prior diagnosis of diabetes.57 Thus, as
suggested in a recent meta-analysis, there is lack of concrete information supporting
the direction of relationship between diabetes and depression with there being
clinical and epidemiological support for both hypotheses.58
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1.4.2 Prevalence of Depression in Diabetes
It is well documented that depression is significantly higher in patients with diabetes
as compared to the general population.48,59 Anderson et al. and Egede et al. found
that the odds of suffering from depression among patients with diabetes are two fold
as compared to the patients without diabetes.47,49 Ali et al. in a systematic literature
review in order to estimate the prevalence of clinically relevant depression in adults
with T2DM had similar results with odds of suffering from comorbid depression being
nearly twice among diabetic patients (OR = 1.6, 95% CI 1.5–1.7).48,60 These findings of
diabetic population being more likely to suffer from depression have been reaffirmed
by World Mental Health Surveys, which indicate an elevated risk of mood (OR=1.38)
and anxiety disorders (OR=1.20) in patients with diabetes compared with persons
without diabetes.60 The reported prevalence of depression in patients with diabetes
varies widely due to an array of factors but most studies estimate that 10 -30% of
individuals with diabetes suffer from various forms comorbid depression with some
studies indicating that the rates may be as high as 39%.47,49,61,62 Li et al. examined
data from the 2006 Behavioral Risk Factor Surveillance System (BRFSS), a
standardized telephone survey of U.S. adults aged 18 and older and found that the
age adjusted rate of depression was 8.3%.63 In a second study by the same authors
investigating the prevalence of undiagnosed depression among individuals with
diabetes found the adjusted and unadjusted prevalence of undiagnosed depression
to be 8.7% and 9.2%, respectively.64 Maraldi and colleagues, in a secondary analysis
from the Health ABC study, a prospective cohort (n=3,075) of community-dwelling
11

adults who are aged between 70 and 79 years, found an increased risk of depressed
mood among people with diabetes.65 D Groot et al. found that the lifetime
prevalence rates of major depression among patients with diabetes to range from
14.4% to 39% which are approximately three times higher than the rates in general
population.66 A population-based epidemiologic study conducted to determine the
behavioral and clinical characteristics of diabetes associated with depression found
that 501 of 4,193 study participants (12%) met Diagnostic and Statistical Manual of
Mental Disorders–Fourth Edition (DSM-IV), criteria for MDD and 357 participants
(8.5%) met criteria for minor depression (10-7,8).67 Ali et al. also found that the
prevalence of depression was significantly higher among patients with T2DM (17.6%)
than those without diabetes (9.8%).48
1.4.3 Clinical Implications Of Comorbid Diabetes And Depression
The clinical implications of occurrence of comorbid depression in patients with
diabetes are of serious concern since it is associated with poorer diabetes
outcomes.48,68 Apart from having a negative impact on the physical, mental and social
wellbeing of the diabetic patients, it might also have implication on quality of life,
rates of mortality and morbidity.49 Studies have shown that depression is associated
with a higher number of diabetes complications and can exacerbate the severity of
these complications.50,52,54,69 A meta-analysis by De Groot and colleagues
demonstrated a clinically significant relation between depression and several diabetic
complications like retinopathy, nephropathy, neuropathy, sexual dysfunction, and

12

macrovascular complications.66 Lustman et al. found that depressive symptoms in
patients are associated with decreased glycemic control.70 Richardson et al. assessed
the longitudinal effects of comorbid depression on glycemic control and observed
that depression was associated with persistently higher A1C levels over the time
period.71 Moreover, Katon et al. in a study of 4,225 patients from nine primary care
clinics of a nonprofit health maintenance organization found that patients with MDD
and diabetes, with or without evidence of cardiovascular disease, were 1.5 to 2 times
as likely as nondepressed patients with diabetes to have ≥3 cardiac risk factors.72 In
another study of 10,704 Medicare beneficiaries in the U.S, Katon et al. reported that
beneficiaries with diabetes and comorbid depression had a 36–38% increased risk for
all-cause mortality over a 2-year period.73 In a study of 10,025 patients from the
NHANES I Epidemiologic Follow-up Study, Egede et al. found that hazard rates for allcause mortality for individuals who had diabetes and depression were 2.50 (95% CI
2.04–3.08) compared with those without diabetes or depression and concluded that
comorbid depression is associated with a significantly higher risk of death.74
1.4.4 Quality Of Life In Patients With Diabetes And Comorbid Depression
In addition, it is increasingly evidenced in the literature that presence of comorbid
depression in diabetes is significantly associated with deterioration of various qualityof-life indices such as physical, mental, and social functioning.75-77 For example, in a
study investigating the effects of depression on the quality of life in type II DM
patients with and without current major depressive episode diagnosed according to
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DSM-IV criteria, Eren et al. found a significant decline in quality of life in individuals
with comorbid depression and diabetes.78 Various instruments have been used in
studies which have proved treatments and complications in patients with comorbid
depression and diabetes adversely affect the quality of life of these patients.76
1.4.5 Health Care Resource Use In Patients With Diabetes And Comorbid Depression
Previous studies evaluating health care expenditures and utilization have found
comorbid depression and diabetes are associated with higher direct and indirect
health care costs due to greater use of resources, lost work time and disability. 49,7981

Simon et al. in a study assessing the relative contributions of diabetes

complications, depression and comorbid medical disorders to health service costs in
adults with diabetes, found that the health care costs were 70% higher in individuals
with comorbid depression and diabetes.82 Analyzing a nationally representative
survey in the United Kingdom, Das-Munshi et al. found an increased use of health
care resources among diabetic patients with depression in the form of higher
frequency of hospital admissions and physician visits.83 Finkelstein et al. found that
treatment of depression was associated with greater use of inpatient and outpatient
medical services.81 Himelhoch et al. found that a diagnosis of depression was
associated with greater use of acute care services (emergency department and
inpatient care) among Medicare beneficiaries with diabetes and other chronic
medical conditions.84 Using Medical Expenditure Panel Survey (MEPS) data, Egede et
al. found that self-reported history of depression was associated with higher total
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health service costs ($247,000,000 vs. $55,000,000, P value < 0.0001)among
respondents with diabetes.49 In a sample of 367 health maintenance organization
members with diabetes, Ciechanowski et al. found that higher Hopkins Symptom
Checklist depression scores were associated with significantly higher health service
costs, with severe depression accounting for up to 86% higher costs.80 In a study of
55,972 adults with diabetes, Le et al. found that patient with diabetes and depression
had higher diabetes-related medical costs ($3,264) than patients with diabetes alone
($1,297). They also found that depressed patients with diabetes had higher total
medical costs ($19,298) than patients without depression ($4,819).6 Egede et al.
found that adults with diabetes and depression were more likely to miss more than 7
workdays in any given year.85
1.4.6 Self Care Behaviors In Patients With Diabetes And Comorbid Depression
Self-care behaviors are of highly critical in the management of diabetes since patients
with comorbid depression and diabetes are at a higher risk for worse health
outcomes as compared to individuals with a single disorder.86 Clinical management
guidelines stress the importance of self-care behaviors in diabetes including
adherence to dietary recommendations, diabetic knowledge, adequate physical
activity and exercise, smoking cessation, adherence to prescribed medication and
other therapies and timely monitoring of blood glucose.55 Previous research indicates
that patients with comorbid depression and diabetes have lower rates of adherence
to these patient initiated components of diabetes care.66,87 For example, in a study
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examining the impact of depression on adherence to oral hypoglycemic agents
(OHAs) of patients identified from a Medicaid claims database using Medication
Possession Ratio (MPR), Kalsekar et al. indicated that patients with depression had 36% lower adherence to OHAs compared with patients without depression.88 There is
also evidence to suggest lower adherence rates to other medication regimens as a
result of co-existing depression in diabetes.55 Apart from non-adherence to
medications, higher body mass index (BMI) and tobacco use are concerning aspects
of poor self-care behaviors since they might cause insulin resistance and increased
morbidity in patients with diabetes.67 Gonzalez et al. in a study examining the
relationship between comorbid depression and diabetes self-care behaviors noted
that controlling for relevant covariates, patients with comorbid depression and
diabetes reported significantly fewer rates of adherence to a full range of self-care
behaviors along with a 2.3-fold increase in the likelihood of missing medication
doses.89
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1.5 Oral Hypoglycemic Agents And Goals Of Therapy
Previous research has identified some of the principal goals of oral antidiabetic
therapy. ADA proposes a glycated hemoglobin (A1C) level of less than 7% and
preprandial blood glucose level of 80–120 mg/dL, a bedtime blood glucose level of
100–140 mg/dL.90,91
Garber et al. and Grant et al. have demonstrated that oral hypoglycemic agents
(OHAs) were effective in lowering A1C by 1–2%.92,93 Achieving lower A1C levels has
demonstrated a significant beneficial impact on reducing diabetes related micro and
macro vascular complications including retinopathy, nephropathy and neuropathy.9497

Results of the U.K. Prospective Diabetes Study (UKPDS) suggested that for every

percentage-point reduction in A1C, it is possible to achieve a 22% to 35% reduction in
microvascular complications.97,98 However, previous literature does not clearly define
the advantages of intensive therapy to achieve lower A1C levels while reducing
macrovascular and microvascular complications.99 With these goals in mind, the
selection of a particular agent is based on factors such as clinical and biochemical
characteristics of patient, safety concerns, severity of diabetes as well as the
available therapeutic options. Recent advances in research have presented clinicians
with a plethora of oral medications which are effective in controlling hyperglycemia
associated with T2DM as well as managing diabetic complications, thus making the
decision making process complex. Moreover, most of the patients require 2 or more
medications to achieve the desired glycemic control over a period of time.100 In 2011,
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there were 8 classes of oral medications approved by the FDA for treating T2DM such
as – biguanides, sulfonylureas, meglitinides, thiazolidinediones (glitazones), alphaglucosidase inhibitors, DPP-4 inhibitors, bile acid sequestrants, dopamine-2
agonists91,101. Mann et al. using a series of cross sectional surveys, reported that the
proportion of US adults who took 2 classes of medications was 35% with an increase
of 6% to 14% in the number of patients who took 3 or more classes of medication.102
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1.6 Hypoglycemia in T2DM

Hypoglycemia is one of the most common as well as dangerous side effects of T2DM
therapy. Even though it is well proven in evidence that tighter glycemic control may
be instrumental in reducing the risk of other serious complications of T2DM like
retinopathy, neuropathy, and nephropathy, it can also present an additional risk of
severe hypoglycemia. In many T2DM patients, hypoglycemia is responsible for
recurrent morbidity and at times, can be a cause of mortality thereby creating a
barrier to the long term benefits of optimal glycemic control.103 Cryer et al. in a
comprehensive review of literature mentioned that though there is no concrete
evidence with respect to the frequency of hypoglycemic episodes in T2DM patients,
the rates of severe episodes requiring medical attention in patients on intensive
insulin therapy varied from 3 to 73 episodes per 100 patient-years, which was about
10% of those in Type 1 Diabetes.103-105 The United Kingdom Prospective Database
Study (UKPDS) reported that 2.4% of patients using metformin, 3.3% of patients
using a sulfonylurea, and 11.2% of patients using insulin reported incidents of severe
hypoglycemia requiring medical attention over the 6 years of follow up period with
hypoglycemia becoming a limiting factor to glycemic control over a period of time.106
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1.7 Persistence to OADs in T2DM
Medication persistence or conforming to the recommendation of continuing
treatment for the prescribed length of time is an important issue in the long term
management diabetes considering the chronic nature of the disease and the nature
of the treatment regimen intended to achieve the desired glycemic targets.107
Cramer et al. in a review of literature to determine the extent to which patients fail
to comply with the doses of medications prescribed for diabetes noted that the rates
for treatment persistence ranged from 16 to 80% when the patients continued taking
their medications for at least 6-24 months. The authors noted that the
methodologies followed by the researchers varied in that the cross-overs to an
alternative OHA or insulin might not have been counted as discontinuation.108
Bocuzzi et al. conducted a retrospective analysis of a large administrative pharmacy
claims database, using data on continuously pharmacy benefit-eligible members
prescribed OHAs, reported that the 12-month persistence rate for the OHA cohort
was low, ranging from 31% for alpha-glucosidase inhibitors to 60% for metformin.109
Guénette et al. studied the 1-year treatment persistence and compliance of new oral
antidiabetic drug (OAD) users and found that 79.3% of the cohort members persisted
with the therapy during their first year of antidiabetic treatment.110 In another
literature review, Cramer et al. reported that 45% of the individuals who newly
initiated oral antidiabetic therapy were non adherent to the regimen and almost 33%
of the patients discontinued their therapies in 12 months.108 Other past studies have
reported persistence estimates for oral antidiabetic medications from a low of 15%
20

to a high of 76% with the variations attributed to differences in methodologies,
definitions of persistence as well as length of the follow up periods. Non-persistence
with therapy most often leads to failure in meeting glycemic goal thus leading to
avoidable undesirable adverse health outcomes.111
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1.8 Conclusions
It is clear from the above literature review that issues with diabetes management are
highly prevalent and are significantly associated with negative health and economic
outcomes. The coexistence of diabetes and depression also results in compromised
self-care behaviors which are essential in the management of both the diseases
especially diabetes. Of greater importance among the self-care behaviors is the
suboptimal utilization of preventive care services since these are particularly
essential in preventing the complications in diabetes. Similarly, medication
persistence and hypoglycemia are issues affecting the achievement of desired
glycemic goals. There is a need to develop strategies to address both patient and
other health care related factors in order to increase the potential effectiveness of
disease management in diabetes. A multifactorial approach might be essential to
counter the adverse health effects of comorbid diseases as well as adverse effects of
diabetic medications in patients with diabetes.
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2.1 Background and Significance
The American Diabetes Association (ADA) publishes Clinical practice guidelines for
persons with diabetes annually. These guidelines are evidenced based and are
intended to improve the quality of care for patients with diabetes.112 Evidence from
previous research has been instrumental in the development of several clinical
practice guidelines that are intended to improve the quality of care for diabetes
patients112. These recommendations suggests that adherence to these recommended
guidelines is likely to have a positive impact on the morbidity and mortality related to
diabetes thereby reducing the clinical as well as economic burden of diabetes as well
as improving the management of diabetes.12,27,28,113,114
Despite this knowledge, the use of the clinical preventive services in the U.S. adult
population is suboptimal and is quite variable.115 For example, The Healthy People
2020 initiative, reported low levels of use of multiple clinical preventive services for
diabetes as well as other diseases.116 Previous research suggests the use of
preventative services ranges from 10% to 85%, depending on the particular
service.117 Evidence from population-based studies in various settings also indicates
that there is a significant difference between reported levels of use of preventive
care practices among people with diabetes and the degree of recommended use for
optimal level of care.118 This discrepancy might be primarily attributed to the effects
of race/ethnicity, income, health insurance coverage, and comorbidities.119-121 For
example, Pu et al., in a study to explore potential mediators linking race/ethnic
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disparities to reduced receipt of preventive care found that patients were less likely
to receive diabetes preventive care if they were younger in age, Hispanic, resided in
rural areas, had lower family income and were uninsured.12
While implementing preventive care measure on a population scale can be costly, the
potential long-term health benefits can certainly offset the healthcare expenditures
over time. To date, many published studies of preventive care services focused solely
on individuals who are diagnosed with diabetes alone.113,122 However, preliminary
data suggests that comorbid depression may have an effect on use of preventive
services among other treatment recommendations persons with diabetes. 49,112,123,124
There is a paucity of conclusive research concerning use of diabetes specific
preventive care service in patients suffering from comorbid depression and diabetes
with some studies yielding an increased rate of receipt of diabetes preventive
care49,125,126 while others indicating lower degree of use82,127,128 or no significant
association.129,130 For example, Lin et al. conducted a study of 4,463 patients in a
large health maintenance organization to assess whether diabetes self-care,
medication adherence, and use of preventive services were associated with
depressive illness.112 This study did not find an association between major depression
and receipt of preventive services for diabetes. In contrast, in a study of 4,398 adult
health plan members with diabetes conducted by Simon et al, reported that
depression was associated with lower visit rates for preventive services.82 Given the
conflicting evidence on the use of preventive services in patients with both diabetes
and depression and the need for improvement in the levels of preventive service use,
32

we sought to quantify the effect of comorbid depression on rates of preventive
service utilization.70,131 For our study, we focused on five important preventive
services, including: 1) A1C testing; 2) Diabetic Foot Exam; 3) Lipid check; 4) Influenza
Vaccination; 5) Dilated Eye Exam; 6) Routine Medical Checkup.
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2.2 Methods

2.2.1. Study Design and Data source
To achieve the aims of our project, we conducted a retrospective cohort study
among adult patients (18 years of age or older) with diabetes. Our study utilized
components of the Medical Expenditure Panel Survey (MEPS), a publicly available
dataset collected by the Agency for Healthcare Research and Quality (AHRQ).132,133
MEPS is a large-scale nationally representative survey of U.S. non-institutionalized
population, medical providers, and employers. The MEPS utilizes a national
probability-sampling scheme and collects household and individual-level data on
medical service utilization information and can be used for cross-sectional or
longitudinal analysis.134-137 The data set is unique in terms of its sample size,
composition and provides a set of variables, which are hypothesized to influence the
receipt of diabetes preventive care. The MEPS sampling frame is drawn from a
subsample of households included in the previous year’s National Health Interview
Survey (NHIS) conducted by the National Center for Health Statistics (NCHS).137 The
MEPS sample design includes stratification, clustering, multiple stages of selection,
and over sampling of certain racial and ethnic minority populations.136,137
To achieve the aims of the MEPS, AHRQ employs an overlapping panel designs
(Appendix 2.2) approach to identify preliminary contacts followed by interviews
during five separate in-person rounds with purposeful oversampling of certain groups
(e.g., low income, racial minorities).138 A new panel of sample households is selected
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each year, and data for each panel are collected during two consecutive calendar
years. The overlapping design of the MEPS provides information on the same people
several times during the year, allowing for repeated observation analyses.139 To
account for the complex design and sampling scheme of the MEPS, sampling weights
are published for each survey which when utilized adjusts for the complex survey
design and survey nonresponse. In addition, the weights allow extrapolation to
reflect rates of medical service utilization in the US general population as derived
from the Current Population Survey.133,136,137,140
In addition to the overarching design of the survey, the MEPS collects several types of
data that are useful for conducting healthcare research. There are three principal
components of the survey; the Household Component (HC), the Insurance
Component (IC), and the Medical Provider Component (MPC).141 For this study, we
included the HC and several sub-surveys that were useful for our analyses. The
household component (HC) file of MEPS, considered the core survey, collects
demographic characteristics, health conditions, self-rated health status, medical
services use, access to care, satisfaction with care, health insurance coverage status,
and income for each person surveyed for a period of two years.136,139 During
interviews, all participants are also questioned regarding healthcare use services and
medical and mental health treatment including prescription drugs and mental health
counseling. Within the HC, the Medical Conditions (MC) file reports information on
health conditions and procedures reported by respondents during the survey. The
medical conditions and procedures reported by the household component
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respondent are recorded by the interviewer as verbatim text, which is then coded by
professional coders to fully specified International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes, including medical condition and V
codes.142 However, to preserve confidentiality, the MEPS data includes only 3-digit
ICD-9 CM codes in the publicly available research files. To foster data analyses, the
MEPS data provide Clinical Classification Codes (CCCs), derived by using the Clinical
Classifications Software (CCS) disease categorization scheme which aggregates ICD-9CM codes into clinically meaningful categories, grouping similar conditions into one
CCC. To minimize underreporting of medical conditions and procedures, the
interviewers use a variety of techniques.137
Since we were primarily interested in assessing the use of preventive care in patients
with comorbid depression and diabetes the preventive services for diabetes, we
specifically utilized the Diabetes Care Survey (DCS) supplement.143 The DCS a special
self-administered paper-and-pencil questionnaire fielded Rounds 3 and 5.
Households received a DCS based on their response to question regarding a health
professional communicating with the individual that he or she has diabetes. The DCS
specifically collects information regarding the diabetes related medical care that is
received by the patients, including medications and previous diagnostic tests
including the receipt of preventive services by the individual in the recent past.
Linking this survey, administered once a year over two years, with the household
components enables a complete examination of the diabetes related health care
received by the patient.136
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2.2.2 Study Cohort
To gain adequate sample size and construct an analytical study cohort for our
analyses, we selected data for individuals from households in Panels 12, 13, 14, 15,
16 coinciding to MEPS survey years of 2008-2011. Data for each year was constructed
based on six rounds of interviews, rounds 1-3 for the panel that was initiated that
year and rounds 3-5 for the panel that was initiated in the previous year. Information
attained in each round of the interviews pertains to a specific frame of time known as
reference period. Thus, the study reference period begins from 1st January 2008 for
panel 12 round 5 and ends on 31st December 2011, which is the end of the last
reference period. Table 2.1 provides an overview of the panels and rounds from
which the study cohort was selected with respect to the year. Within these included
years, we focused on all respondents aged 18 years or older, who self-reported a
diagnosis of diabetes with a positive sampling weight.
2.2.3 Cohort Eligibility-Identification Of Diabetes
We defined the inclusion criterion for the study sample as the presence of diabetes in
individuals, with or without comorbid depression. We identified diabetes-using
patient self-report in answering to survey question regarding diabetes, where
respondents were asked, “Have you ever been told by a doctor that you have
diabetes ?”.143 If the individual responded affirmatively, we considered them eligible
for entry into the final cohort. Individuals who were aged 17 years or younger and
those who responded “not sure,” “don't know,” “refused” or “missing.” were
37

considered ineligible59. Similarly, we excluded cases of gestational diabetes. During
the process of this survey, every person who reported to have received a diagnosis of
diabetes was further asked to complete the DCS. In previous studies, Richard et al.
and Dismuke et al. have utilized similar procedures to recognize diabetic population
in this dataset to investigate the racial disparities in the quality of diabetes care and
association between major depression, number of depressive symptoms and
personal income among the diabetic population respectively.68,139
2.2.4 Exposure Definition-Comorbid Depression
To conduct our retrospective cohort study, we created two groups, 1) those with
comorbid depression, and 2) those without comorbid depression. We identified
study participants with depression using individual’s self-reports as well as diagnosis
codes captured on the MC survey. As part of the MC survey, the two-item, Patient
Health Questionnaire (PHQ-2) is collected from participants. The PHQ-2 is a
previously validated instrument to identify depression. The PHQ-2 was designed to
report the feelings of depressed mood and anhedonia in patients over the past 2
weeks, with the scores ranging from 0 ("not at all") to 3 ("nearly every day") for each
criterion. Kroenke et al. reported that the PHQ-2 has a 83% sensitivity and 92%
specificity for identifying major depression.144,145 Utilizing this information, we
identified survey respondents with a score of ≥3 on the PHQ-2 as having comorbid
depression. To comprehensively identify persons with depression and taking into
account some respondents may have not demonstrated signs of depression at the
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time of survey (e.g. symptoms managed with antidepressant medication); we further
identified individuals who had reported ICD-9 CM codes 311, 296 or a CC code 657 or
both. Egede et al. suggested that for approximately 70% of the MEPS population in
the year 1996, ICD 9 CM code 311 was appropriate.49 Kim et al. in a study to assess
the impact of workplace injury on depression and identify the potential risk factors
associated with post-injury depression in the US working population, used ICD 9 CM
codes 296 and 311 to identify depression in the study population.146 Similarly,
Bhattacharya et al. identified depression using the CCC 657 to examine the excess
risk of chronic physical conditions associated with depression.147 Frayne and
colleagues developed an algorithm to identify the patients with depression, which
utilizes a more inclusive set of codes, namely 296 and 311.148
The prevalence of depression in the final study cohort was 25.8% with 1,208 patients
suffering from depression as identified by the self-reported PHQ-2, ICD 9 CM/CC
codes or both. Of the 4,668 identified respondents, 731 had a score of 3 or higher on
the depression scale. Of these, 288 had an ICD 9 CM/ CC code for depression while
443 respondents did not record an ICD 9 CM/ CC code for depression. Out of the
3,937 respondents who did not have a score of 3 or higher on the depression scale,
477 respondents (12.1%) had an ICD 9 CM/ CC code for depression and therefore we
classified them as having comorbid depression. Thus, the final sample for inclusion
included 1,208 persons with depression and 3,460 persons without depression.
Figure 2.1 outlines the process of selecting the patients with diabetes and comorbid
depression.
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2.2.5 Outcome: Use of Preventive Services in the Past Year
The main outcome variable of this study was the suggested use of diabetes
preventive care services according to the ADA guidelines. The self-reported receipt of
seven recommended diabetes-specific preventative services was examined within
the past year using the DCS, based on the inclusion in the MEPS and consistent with
the guidelines of the national organizations.91 For this study, the seven outcomes of
focus were annual receipt of:
1.

Hemoglobin A1C (A1C) testing

2.

Foot exam

3.

Dilated eye exam

4.

Influenza vaccination

5.

Cholesterol testing

6.

Blood pressure screening

7.

Physical exam

For information regarding the frequency testing of the hemoglobin A1C, the
individuals were asked about the number of times a doctor, nurse or other health
professional checked their blood for A1C in the past year. In contrast, questions with
reference to the remaining preventive care services were constructed in a manner
40

which asked the respondent to report the last time they underwent a preventive
service in the recent past (alternatives restricted to same year, past year, year before
past year, not in the past 2 years and never had the preventive service). Using this
information, we created seven binary outcome variables for each of the self-reported
preventive health care utilization over the prior year. Table 2.2 summarizes the MEPS
questions asking about use of these services, the coding scheme for the receipt or no
receipt of these services and the ADA recommendations for the services.91 During
the study, respondents with missing data reported for any of the preventive services
were considered ineligible for further analyses.
2.2.6 Identification of Potentially Confounding Factors
Based on the available literature, we identified and evaluated a set of sociodemographic characteristics that was associated with differences in the use of
preventive care services in patients with comorbid depression and diabetes. The
variables describing demographic status of the person were constructed as per the
self-reported status of the person on the 31st of December of the survey year. These
variables are updated in every round of data collection. Since the DCS was a crosssectional survey, the variables represented current status only. In our study analyses,
some categories of the variables were merged and reconstructed to have a
preferable distribution of the population within these categories. These factors
included age (18–34 years, 35-49 years, 50-64 years and 65 and above), gender (male
versus female), marital status (married, widowed/divorced/separated and never
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married), race/ethnicity (Hispanic, White non-Hispanic, black non-Hispanic and
others), income level based on the federal poverty line (FPL) (poor/near poor [<125%
FPL], low income [125% -<200% of FPL], middle income [200%-<400 of FPL] and high
income [>400% of FPL]), educational status (less than a high school degree, high
school degree, advanced education and others), perceived health status (excellent or
very good, good and others), health insurance status (private insurance coverage,
public insurance coverage only, uninsured), insulin use (Yes versus No), Metropolitan
Statistical Area (MSA; MSA versus Non-MSA), employment status (Employed versus
not employed), Body Mass Index (BMI; underweight [BMI <18.5], normal weight [BMI
≥18.5 and ≤24.9], overweight [BMI ≥25.0 and ≤29.9] and obesity [BMI ≥30.0 ]) and
smoking status (Yes versus No).
2.2.7 Identification of Comorbidities
Based on the available literature, we identified and evaluated a set of sociodemographic characteristics that was associated with differences in the use of
preventive care services in patients with comorbid depression and diabetes. The
variables describing demographic status of the person were constructed as per the
self-reported status of the person on the 31st of December of the survey year. These
variables are updated in every round of data collection. Since the DCS was a crosssectional survey, the variables represented current status only.15 In our study
analyses, some categories of the variables were merged and reconstructed to have a
preferable distribution of the population within these categories.138
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Comorbidities were defined by using the patients’ clinical records in the medical
conditions file. The CCCs were used to identify presence of clinically relevant
comorbidities. The methodology defined by Machlin et al. was used to select
comorbidities based on sample size considerations and relevance to association with
use of preventive care services.149 Single or multiple CCCs were chosen to define each
comorbidity and the presence of each comorbidity was recorded as a dichotomous
variable. Appendix 2.3 provides more detailed information on the identified
comorbidities including the CCCs that utilized to ascertain each of the comorbidities.
2.2.8 Statistical Analysis
As we conducted a retrospective cohort study, we conducted all analyses comparing
the two created exposure groups, those with comorbid depression (n= 1,208) and
those without comorbid depression (n= 3,460). We first checked for comparability in
background characteristics of the two groups focusing on age, gender, comorbidity
conditions, and other aforementioned socio-demographic factors. This was done to
understand and profile the study population and identify potentially confounding
factors between the two groups. We generated descriptive statistics within each of
the groups including means and standard deviations for continuous variables and
percentages were reported for categorical variables. We examined differences
between the two exposure groups using the Pearson's chi-square test or Fisher exact
test for categorical variables and T tests for continuous variables.
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After baseline comparison of the two exposure groups, we next assessed the
prevalence of use of preventive care service use in the diabetic population with and
without depression. Percentages were reported to compare the use of preventive
services between diabetic individuals with and without depression. To further
quantify the effect of comorbid depression on use of preventive services after
controlling for confounding, we employed logistic regression modeling.

We

identified potentially confounding variables that varied between the two exposure
groups (during bivariate analyses). In addition to these, variables of known clinical
importance (age, gender race/ethnicity) were selected as potential confounders.
Initially, we constructed unadjusted odds ratios for use of preventive care services in
diabetic patients with and without comorbid depression. Then, we used a series of
multivariate logistic regression models to determine the independent effect of
comorbid depression on the use of preventive services. Controlling for all the
aforementioned patient level covariates that might influence the use of preventive
services, we calculated the adjusted odds of receiving at least 2 A1C tests, a diabetic
foot examination, an eye examination, an influenza vaccination, a blood cholesterol
check and a routine medical checkup in the past year. Because of the complex survey
design of the MEPS HC file, we used special diabetes weights from MEPS to compute
robust standard errors of the estimates.150
During the process of building the logistic regression models for each mentioned
preventive care services individually, we used a non-computer generated stepwise
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approach. Variables that were identified as potential confounders in the bivariate
analysis were added to the model for each service sequentially in the order on the
largest significant difference between the depressed and non-depressed groups with
respect to the particular variable. Thus, nested models were fitted in an iterative,
manual process using an inclusion threshold of a 10% change in the β estimate of the
principal independent variable, comorbid depression (indicator of exposure group).
Iterations continued in this manner until the most parsimonious model was fitted. At
the end of this process, we added all the excluded variables back to the final model
to assess the potential for residual confounding. This model with all the variables was
compared to the final model constructed at the end of the stepwise process. We
used the Akaike Information Criterion (AIC) at this step of the model building process
since AIC is asymptotically equivalent to cross-validation and the bootstrap, two most
popular validation methods. We conducted a Hosmer and Lemeshow Goodness-ofFit Test to examine the fit of the model as well as a likelihood ratio test to evaluate
the final fitted model151-154. We further assessed multicollinearity in the model. For
this purpose, we used the variation inflation factor (VIF), tolerance and eignevalues
to make the decisions on exclusion of collinear variables. These were calculated
utilizing a separate regression model and specifically using the VIF, TOL, and Collin
options. If two variables were found collinear, we included the variable that was
clinically more relevant to our analysis. All statistical tests were conducted with twotailed alpha 0.05. At the end of this process, we compared the models using the
above procedures and selected the best fitting model. We then reported
45

multivariable (adjusted) odds ratios (AORs), including their respective 95%
confidence intervals (95% CI).
Due to the clustered and correlated nature of the survey data, analyses were
conducted using SAS software, Version 9.3 (SAS Institute Inc., Cary, N.C.) and SAS
callable SUDAAN, Release 9.0.1 (Research Triangle Institute, Research Triangle Park,
N.C.) to account for complex survey design.155 This study was reviewed and approved
as exempt by the University of Rhode Island’s Institutional Review Board.
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2.3 Results
2.3.1 Final Cohort
Within the four years of MEPS data utilized for our analyses (2008-2011), we
identified 138,030 survey respondents included in the dataset. Figure 4 describes the
steps that were followed for the selection of final cohort of respondents. As per the
recommended data estimations procedures, we did not consider respondents with
non-positive person level weights for further analyses since only data for persons
with a positive person-level weight can be used to make estimates for the civilian no
institutionalized U.S. population. Further, we restricted the population to
respondents who were above 17 years of age, who had responded “yes” to the
question regarding diabetes and had a positive diabetes weight, which adjusts for
DCS nonresponse and weights to the number of diabetics in the US civilian noninstitutionalized population. This selection process resulted in the initial sample of
7,780 respondents with diabetes. Out of this population, only the respondents who
had information on all the required variables were selected for the study. Thus, the
final sample for the study comprised of 4,468 respondents. This sample size
represented 60% of the population that was eligible for the study.
The prevalence of depression in the final study cohort was 25.78% with 1,208
patients suffering from depression according to the self-reports of PHQ-2 or ICD 9
CM/CC codes or both (Figure 2.1). Moreover, 288 patients had depression according
to the PHQ score as well as ICD 9 CM/ CC code for depression while 443 respondents
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did not record an ICD 9 CM/ CC code for depression even though they had a PHQ
score 3 or more. Out of the 3,937 respondents who did not have a score of 3 or
higher on the depression scale, 477 respondents had an ICD 9 CM/ CC code for
depression and were considered as suffering from comorbid depression.
2.3.3 Demographic and Clinical Characteristics of the Cohorts of Individuals With and
Without Depression
Table 2.3 presents an overview of the descriptive statistics of the final sample of
individuals with diabetes and compares the demographics characteristics of the
sample by depression status. With respect to depression status, those with existing
comorbid depression were primarily between ages 50 and 64 (42.2%), females
(59.2%), married (50.88%), high school graduates (49.1%) and non-Hispanic whites
(72.7%). A high fraction of these respondents with depression had a fair or poor
perceived health status (55.04%), private health insurance coverage (54.1%), did not
use insulin (63.2%), resided in metro areas (78.6%), were not employed (65.2%),
were overweight (87.1%), were nonsmokers (79.2%) and had a primary care
physician (94.6%).
Apart from a few variables (metro status, primary care provider status and insulin
use), all the other variables demonstrated statistically significant differences with
respect to the depression status among individuals with diabetes. With respect to the
age groups, people with diabetes and comorbid depression were more likely to be
in the age groups 35-49 (17.8%) and 50-64 (42.2%) as compared to people without
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comorbid depression (15.4% and 36.9% respectively p=0.002). In contrast, people
without comorbid depression were more likely to be in the age group 65 and above
(38.7% vs 30.7%). With respect to gender, the proportion of women in the comorbid
depression group was higher as compared to those in the non-depressed group
(59.2% vs 48.5%, p <0.001). Individuals with diabetes and depression were more
likely to be unmarried as compared to people suffering from diabetes alone (49.1%
vs 36.8%, p <0.001). In contrast, the percentage of people without comorbid
depression and diabetes was significantly higher in the high income group as
compared to the people with comorbid depression and diabetes (40.6% vs 25.9%, p
<0.001). The prevalence of higher education was significantly lower in the
respondents with comorbid depression and diabetes as compared to the
respondents without comorbid depression (16.4% vs 23.3%, p = 0.001). With respect
to the racial and ethnic distribution of the population, people with comorbid
depression and diabetes are more likely to be non-Hispanic whites as compared to
the diabetic people without depression (72.7% vs 66.8%, p=0.003). A significantly
higher proportion of people with comorbid depression and diabetes reported being
in fair or poor health status in contrast to the individuals with only diabetes (55.0% vs
25.0%, p <0.001). In comparison to the individuals without depression, people with
depression were more likely to have some form of public insurance (37.7% vs 25.7%,
p < 0.001). There was a lower proportion of depressed people with current
employment (34.5% vs 50.2%, p=0.001) and normal BMI status (10.2% vs 14.2%, p =
0.013) in contrast to the non-depressed diabetic individuals. Respondents with
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comorbid depression and diabetes were more likely to be smokers that the
respondents with diabetes alone (18.6% vs 12.8%, p < 0.001).
The prevalence of selected comorbidities was significantly higher in diabetes patients
with comorbid depression as compared to the patients with diabetes alone. Table 2.4
outlines the differences in the diabetic patients with and without comorbid with
respect to the presence of clinically significant comorbidities. It could be seen that
heart disease (16.4% vs 10.4%, p<0.001) and injury (16.1% vs 11.2%, p=0.005) were
reported more frequently in diabetes patients with comorbid depression relative to
patients suffering from diabetes alone. Similarly, back disorders (23.6% vs 15.2%,
p<0.001), upper respiratory disorders (20.1% vs 14.1%, p=0.003) and thyroid
disorders (17.3% vs 13.2%, p=0.023) had a higher prevalence in patients with
comorbid depression and diabetes. Overall the most prevalent comorbidity for
patients in the final cohort was hypertension, with patients suffering from comorbid
depression and diabetes having a higher occurrence of hypertension than the
patients with diabetes alone (78.6% vs 73.0%, p=0.004). Similarly, the reported rates
for hyperlipidemia were high and differences between the diabetic patients with and
without depression were remarkable (74.2% vs 67.9%, p=0.001). The occurrence of
cerebrovascular disease (8.4% vs 4.9%, p=0.004), urinary tract infections (9.3% vs
6.4%, p=0.037), headaches (11.6% vs 4.3%, p<0.001) and anemia (6.6% vs 4.2%,
p=0.018) was also higher amongst the diabetic patients with comorbid depression.
Differences in the rates of kidney disease (6.8% vs 6.6%, p=0.874) and eye disorders
(10.1% vs 9.3%, p=0.554 were not significantly different in the diabetic patients with
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and without comorbid depression. Similarly, the prevalence of epilepsy and
convulsions (1.9% vs 0.9%, p=0.077), gall bladder disease (2.4% vs 2.1%, p=0.713),
hernias (3.1% vs 2.3%, p=0.322) and osteoporosis (3.0% vs 2.8%, p=0.758) was
relatively low and not significantly different between the two groups. In summary,
the most frequently occurring comorbidities in the final cohort hypertension,
hyperlipidemia, and back disorders while the least prevalent comorbidities were
epilepsy and convulsions, gall bladder disease and osteoporosis.
2.3.4 Prevalence of Use of Preventive Care Services In the Diabetic Population
Table 2.5 describes the estimates of diabetes specific preventive care behaviors. In
the final sample, about 79.1% of the people reported having undergone an A1C test
in the previous year. Similarly, about 52.1% of the respondents reported having
undergone an annual diabetic foot examination in the past 12 months while 65.8% of
the sample reported having their blood cholesterol in the previous year. About 49.9%
of the individuals with diabetes reported taking an influenza vaccine in the past year
while 51.2% reported having a retinal eye examination performed during the past
one year. Majority of the respondents indicated that they underwent a blood
pressure check (96.8%) and a routine medical checkup (89.1%).
Examining the trends in the use of these services, it could be seen that there were
significant changes observed over the four years of data for some preventive care
services. There was a steady increase in the rate of A1C testing, with 83.5% of the
respondents reporting undergoing an A1C test in past year for data year 2011 as
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compared to the 79.1% who disclosed testing for A1C in the last year for data year
2008. Similar results could be seen for the diabetic foot exam, in which case the rate
for testing in the past year rose from 49.8% in 2008 to 56.4% in 2011 representing a
weighted increase of almost 7 percentage points. Rates for blood cholesterol checks
progressed from data year 2008 (65.0%) to data year 2010 (73.4%) but exhibited a
slight decline for the data year 2011 (72.9%). The number of respondents who
reported taking an influenza vaccination also displayed an increase of approximately
6% from data year 2008 (50.0%) to data year 2011 (56.3%). There was a significant
rise in the number of people who reported having a retinal eye examination in the
previous year with 49.2% respondents having undergone the test in data year 2008
and 58.6% respondents having their eyes tested in data year 2011.
Figure 2.3 describes the differences in the use of preventive services by presence or
absence of comorbid depression. It was seen that people with comorbid depression
(82.4%) had a higher rate of undergoing more than one A1C test in the previous year
as compared to people without comorbid depression (80.4%). Similar results were
found for annual diabetic foot exams (56.6% vs 52.3%), annual lipid check (71.1% vs
68.8%), annual influenza vaccination (53.7% vs 52.7%) and blood pressure checks
(98.1% vs 97.3%). In contrast, with respect to annual dilated eye examinations (52.3%
vs 54.0%) and annual routine medical checkup (88.6% vs 90.6%), people without
comorbid depression had a higher rate of receipt of these services.
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2.3.5 Multivariable Modeling-the Effect Of Comorbid Depression On The Receipt Of
Diabetes Preventive Care Services.
Crude and adjusted odds ratios with the 95% confidence intervals from multivariate
logistic regression models describing the associations between presence of comorbid
depression in diabetes and receipt of the preventive care services are described in
Table 2.6. Among patients with diabetes, patients with depression were significantly
more likely to receive >1 A1C tests in the previous year (Crude Odds Ratio [COR] 1.19;
95% Confidence Interval [CI] = 1.01-1.44). However, after adjusting for confounding
factors the receipt of A1C tests were not statistically significant (Adjusted Odds Ratio
[AOR] = 1.03; 95% [CI] 0.83-1.28). Similarly, in unadjusted analyses, patients suffering
from comorbid depression and diabetes are 20% more likely to receive an annual
diabetic foot exam as compared to patients without comorbid depression (COR
=1.20; 95% [CI] 1.01-1.44), which did not persist after adjustment (AOR= 1.12; 95%
[CI] 0.94-1.34). The unadjusted odds of patients with comorbid depression and
diabetes receiving an annual lipid check were slightly higher than diabetic patients
without depression (COR =1.11; 95% [CI] 0.94-1.32). These differences, however,
were statistically insignificant. In adjusted analyses, depression had an insignificant
association with the receipt of an annual lipid check in patients suffering from
comorbid diabetes and depression (AOR= 1.07; 95% [CI] 0.88-1.30; p=0.47). The
association between receipt of an annual influenza vaccination and presence of
comorbid depression in diabetes was statistically insignificant in both unadjusted
(COR =1.06; 95% [CI] 0.88-1.28; p=0.66) as well as adjusted analysis (AOR= 1.02; 95%
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[CI] 0.83-1.25; p=0.87). Depression was not significantly associated to the receipt of
an annual dilated eye examination in patients with diabetes. The odds of receiving an
annual dilated eye exam was marginally lower for patients with comorbid depression
and diabetes in both unadjusted (COR =0.94; 95% [CI] 0.79-1.11; p=0.45) and
adjusted analyses (AOR= 0.93; 95% [CI] 0.76-1.12; p=0.44), but these differences
were statistically insignificant after adjusting for confounding factors.
Contrary to other preventive services, before adjusting for the specified confounders,
people with comorbid depression and diabetes were less likely to receive a routine
medical checkup as compared to the diabetic patients without depression (COR
=0.80; 95% [CI] 0.63-0.99; p=0.04). However, similar to the results for other
preventive services that were explored, these differences between people with and
without depression were not significant after controlling for various sociodemographic and clinical factors.

54

2.4 Discussion
Using a nationally representative probability survey, we performed a study that had 2
principal goals. The first was to examine patterns of preventive care service use
among individuals with and without diabetes using data on non-institutionalized
civilian US population. The second was to examine the relationship between the
status of comorbid depression and receipt of diabetes specific preventive health
practices. This study advances the current body of literature regarding the
differences in the quality of preventive care in diabetic patients with and without
comorbid depression by exploring the impact of depression as an independent factor
on receipt of these services.
The ADA recommends that diabetic patients have their blood A1C test done twice a
year if their glycemic control is meeting its goals and quarterly in case of poor
glycemic control or changes in diabetic management. The ADA further recommends
diabetic patients to undergo certain other preventive care practices like diabetic foot
exam, retinal eye exam, influenza vaccination, blood cholesterol check and a routine
medical checkup annually.91,156 From the results of this study, we conclude that a
significantly high percentage of the American diabetic population that was studied
did not receive the recommended standard of care, thus highlighting the need and
opportunity for improvement in the status of preventive care among adults with
diabetes. For instance, nearly half of the study population did not receive a diabetic
foot exam, influenza vaccination and dilated eye exam in the past year. In this study,
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we observed that the levels of use of certain preventive services were considerably
lower than those previously reported.22,116 For example, Harris et al. in a study of the
Behavioral Risk Factor Surveillance System data examining the change in rates of
adults with diabetes receiving 4 essential preventive care services found that the
overall age adjusted rate of receiving all 4 preventive care services increased from
10% in 1997 to 20% in 2007, but remained suboptimal. In the same study the
proportion of adults receiving an annual foot examination was reported as 69% while
that of receiving a pneumococcal vaccination was mush lower at 39%.157 Beckles et al
assessed the use of preventive care services, concluding that most adults do not
meet recommendations for standards of diabetes care with only 72% of the patients
visiting a health care provider for diabetes care at least once, 61% having their feet
inspected at least once, and 61% reporting having received a dilated eye exam.118
Moreover, Pu at al reported that among diabetes patients, 74% received the
recommended levels of A1C tests, compared to 65% getting a foot exam and an 63%
receiving an eye exam.12 Moreover, based on a cross-sectional observational study
conducted by Wang et al. using the Medical Expenditure Panel Survey (MEPS) from
2005, the percentage of people receiving an annual diabetic foot exam, annual
cholesterol check and annual influenza vaccination was demonstrated to be 74.3%,
89.5%, 57.5%, respectively.22 Similarly, according to a study based on National Health
and Nutrition Examination Survey (NHANES) and Behavioral Risk Factor Surveillance
System survey (BRFSS), the proportions of annual foot exams (68.3%), annual
cholesterol checks (84.6%), and annual influenza vaccinations (52.5%) were all
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suboptimal. According to the Centers for Disease Control and Prevention (CDC), the
age adjusted estimates of adults >18 years of age who reported receiving preventive
care practices were 68.5% for receiving > 1 A1C test and 67.5%, 50.1% and 62.8% for
an annual diabetic foot exam, influenza vaccination and dilated eye exam
respectively.158 Gold et al. in a study of patients receiving care at Federally Qualified
Health Centers (FQHCs) found that 32% of OCHIN (Our Community Health
Information Network) patients with diabetes received a flu vaccination in 2005, 36%
an LDL screening, 54% at least one HbA1c screening, and 21% a nephropathy
screening. In our study, the proportions observed on these services were 81.0%,
53.4%, 69.4%, and 53.5% respectively for >1 A1C tests, annual foot exam, annual
cholesterol check, annual influenza vaccination and annual dilated eye examination
in the previous year. This suboptimal use of preventive services is a major concern for
policy makers since the benefits of implementing these services on reducing the
mortality as well as micro- and macro-vascular complications of diabetes are well
documented. It has also been reported widely in literature that timely receipt of foot
care and eye examinations reduce the risk of foot complications by 50-60% and that
of severe vision loss by approximately 60% in people with macular edema and 90% in
people with proliferative retinopathy.156 Thus, it is imperative that strategies be
designed to ensure effective mechanisms are in place to deliver preventive care that
adheres to the standards recommended by the ADA.156
Our study demonstrates that depression is not significantly associated with increased
use of the recommended diabetes preventive care services. To our best knowledge,
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this study adds substantially to the scarce literature that examines the effect of
depression on the use of diabetes specific preventive care services. Other studies
have yielded inconclusive findings with respect to differences in the utilization of
preventive services in patients with and without depression.112,127,128,130,159 Before
adjusting for clinically relevant covariates, presence of depression was associated
with associated with the receipt of three diabetes specific quality of care indicators
within the past year—an A1C measurement, a diabetic foot check, a retinal eye
examination, with depressed people more likely to undergo the recommended levels
of A1C testing and diabetic foot testing but less likely to undergo a retinal eye
examination. However, after controlling for various demographic and health
characteristics, we found that comorbid depression did not significantly influence the
likelihood of receipt of these services. Our findings are consistent with some previous
conducted studies that have concluded that presence of depression is not associated
with higher use of preventive care services.124,128,156,160 Lin et al. found that major
depression was mainly associated with patient-initiated behaviors that are difficult to
maintain (e.g., exercise, diet, medication adherence) but not with preventive services
for diabetes.112 Similarly, Egede et al. in a study to examine the effect of minor and
major depression on self-care behaviors and quality of care among adults with
diabetes, found no significant association between both major as well as minor
depression and use of preventive care services like A1c testing (AORs 1.02, 95%
CI[0.80 – 1.31] and 0.84, 95% CI [0.68 – 1.04] respectively) and diabetic foot exams
(AORs 0.88, 95% CI [0.72 – 1.08] and 0.81, 95% CI [0.62 – 1.04] respectively).128 Desai
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et al. studied the relationship between mental disorders and quality of diabetes care
in a national sample of veterans and found that diabetic patients with or without
depression did not differ significantly with respect to the receipt of A1C tests (AOR
0.98, 95% CI [0.88 – 1.08]) and diabetic foot examinations (AOR 1.06, 95% CI [1.00 –
1.12]).130 Similarly, Hutter et al. in a meta-analysis to review the impact of comorbid
mental disorders on healthcare costs in persons with diabetes reported inconclusive
evidence for differences in the use of retinal eye examinations.159
The results of our study are in contrast to some studies in the literature that
conclude that coexisting major depression was associated with lower rates of
preventive care service use in patients with diabetes and comorbid depression than
in those without depression.112,128,159 For example, Jones et al. compared the use of
preventive health services among diabetes patients with and without mental
disorders during the years 1996 – 2001 and demonstrated a lower hazard ratio (HR)
of A1C determinations (HR 0.92; 99.9% confidence interval [CI] 0.87-0.97) as well as
cholesterol checks (HR 0.92; 99.9% CI 0.86-0.98) in patients with diabetes and mental
disorders.127 Moreover Egede et al., after adjusting for clinically relevant covariates,
individuals with minor and major depression were significantly less likely to receive a
dilated eye examination (AORs 0.81, 95% CI [0.66 – 0.99] and ⁎ 0.70, 95% CI [0.54 –
0.89] respectively) in the past year and a flu shot in the past 12 months with the
latter significant only in patients with minor depression (AOR 0.79, 95% CI [0.65 –
0.95]).128 Similarly, Simon et al. assessed the contribution of depression as one of the
factors affecting health service costs in adults with diabetes and found that rate of
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outpatient preventive care visits in patients with diabetes and depression was lower
as compared to those without depression (SMD −0.09 [95% CI −0.16, −0.01]).82
The likely explanation for the non-significant results with respect to depression and
receipt of preventive services is that various patient characteristics likely affect the
rates of service receipt. In our study, depression was not found to be a significant
factor increasing the frequency of A1C testing. However, factors like age, race and
ethnicity, income levels, BMI status, marital status, insulin use, presence of a primary
care provider and comorbidities like hypertension, hyperlipidemia, and anemia were
found to be significant predictors of A1C testing. These findings are similar to other
studies analyzing the effects of patient characteristics on receipt of diabetes
services.12,113 DeVeo et al. conducted a secondary analyses of data from 6,562
diabetic individuals aged >17 years of age and found that the odds of receiving this
test increased with increase in age and in people with higher incomes.138 Hu et al.
found that both non-Hispanic black and other minority adults had a lower likelihood
of reporting receiving a hemoglobin A1C measurement at least once in the past year
compared with non-Hispanic white adults.15 He et al. concluded that primary care
physicians and practice features seem to steer diabetes preventive services.24 In
contrast, other studies do not find any significant association between these factors
and annual testing for A1C.123 In our study, there no significant association was
evident between depression and receipt of a diabetic foot exam after adjusting for
various covariates. We observed several other vital patterns in the receipt of this
test. Age, race and ethnicity, insulin use and comorbid hyperlipidemia were found to
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be significant predictors of the likelihood of undergoing this test. Previous studies
have shown some of these factors to be associated with odds of receipt of a diabetic
foot exam annually.12,15,122,138 On the other hand, our results were in contrast to
some studies that did not find a significant association between these
sociodemographic characteristics and use of preventive services.118,139,161 In both
unadjusted and adjusted analyses, depression was not significantly associated with
receiving an annual lipid exam. In adjusted analyses, we uncovered associations
between this preventive care service and some independent variables like age, race
and ethnicity, insulin use as well as co-existence of hyperlipidemia. Various studies
have found age to be significantly associated with the receipt of an annual
cholesterol screening.12,15,138,162,163 With respect to the relationship between
race/ethnicity and the likelihood of undergoing an annual lipid exam, our results are
corroborated by some studies12,163 but are in contrast to results of others.15,138
Although the effect of depression was insignificant on the likelihood of receiving an
annual influenza vaccination, we found that in adjusted analyses age, race/ethnicity,
insulin use, and comorbidities were significant predictors of a flu shot. Our findings
suggesting that other factors (apart from depression) may be related to the lack of
receipt of preventive services rather than depression itself. These findings are
consistent with previous reports that provide an evidence of a strong association
between these factors and receipt of the preventive service.119,138,163 After we
controlled for the effects of all other sociodemographic covariates, depression was
not found to significantly affect the receipt of an annual retinal eye examination.
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However, as mentioned in the previous literature, we found that several covariates
like age, educational status, smoking status, marital status, presence of primary care
provider and comorbidities that we adjusted for in the multivariable logistic
regressions, had a significant association with the receipt of a dilated eye
examination. Richard et al. reported that elderly patients with college degrees were
more likely to report receiving an eye examination compared to those who did not
complete high school. Similarly, other studies have also concluded that age, marital
status, comorbidities.15,118,138,161,162 Though depression was found to be insignificantly
associated with a receipt of a routine medical checkup in the previous year, we found
several demographic characteristics that affected the receipt of this recommend
quality of care indicator, a finding supported by DeVeo et al. who found a significant
association between routine medical check and factors like age, geographic region
and income.138
The findings of this study are unique and add to the body of literature regarding the
impact of depression on diabetes specific preventive care services. It confirms that in
a large population of non-institutionalized patients with diabetes, the overall rates of
receiving diabetes specific preventive care services are sub-optimal. Though the selfmanagement of diabetes has been widely considered as having a beneficial effect on
control of the disease, we found that major gaps in the use of ADA recommended
preventive care practices persisted.118 Our findings suggest that, as reported earlier,
there is a need for policy makers and physicians alike to place greater emphasis on
diabetes preventive care practices.59 Many patient related factors contributing to
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differing levels of health care use and overall health of patients were found
significant in our analyses. Our findings could be vital in the management of diabetic
patients with depression since it will allow researchers to focus on specific action
areas that need greater importance and attention since they could affect these selfcare activities critical to health outcomes.59 It also highlights an insignificant
association between presence of comorbid depression and adherence to ADA
recommended levels of diabetes preventive care. Patients that suffered from
depression in our study, though statistically insignificant, were marginally more likely
to receive these recommended tests. This might be attributed to the higher
frequency of visits to the physicians, since most of these are physician-initiated
activities.164,165 Age, racial differences, insulin use, socioeconomic factors and access
to care measured by presence of primary care physician emerged as principal factors
related to use of diabetes specific preventive care services.
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2.5 Limitations And Conclusions
The interesting findings of this study should be viewed in context of some study
limitations. Primarily, one limitation was the use of self-report in diagnosing both
diabetes and depression and for identifying use of studied preventive services. As
with all the observational studies that utilize self-reports in their design, the study
had potential for recall bias. Further, MEPS does not provide information about
several measures of diabetes severity. For example, the MEPS does not collect
information on the presence of micro albuminuria, serum cholesterol levels (LDL-C),
or A1C levels in patients. It would be interesting to see if better quality of care results
in better health outcomes as measured by these quality indicators.123 Undiagnosed
diabetes as well as severe diabetes is known to be critical factors that affect diabetes
care and outcomes. It was not possible to account for these factors.161 The issue of
surveillance bias and measuring the disease severity were beyond the scope of the
study. In case of this bias, stratification is often seen as a remedial measure.
In conclusion, our study provides valuable insights into the differences in use of
diabetes preventive services with evaluation of the effect of depression as a
comorbid condition. The extent of use of preventative services was comparable for
diabetic patients with and without comorbid depression but suboptimal overall.
Many of the factors that were found significantly associated with the use of
preventive services are modifiable and hence strategies and interventions focusing
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on these could improve the outcomes in diabetes patients. This data also
demonstrates the need to study effective management of depression in diabetic
patients since depression potentially affects various self-care activities. Future
research should focus on the underlying causes of this suboptimal use of preventive
services as well as establishing a causal relationship between depression and selfcare behaviors.
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Table 2.1: Distribution of Panels, Rounds, and Population for the Data Years
Year
2008
2009
2010
2011

Panels
12
13
13
14
14
15
15
16

Rounds
3,4,5
1,2,3
3,4,5
1,2,3
3,4,5
1,2,3
3,4,5
1,2,3
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Total Population
33,066
34,920
31,228
33,622

Table 2.2: Preventive Services: ADA Recommendations, Survey Questions and
Coding Schemesa
Preventive
Service

ADA Recommendations

Coding
Scheme

Survey Questions
During 2007, how many
times did a doctor,
nurse, or other health
professional check your
blood for glycosylated
hemoglobin or
"hemoglobin A-one-C"?
Which of the following
year(s) did you have an
eye exam in which your
pupils were dilated?
This would have made
you temporarily
sensitive to bright light.
Which of the following
year(s) did a doctor or
other health
professional check your
feet for any sores or
irritations?
Which of the following
year(s) did you have
your blood cholesterol
checked?
Which of the following
year(s) did you get a flu
vaccination (shot or
nasal spray)?

A1C Testing

Perform the A1C test at
least two times a year.

(0,1)

Dilated Eye
Exam

Perform an annual
dilated eye exam.

(0,1)

Diabetic Foot
Exam

Perform an annual
comprehensive foot
examination.

(0,1)

Lipid Screening

Perform an annual lipid
screening examination.

(0,1)

Influenza
Vaccination

Have an annual
influenza vaccination.

(0,1)

Blood Pressure
Check

Blood pressure should
be measured at each
routine visit.

(0,1)

How long since last
blood pressure check?

(0,1)

How long since last
routine check-up by
doctor or other health
professional for
assessing overall
health?

Regular
Medical
Checkup

Perform an annual
medical checkup.

a: Adapted from Standards of medical care in diabetes91 & Diabetes Care Survey (DCS)143
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Figure 2.1: Final Patient Selection To Stratify Patients With And Without Depression

a: DCS Question: Have you ever been told by a doctor or other health professional that you
have diabetes or sugar diabetes?
b: Depression Scale: PHQ 2 (Patient Health Questionnaire 2).
c: International Classification of Diseases, Ninth Revision, And Clinical Modification (ICD 9 CM
Codes): 296, 311.
d: Clinical Classification Code (CCC): 657.
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Figure 2.2: Selection Of Final Study Population (Weighted)
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Table 2.3: Demographic Characteristics of U.S. adults with Diabetes
(Aged >17, MEPS 2008-2011) Stratified By Depression Status

Variables

a

Age
17-34
35-49
50-64
65 And Above
Missing
Gender
Male
Female
Marital Status
Married
Widowed/Divorced/Separated
Never Married
Income Level
Poor/Near Poor
Low Income
Middle Income
High Income
Education Level
Less Than High School
High School
Advanced Education
Others
Missing
Race/Ethnicity
Hispanic
White Non-Hispanic
Black Non-Hispanic
Others
Perceived Health Status
Excellent/Very Good
Good
Fair/Poor
Insurance Coverage
Any Private

DEPRESSION (+)
Unwtd
Wtd %
Freq
(1,208)

DEPRESSION (-)
Unwtd Wtd %
Freq
(3,460)

P Value
0.002*

41
204
513
377
73

2.9
17.8
42.2
30.7
6.2

163
612
1,264
1,254
167

3.9
15.4
36.9
38.7
4.9
<0.001*

440
768

40.7
59.2

1,625
1,835

51.4
48.5
<0.001*

591
475
142

50.8
37.6
11.4

2,028
1,060
372

63.1
27.9
8.9
<0.001*

430
215
330
233

27.4
17.1
29.6
25.9

740
567
1,083
1,070

15.1
13.7
30.5
40.6

408
537
155
100
8

24.5
49.1
16.4
9.3
0.5

973
1,531
676
270
10

19.6
47.9
23.3
8.8
0.2

0.001*

0.003*
276
658
208
66

12.
72.7
9.8
4.8

766
1,563
818
313

12.3
66.8
13.9
6.7
<0.001*

147
361
700

13.3
31.5
55.1

986
1,478
996

30.4
44.5
25.1
<0.001*

552
70

54.0

2,072

67.1

Public Only
Uninsured
Insulin Use
Yes
No
Missing
MSA Status
Non MSA
MSA
Employment Status
Employed
Not Employed
Missing
BMI Status
Under /Normal
Over
Missing
Smoking Status
Yes
No
Missing
Primary Care Provider
Yes
No
Missing

537
119

37.7
8.2

1,025
363

25.7
7.1
<0.001*

434
770
4

36.6
63.2
0.1

929
2,518
13

27.1
72.6
0.3

246
962

21.3
78.6

587
2,873

17.6
82.3

0.029*

<0.001*
367
840
1

34.5
65.2
0.1

1,698
1,759
3

50.2
49.5
0.1
0.013*

134
1,042
32

10.2
87.1
2.5

512
2,881
67

14.2
83.9
1.7
<0.001*

222
953
33

18.6
79.2
2.1

425
2,977
58

12.1
86.5
1.3

1,131
71
6

94.6
4.9
0.4

3,168
271
21

93.2
6.2
0.4

0.287

(+) : Prescence of Depression according to the PHQ-242 and/or ICD and CC Codes.
(-) : Absence of Depression according to the PHQ-242 and/or ICD and CC Codes.
a: n(%) & the Cochran-Mantel-Haenszel statistic / Fischer’s Exact Test were used to compare categorical variables.
*: Significance at p value 0.05 as derived from ChiSquare
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Table 2.4: Comorbidities of U.S. adults with Diabetes
(Aged >17, MEPS 2008-2011) Stratified By Depression Status

1,181
956
889
255
271
227
193
203
186
125
106
105

98.1
78.6
74.2
23.6
23.5
20.1
17.3
16.4
16.1
11.6
10.1
9.3

Unwtd
Frequen
cy
3,334
2,497
2,286
468
397
473
423
322
356
159
285
194

110

8.4

82
84
47
38
35
25
19
7
2

6.8
6.6
4.2
3.1
3.1
2.4
1.9
0.3
0.1

Unwtd
Comorbidity
Frequency
Diabetes W/O Coml.a
Hypertension
Hyperlipidemia
Back Disorders
Lower Resp. Disordersb
Upper Resp. Disordersc
Thyroid Disorders
Heart Disease
Injury
Headache
Eye Disorders
Urinary Tract Infections
Cerebrovascular
Disease
Kidney Disease
Anemia/Deficiencies
Diabetes W. Compl.d
Hernias
Osteoporosis
Gall Bladder Disease
Epilepsy/Convulsions
Cancer
Substance Abuse

Wtd %

P value
Wtd %
97.1
73.1
67.9
15.2
13.5
14.1
13.2
10.4
11.2
4.3
9.3
6.4

0.122
0.004*
0.001*
<0.001*
<0.001*
0.003*
0.023*
<0.001*
0.004*
<0.001*
0.554
0.037*

172

4.9

0.004*

203
147
81
61
97
57
41
4
14

6.6
4.2
2.6
2.3
2.8
2.1
0.9
0.1
0.4

0.874
0.018*
0.117*
0.032*
0.758
0.713
0.077*
0.327
0.051^

a: Diabetes without complications.
b: Diabetes with complications.
c: Lower respiratory disorders.
d: Upper respiratory disorders.
*: The Cochran-Mantel-Haenszel statistic was used to compare categorical variables. Significance at p value 0.05
as derived from ChiSquare.
^: The Fischer’s Exact Test was used to compare categorical variables. Significance at p value 0.05 as derived from
Fishcer’s Exact Test.
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Table 2.5 Frequency Of Preventive Care Service Use Stratified By Year
(2008 – 2011)

Year

Total

2008

2009

2010

2011

Receip
t

Unwtd Freq
(WTD%)

Unwtd Freq
(WTD%)

Unwtd Freq
(WTD%)

Unwtd Freq
(WTD%)

Unwtd Freq
(WTD%)

YES

3,689 (81.1)

867 (78.9)

946 (79.2)

891 (82.8)

985 (83.4)

NO

979 (18.9)

254 (21.1)

279 (20.7)

215 (17.2)

231 (16.5)

YES

2,433 (53.4)

533 (49.8)

619 (51.6)

599 (54.8)

682 (56.4)

NO

2,235 (46.5)

588 (50.1)

606 (48.3)

507 (45.1)

534 (43.5)

YES

3,073 (69.4)

695 (64.9)

775 (66.6)

757 (73.4)

846 (72.8)

NO

1,595 (30.5)

426 (35.0)

450 (33.3)

349 (26.5)

370 (27.1)

Influenza
Vaccination

YES

2,330 (53.1)

530 (50.1)

588 (51.5)

566 (54.4)

646 (56.2)

NO

2,338 (46.9)

591 (49.9)

637 (48.4)

540 (45.5)

570 (43.7)

Dilated Eye
Exam

YES

2,388 (53.5)

527 (49.2)

620 (51.4)

574 (55.1)

667 (58.6)

NO

2,280 (46.4)

594 (50.7)

605 (48.5)

532 (44.9)

549 (41.3)

Blood
Pressure
Check

YES

4,517 (97.5)

1,086 (97.4)

1,184 (97.1)

1,074 (98.2)

1,173(97.6)

NO

151 (2.4)

35 (2.5)

41 (2.8)

32 (1.7)

43 (2.3)

Routine
Medical
Check

YES

4,158 (90.1)

977 (87.9)

1,076 (88.6)

986 (90.6)

1,119 (93.1)

NO

510 (9.8)

144 (12.1)

149 (11.3)

120 (9.4)

97 (6.9)

Preventive
Service

A1C Tests

Diabetic
Foot Check

Lipid Check
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Figure 2.3: Comparing The Utilization Of Preventive Care Services In Diabetic
Patients With And Without Depression

(+): Presence of Depression
(-): Absence of Depression
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Table 2.6: Results Of The Multivariable Logistic Regression: Effect Of Comorbid
Depression On The Receipt Of Diabetes Preventive Care Services.
Preventiv
e
Service

Samp
le
Size

Crude
Odds Ratios
(95% CI)

Adjusted
Odds Ratios
(95% CI)

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

1.19
(1.01 – 1.44)

1.03
(0.83 – 1.28)

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

1.20
(1.01 – 1.42)

1.12
(0.94 – 1.34)

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

1.11
(0.94 – 1.32)

1.07
(0.88 – 1.30)

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

1.06
(0.88 – 1.28)

1.02
(0.83 – 1.25)

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

0.94
(0.79 – 1.11)

0.93
(0.76 – 1.12)

Depressio
n Status

A1C
Testing

Diabetic
Foot
Exam

Lipid
Check

Influenza
Vaccination

Dilated Eye
Exam
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Adjusted For
Age, Gender, Race and
Ethnicity
Insulin use, Income level,
Employment Status, Perceived
health Status, BMI Status,
Marital Status, Smoking Status,
Primary Care Provider,
Anemia, Back Disorders,
Hyperlipidemia and
Hypertension.

Age, Gender, Race and
Ethnicity, Insulin Use,
Perceived Health Status,
Hyperlipidemia

Age, Gender, Race and
Ethnicity, Income Level, Insulin
Use, Educational Status,
Perceived Health Status,
Smoking Status, Marital
Status,,
Primary Care Physician,
Hyperlipidemia, and
Headaches.
Age, Gender, Race and
Ethnicity, Insulin Use, Income
Level, Perceived Health Status,
Educational Status,
Employment Status, Smoking
Status,, Primary Care
Physician, Headaches, Back
Disorders, Upper Respiratory
Disorders, Hypertension,
Hernia and Hyperlipidemia.
Age, Gender, Race and
Ethnicity, Income Status,
Perceived Health Status,
Educational Status,
Employment Status, Insurance
Status,
Primary Care Provider, Marital
Status,
Hypertension, Hyperlipidemia
and Back Disorders.

Routine
Medical
Checkup

Non
3,460
Depressed

1.00
(REF)

1.00
(REF)

Depressed 1,208

0.80
(0.63 – 0.99)

0.81
(0.60 – 1.10)

76

Age, Gender, Race and
Ethnicity, Income Status,
Perceived Health Status,
Educational Status,
Employment Status, Back
Disorders, Insurance Status,
Primary Care Provider,
Hypertension, Marital Status
and Hyperlipidemia
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3.1 Background

Hypoglycemia is a serious complication that is associated with the treatment of
diabetes resulting in a significant burden to the patients with diabetes. 166While most
hypoglycemic events are mild and self-managed, more severe hypoglycemic events
require medical assistance and result in the development of serious complications. It
is well documented that despite the variations in severity, hypoglycemia is known to
cause negative health outcomes including increased morbidity, decreased quality of
life, and rare occurrences of mortality in patients with diabetes.167 The most common
symptoms associated with hypoglycemia include palpitations, trembling, sweating,
hunger, and confusion.168 Long-term consequences of hypoglycemia include weight
gain, cardiovascular diseases, and coma.167 Even though the symptoms and
complications of diabetes differ among patients, a great degree of decline in
cognitive and motor function as well as hormonal counter regulation has been
previously documented.169 The fear of severe hypoglycemia requiring clinical
assistance can seriously compromise the self-management of diabetes thereby
causing the patients to prefer sub-optimal blood glucose control over incidents of
hypoglycemia.170
Though the estimates regarding the incidence of hypoglycemia in Type 2 Diabetes
(T2DM) are varied, previous studies identify several factors associated with
hypoglycemia.167,168,171-174 For example antidiabetic medications, particularly insulin
and sulfonylureas (SUs), are among the principal risk factors for developing
hypoglycemic events.175-178 This is concerning as intensive therapy with antidiabetic
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drug agents is strongly associated with improvement in diabetes control including
reducing the risk of developing micro- and macrovascular complications.95,179,180
Similarly, many patient specific factors are also associated with the development of
hypoglycemia. These factors include age and gender as well as physiological factors
(e.g. chronic kidney disease and liver disease).177,181 Lastly, certain behaviors like
continuity of physical exercise, intake of food and consumption of alcohol also
increase the risk of hypoglycemia.168,173
Apart from the clinical impact, hypoglycemia has also been shown to pose a
significant financial burden to the patient as well as the health care system 167,177,182.
For example, Pelletier and colleagues estimated that the mean annual allowed
charge for hypoglycemia was $345 (2007 US dollars).183 Similarly, Quilliam et al.
estimated the rate and costs of hypoglycemia among working-age patients with type
2 diabetes and found the total hypoglycemia costs accounted for 1.0% of all inpatient
costs, 2.7% of ED costs, and 0.3% of outpatient costs. The mean costs for
hypoglycemia visits were estimated to be $17,564 for an inpatient admission, $1387
for an ED visit, and $394 for an outpatient visit. The authors concluded that
hypoglycemia was associated with higher costs as compared to other diabetic and
non-diabetic costs.184 These higher costs might be direct costs because of primary
care visits, emergency room visits, hospitalizations etc. or indirect costs resulting
from absence from work, disability, premature retirement and reduced
productivity.185,186
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The incidence and effects of hypoglycemia are more pronounced in insulin treated
type 1 diabetes mellitus (T1DM). Hence, though the predictors and costs of
hypoglycemia have been well outlined for T1DM, there is a paucity of research
regarding the factors that cause hypoglycemia specifically in patients with type 2
diabetes mellitus (T2DM). Moreover, due to the varied definitions of hypoglycemia
operationalized in various studies and other methodological differences, findings
from these studies often lack generalizability. As the incidence rates of people
suffering from diabetes will almost double by 2050,

2

more research on this

devastating complication of antidiabetic treatment is warranted. Hypoglycemic
events will continue to place a greater strain on the health care costs and resources.
To expand on previously published studies, we conducted a cross sectional study of
persons with T2DM using an insurance claims database to identify predictors and
outline the costs of hypoglycemia treated in an outpatient or inpatient setting.
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3.2 Methods

3.2.1 Datasource
For the purpose of our study, we used the Blue Cross and Blue Shield Of Rhode Island
(BCBSRI) administrative claims data for the years 2009 - 2012. BCBSRI is a non-profit
hospital service and medical service corporation covering more than 600,000
members. In the data extract used for our analyses, all the members had at least one
International Classification of Disease-9 (ICD-9) code for diabetes (ICD-9 250.XX)
between 2009 and 2012. To achieve the aims of our study, we utilized three
administrative files, including: eligibility files, medical claims (inpatient and
outpatient) and pharmacy claims. The enrollment file included age, gender as well as
the start and end dates for enrollment in the health plan. Similarly, the outpatient
and inpatient files include diagnosis information (ICD-9 codes), Current Procedural
Terminology (CPT) codes, admit and discharge dates as well as cost and copayment
information. The medication claims dataset included prescription medications
dispensed during the study period and included the National Drug Codes (NDC), drug
product names, prescription quantity (number of units dispensed) and days supplied
at the time of dispensing (e.g. 30 day supply of medication). Due to the
comprehensive nature of the claims provided in the dataset, it can be assumed that
this dataset provides a near complete picture of an individual’s health care.
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3.2.2 Research design and study population
Using the medical claims, inpatient and outpatient, as well as prescription claims, we
conducted a cross sectional study. All the patients included in the dataset had a
diagnosis of diabetes. As our interest was in factors associated with hypoglycemia in
T2DM, we further excluded patients who had at least one claim for type 1 diabetes
(ICD-9 250.X1 or 250.X3) or gestational diabetes (ICD-9-CM 648).
3.2.3 Identification of Hypoglycemia
The principal objective of our study was to identify independent predictors of
hypoglycemia in T2DM. In order to identify hypoglycemia in the inpatient and
outpatient medical settings, we used an algorithm designed by Ginde and
colleagues187. Within this algorithm, specific codes related to hypoglycemia (251.0
251.1 251.2 270.3 775.0 775.6 962.3) are first directly classified as a hypoglycemic
event. Secondarily, additional instances of hypoglycemia are identified using ICD- 9
code of 250.8 in the absence of other contributing diagnoses (ICD -9 259.8, 272.7,
681.XX, 682.XX, 686.9X, 707.1-707.9, 709.3, 730.0-730.2, or 731.8). This algorithm is
well validated and demonstrated a positive predictive value of 89% for detecting
hypoglycemia visits.187 As all episodes of hypoglycemia identified in our study
required medical intervention, we considered these events as serious and thus will
utilize this terminology in the presentation of our results. Using this information, we
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created two groups, those with at least one serious hypoglycemic event (n=1243) and
those who did not have a serious hypoglycemic event (n=28,128).
2.4 Identification of Independent Predictors
We assessed the relevant demographic characteristics of the sample population
including age (18-34, 35-49, 50-64, 65 and above) and gender. We used the
Charlson’s Comorbidity Index in order to examine the composite impact of the
burden of comorbid diseases on the risk of having a hypoglycemic event. In addition,
we also defined the prevalence of specific individual comorbidities predictors of
hypoglycemia using the Elixhauser Comorbidity Index. Previous studies have
identified other diabetes micro- and macrovascular complications that might be
predictive of hypoglycemia in patients. We also identified the presence of these
complications as well as other diseases like influenza and pneumonia, which can
potentially to increase the likelihood of a hypoglycemic event.183,188,189 In case of an
overlap of the conditions, we considered the condition defined under one set of
comorbidities preferably in the order of elixhauser comorbidity index, micro and
macrovascular complications and other diseases.
3.2.5 Characterizing The Use Of Medications
We use a combination of National Drug Codes (NDC) and drug product names in
order to identify the use of both diabetic and non-diabetic medications that might
have an association with the incidence of hypoglycemia. Among the antidiabetic
medications, we specifically identified the use of all the major classes of oral
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antidiabetic medications including biguanides, sulfonylureas (SUs), a-glucosidase
inhibitors, DPP-4 inhibitors (DPP), meglitinides , thiazolidinediones (TZDs) as well as
insulin. With respect to the other medications, we identified use of other
medications previously suggested to cause hypoglycemia: angiotensin-converting
enzyme (ACE) inhibitors, allopurinol, angiotensin II receptor blockers (ARBs),
benzodiazepines,

b-blockers,

fibrates,

fluoroquinolones,

nonsteroidal

antiinflammatory drugs (NSAIDs), trimethoprim, and warfarin.173,190-192
3.2.6 Estimating Costs
In order to examine the medical costs for hypoglycemia, we used the total allowed
amount paid for the services for both inpatient and outpatient encounters. In
addition to the measurement of total costs, we also stratified the costs into 3
mutually exclusive groups namely costs related to hypoglycemia as identified using
the Ginde algorithm;187 costs related to other diabetes-related claims as identified by
primary ICD-9 250.XX); and costs related to all other claims. We classified all the
episodes occurring on the same day as a single episode of care. All the costs were
adjusted to 2012 equivalents (final year of available data) using the regional
Consumer Price Index medical care expenditure category in order to make accurate
comparison of costs across all study years.
3.2.7 Statistical Analyses
We created two groups for comparison in our study, those with a serious
hypoglycemic event and those without. We compared the prevalence of the selected
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covariates among the patients with or without any hypoglycemic events by
examining the frequencies and thereafter using the Cochran-Mantel-Haenszel
statistic for categorical variables and Student's t-test for continuous variables. We
then selected all the variables with a p-value of less than 0.25 in these preliminary
bivariate analyses. We then developed a predictive logistic regression model using
the variables identified in the above process, initially fitting a preliminary model
containing all of the above variables and then further refining it using a manual
iterative process of refinement. During this process, we sequentially excluded
variables that were not contributing significantly to the model (Wald p-value >0.10)
and thus were potentially not associated with hypoglycemia. Further, we carried out
likelihood ratio testing in order to confirm the exclusion. After identifying a working
model with all of the relevant predictors included, we further assessed
multicollinearity in the model. For this purpose, we used the variation inflation factor
(VIF), and Eigen values to make the decisions on exclusion of collinear variables.
These were calculated utilizing a separate regression model and specifically using the
VIF, TOL, and Collin options. If two variables were found collinear, we included the
variable that was clinically more relevant to our analysis. We tested all two-way
interactions between the independent variables in a stepwise process that was
similar to the one used to in order to build the initial model (using likelihood ratio
testing for confirmation). We retained each interaction term if it was significant and
continued this process until all interaction terms were either removed from the
model, or retained if found significant. We used AIC (the Akaike Information
90

Criterion) and Hosmer-Lemeshow test to assess goodness of fit at all steps of building
the final model. At the end of this process we then reported multivariable (adjusted)
odds ratios (AORs), including their respective 95% confidence intervals (95% CI). For
the cost analyses, we conducted Student t-tests to compare mean costs across the
created cost subgroups. All statistical tests were conducted with a 2-tailed alpha of
0.05. All analyses were performed using SAS software version 9.3 (SAS Institute Inc.,
Cary, NC). This study was reviewed and approved as exempt by the University of
Rhode Island’s Institutional Review Board.

91

3.3 Results
3.3.1 Demographics
The initial dataset of patients with diabetes was compromised of 36,954 individuals
identified as having diabetes (ICD-9 250.xx). After excluding the patients with type 1
diabetes or gestational diabetes (n=7,240) as well as patients below the age of 18
(n=343), our final analytic sample included 29,371 patients with T2DM. Among the
eligible sample, 1,243 (4.2%) patients experienced a serious hypoglycemic event over
the three-year period while 28,128 (95.7%) patients did not have any reported
hypoglycemic events. The demographic characteristics of the study sample stratified
by the presence of serious hypoglycemia are described in Table 3.1. Overall, the
mean age was 61.4 years and was slightly higher in the patients with serious
hypoglycemic events as compared to those who did not (65.3 Vs 61.2, respectively).
When divided into specific age groups, it could be seen that that 46.7% (580 patients)
of the hypoglycemic group had an age above 65 years in comparison to the 9,716
patients(46.7%) in the non-hypoglycemic group (χ2: 80.62, p-value: <0.001).
Moreover, the observed gender distribution was similar across both groups with the
proportion of females being lower in both hypoglycemic (567 patients, 45.6%) and
non-hypoglycemic groups (13,275 patients, 47.2%)
3.3.2 Clinical Characteristics
Comparison of clinical characteristics in patients with or without serious
hypoglycemia revealed a higher prevalence of comorbidities in the hypoglycemic
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group (Table 3.2). Overall, the Charlson’s comorbidity score describing the burden of
other diseases was found to be higher in the hypoglycemic group (mean = 2.97 +/1.18) than the non-hypoglycemic group (mean=2.15 +/- 1.20; t=36.22; p value
<0.001). When divided into separate groups, it was found that 250 patients in the
hypoglycemic group (20.1%) and 12,690 patients in the non-hypoglycemic group
(45.1%) had a score of 0 indicating a higher percentage of patients in the nonhypoglycemic group did not suffer from any comorbidities. In contrast, 607 patients
in the hypoglycemic group (48.8%) and 6,160 patients from the non-hypoglycemic
group (21.9%) had a score of greater than 3, indicating a greater proportion of
patients in the hypoglycemic group suffering a higher burden of comorbidities
(X2=566.30; p-value: <0.001). Table 3.3 also provides more detail on individual
comorbidities (as identified using the Elixhauser Comorbidity Index). 193 The most
commonly observed comorbidities had a higher prevalence in the hypoglycemic
group as opposed to the non-hypoglycemic group. For example, congestive heart
failure (28.3% vs 8.0%, χ2: 353.31, P value <0.001), cardiac arrhythmias (26% vs 13%,
χ2: 170.5, p value: <0.001), valvular disease (13.4% vs 7.4%, χ2: 60.79, χ2: 60.79 p
value <0.001), peripheral vascular disorders (27.8% vs 11.6%, χ2: 289.3, p value:
<0.001), hypertension uncomplicated (61.85%), chronic pulmonary disease (66.3% vs
61.6%, χ2: 11.24, p value: 0.0008), hypothyroidism (16.7% vs 13.3%, χ2: 11.43, p
value: 0.0007), solid tumor without metastasis (16.0% vs 10.5%, χ2: 36.22, p value:
<0.001)and depression (19.7% vs 13.7%, χ2: 2339.59, p value: <0.001). Some of the
least frequent comorbidities also displayed a higher prevalence in the hypoglycemic
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group. For example, paralysis (1.7% vs 0.4%, χ2: 43.03, p value <0.001), peptic ulcer
disease excluding bleeding (1.5% vs 0.7%, χ2: 9.28 p value : 0.002), lymphoma (1.7%
vs 0.9%, χ2: 7.83 p value: 0.005) and metastatic cancer (2.9% vs 1.3%, χ2: 20.86, p
value: <0.001). Moreover, as seen in table 3.4the most prevalent macrovascular and
microvascular complications of diabetes demonstrated higher prevalence in the
hypoglycemic group. . For instance coronary artery disease (33.0% vs 18,7%, χ2:
156.77, p value: <0.001),arrhythmias (15.7% vs 7.1%, χ2:126.45, p value: <0.001),
stroke (7.5% vs 2.2, χ2: 98.32, p value: <0.001)peripheral vascular disease (36.2% vs
15.4%, χ2: 380.37, p value: <0.001), diabetic retinopathy (20.8% vs 13.7%, χ2: 49.9, p
value <0.001), diabetic neuropathy (5.7% vs 2.0%, χ2: 74.7, p value: <0.001) and
ulcers (27.2% vs 5.3%, χ2: 969.8, p value: <0.001) were all observed to a higher
degree in the hypoglycemic group. Among the other diseases that might contribute
to the increased likelihood of having a hypoglycemic event, liver disorders (6.6% vs
4.3%, χ2: 14.07, p value: 0.0002) were highly prevalent while Addison’s disease (1%
vs 0.1%, χ2: 38.13, p value: <0.001) were rarely observed. The presence of these
comorbidities was also significantly higher in the patients who had any events of
hypoglycemia.
3.3.3 Use of Medications
The mean number of medications (SD) taken was higher in the patients in the
hypoglycemic group (mean=15.31 +/- 12.21) as compared to those in the nonhypoglycemic group (mean=10.97 +/- 9.63; t=56.78; p value 0.001). We further
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assessed the use of diabetes and non-diabetes medications (Tables 3.5 - 3.7). Overall,
the use of diabetic medications was common. Moreover, the use of these
medications was significantly higher in the hypoglycemic group as compared to the
non-hypoglycemic group. Specifically, 2,873 (9.5%) patients were using insulin with
the use being significantly higher in the hypoglycemic group as compared to the nonhypoglycemic group (24.14% vs 9.14%; χ2= 303.24; p-value: <0.001). The use of
metformin (42.8%) was found to be high within the overall sample but comparable in
the hypoglycemic and non-hypoglycemic groups (42.5% vs 42.8%). Furthermore,
7,821 patients (26.6%), 2,881 patients (9.8%) and 2,458 (8.4%) patients were being
prescribed sulfonylureas, TZDs and DPP respectively with the use being higher in
patients in the hypoglycemic group. More specifically, use of sulfonylureas (41.5% vs
26.0%; χ2=147.17; p-value: <0.001), TZDs (11.6% vs 9.7%; χ2=4.62; p value: 0.03) and
DPP-4 (9.7% vs 8.3%; χ2=2.79; p value: 0.09) were more prevalent in those with
serious hypoglycemia compared to those without. The use of other classes of
diabetic medications like alpha glucosidase inhibitors (0.3%) and meglitinides (0.9%)
was relatively rare and comparable in the hypoglycemic and non-hypoglycemic
groups. Overall, it can be seen from Table 3.5 that 34.9% of the hypoglycemic group
and 46.8% of the non-hypoglycemic group were not taking antidiabetic medication.
Similarly, as seen in Table 3.6, the prevalence of use of non-diabetic medications was
also significantly higher in the hypoglycemic group as compared to the nonhypoglycemic group. Furthermore, 11,097 patients and 7,888 patients were
prescribed ACE inhibitors (44.2% in hypoglycemic group and 37.5% in non95

hypoglycemic group; χ2=22.51; p value: <0.001) and beta-blockers (38.9% in
hypoglycemic group and 26.3% in non-hypoglycemic group; χ2=96.44; p value:
<0.001). Use of ARBs was more comparable between the two groups) 9.7% in
hypoglycemia group versus 8.6% in non-hypoglycemia group). In contrast, use of
other medications was much more common in those with hypoglycemia than those
without hypoglycemia. For example warfarin (12.71% in hypoglycemic group and
5.40% in non-hypoglycemic group; χ2=118; p value: <0.001), fluoroquinolones (33.1%
in hypoglycemic group and 21.8% in non-hypoglycemic group; χ2=87.37; p value:
<0.001), fibrates (8.6% in hypoglycemic group and 7.6% in non-hypoglycemic group;
χ2=1.61; p value: 0.20) and NSAIDs (27.7% in hypoglycemic group and 28.5.% in nonhypoglycemic group; χ2=0.37; p value: 0.53). Use of other evaluated agents was
similar between the two groups and is presented in Table 3.6.
3.3.4 Results Of Multivariable Logistic Regression
The results of the multivariable logistic regression analyses are presented in Table
3.7. While using the age group of 18 – 34 years as our reference, it was seen that
with increasing age the relative likelihood of hypoglycemia generally decreased. For
example, the AOR of patients aged 35 – 49 years was 22% lower (AOR 0.78; 95% CI
0.51 to 1.18) while the AOR for patients aged 50 – 64 years decreased by 24% (AOR
0.76; 95% CI 0.78 to 0.85). The lowest risk of a hypoglycemic event was found in the
patients who were aged 65 or above (AOR 0.71; 95% CI 0.47 to 1.07). With respect to
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gender, it could be seen that both male enrollees had a 4% higher but statistically
insignificant relative rate of hypoglycemia (AOR 1.04; 95% CI 0.92 to 1.18).
For other factors, there was an increased likelihood of severe hypoglycemia in
patients with higher overall burden of disease as measured by the Charlson’s
comorbidity index. As compared to patients with a comorbidity score of 0, patients
with a comorbidity score of 1 were 38% (AOR 1.67; 95% CI 1.01 to 2.78) more likely
to have a serious hypoglycemic event. Similarly, the relative risk of a serious
hypoglycemic events in patients with a comorbidity score 2 (AOR 2.05; 95% CI 1.70)
and those with a 3 or more (AOR 2.12; 95% CI 1.73 to 2.59) were more than twice
that of patients with a comorbidity score of 0. In addition, presence of any claims for
congestive heart failure (AOR 1.24; 95% CI 1.04 to 1.49), peripheral vascular disorders
(AOR 1.19; 95% CI 1.02 to 1.40), paralysis (AOR 1.67; 95% CI 1.01 to 2.78),
neurological disorders (AOR 1.52; 95% CI 1.22 to 1.89), obesity (AOR 1.30; 95% CI
1.01 to 1.67), fluid and electrolyte disorders (AOR 1.31; 95% CI 1.09 to 1.57),
deficiency anemia (AOR 1.37; 95% CI 1.13 to 1.67) and psychoses (AOR 1.60; 95% CI
1.19 to 2.14) was associated with a higher relative rate of any serious hypoglycemic
events. Among other macro-and microvascular complications of diabetes, claims for
acute renal failure (AOR 1.67; 95% CI 1.01 to 2.78), ulcers (AOR 4.07; 95% CI 3.50 to
4.72), amputations (AOR 2.73; 95% CI 1.26 to 5.91) and Addison’s disease (AOR 3.17;
95% CI 1.64 to 6.14) displayed a significantly higher relative risk of hypoglycemia. In
contrast, patients who suffered from hypertension demonstrated a 16% reduction in
the relative rate for hypoglycemia events (AOR 0.84; 95% CI 0.74 to 0.97).
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While evaluating the effect of medication use on the likelihood of hypoglycemic
episodes, it was seen that patients who were using 4-7 unique drugs were least likely
to suffer any hypoglycemic event (AOR 0.48; 95% CI 0.36 to 0.64). Similarly, patients
using between 8 – 10 medications (AOR 0.59; 95% CI 0.44 to 0.80) as well as patients
using more than 10 medications (AOR 0.66; 95% CI 0.56 to 0.79) had a 41% and 34%
reduction in the risk of any hypoglycemia event. Most of the antidiabetic medications
were associated with higher relative rates of hypoglycemia. Moreover, patients using
insulin were more than twice as likely as those not using insulin to have any
hypoglycemia related claims (AOR 2.20; 95% CI 1.88 to 2.56). Similarly, among the
oral antidiabetic medications, sulfonylureas (AOR 1.71; 95% CI 1.49 to 1.97) and
meglitinides (AOR 1.75; 95% CI 1.14 to 2.70) were associated with a 71% and 75%
increased relative risk for a serious hypoglycemic events.
3.3.5 Results Of Cost Analyses
Table 3.8 presents the results of the costs analyses. We estimated that 0.5% of
inpatient encounters were associated with hypoglycemia. Moreover, 6.9% of the
inpatient visits were for other diabetes related outcomes while the remaining 92.6%
of the visits were recorded for non-diabetes related care. Hypoglycemia related visits
accounted for 0.7% of the total inpatient costs while non-hypoglycemia related
diabetes costs accounted for 1.4%. The mean cost for inpatient visits for
hypoglycemia was $1,514.60. In comparison, the mean cost for an inpatient visit for
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non-hypoglycemia related diabetes outcomes and non-diabetes related outcomes
was $232.71 and $1,171.60 respectively (p value <0.001). Similarly, hypoglycemia
accounted for 0.2% of the total outpatient visits while non-hypoglycemia related
outcomes and non-diabetes related outcomes were responsible for 14.4% and 54.4%
of the outpatient visits respectively. In case of the outpatient visits, the estimated
costs for hypoglycemia were 0.2% of the total costs while non-hypoglycemia related
diabetes costs were 7.6% of the total outpatient costs. The mean cost of outpatient
visits for hypoglycemia, non-hypoglycemia related diabetes outcomes and nondiabetes related outcomes were $142.91, $83.93 and $182.63 respectively (p value
<0.001).
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3.4 Discussion
Our cross sectional study sought to identify the principal predictors of serious
hypoglycemia (requiring inpatient or outpatient medical intervention) and estimate
the related costs. Within our analyses, we considered a range of demographic and
clinical factors such as age, gender, comorbid diseases, as well as medication use as
potential predictors in our analysis. Though there have been previous studies
highlighting the risk factors for hypoglycemia in various settings (for example, solely
in the emergency department), our results provide a comprehensive evaluation of
serious hypoglycemic events requiring medical intervention. Our study adds to the
valuable literature thereby providing greater insights into management of
hypoglycemia and health care resource use in patients with diabetes.
Previous literature has found several clinical, physiological as well as drug related
factors to have a significant impact on the rates of hypoglycemia in patients.190,194,195
Some of the important predictors that we identified in our study were comorbidities
including congestive heart failure, peripheral vascular disorders, hypertension,
paralysis, neurological disorders, obesity, fluid and electrolyte disorders, anemia,
psychoses, acute renal failure, ulcers, amputations, Addison’s disease as well as a
combined Charlson’s comorbidity score. For example, in a case control study to
analyze the clinical characteristics as well as risk factors that might be associated with
hypoglycemia in non-diabetic hospitalized older adults, Shilo et al. found that low
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plasma albumin level, liver disease, malignancy, and congestive heart failure were
significant predictors of hypoglycemia.196 Similarly, Simeone et al., conducted a study
to identify predictors of hypoglycemia-related emergency department and
outpatient visits in patients with type 2 diabetes. They found that coronary artery
disease (AOR 1.38; 95% CI 1.29 to 1.49), heart failure (AOR 1.70; 95% CI 1.49 to 1.93),
peripheral vascular disease (AOR 1.80; 95% CI 1.60 to 2.02), arrhythmia (AOR 1.22;
95% CI 1.04 to 1.44), and stroke (AOR 1.81; 95% CI 1.41 to 2.32) were all significantly
increasing the risk of a hypoglycemic event with ulcer demonstrating a 6 fold increase
in the likelihood of hypoglcyemia.173 Similarly, renal failure has also been shown to
have a significant association with incidence of hypoglycemia.197 For example, DuránNah and colleagues attempted to identify risk factors associated with symptomatic
hypoglycemia and found a threefold increase in the rate of hypoglycemia in patients
suffering from renal failure (AOR 3.0; 95% CI 1.20 to 7.70).198 Furthermore, our
findings are also consistent with other studies, which have previously identified
various macrovascular, microvascular, as well as other comorbidities as important
risk factors for hypoglycemia.166,169,199,200 Our results were in contrast with some
studies that have previously found a protective effect with an increase in the Body
Mass Index (BMI).172,197,201 For example, while exploring the potential determinants
for severe hypoglycemia 10,251 participants, Miller et al. found that BMI of 30 or
higher resulted in a 35% reduction of hypoglycemia as compared to a BMI of less
than 25 (Hazard Ratio[HR] 0.65, 95% CI 0.5 to 0.85). Possible reasons for this might
be poor nutrition as well as irregular food intake.
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With respect to other patient level factors like age, gender as well as certain
comorbidities, we found that there was no significant association with the incidence
of hypoglycemia. There has been contrasting evidence in literature regarding the risk
of hypoglycemia associated with these factors. Age has been previously
demonstrated to be a significant predictor of hypoglycemia. For example, the
ACCORD and ADVANCE trials reported a 3% and 5% increase in risk for hypoglycemia
with each additional year of age, respectively.178,200-203 Previous research suggests
that along with the physiological changes that occur in the body with advancing age,
other mechanisms that might contribute to incidence of hypoglycemia include
decreased hypoglycemia awareness as well as decreased counter regulatory
response to low blood glucose.175,204 However, in contrast some studies hypothesize
age to have a protective effect with the risk of hypoglycemia decreasing with
increasing age.173,198 Other studies demonstrate no association between age and
hypoglycemia.166,205 In our study, we found a clinically significant (but non-statistically
significant) trend towards a protective effect. While evaluating gender as a predictor,
there have been conflicting results in literature. For example, studies including the
ADVANCE trial demonstrated no significant association between gender and the
likelihood of hypoglycemia.166,197,201On the other hand, the ACCORD trial,
demonstrated a higher risk of a hypoglycemic event for women (Hazard Ratio= 1.21,
95% CI 1.02 to 1.43).200 Some observational studies have provided evidence of a
lower rate of hypoglycemia in females as compared to males.173,205 A possible
explanation that is postulated for this gender variation in the incidence of
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hypoglycemia is that even though women are more likely to use health care
resources to a higher degree, it might be a result of a higher morbidity rate compared
with men.206 On the other hand there are known physiological differences between
males and females with a known relative reduction of counter regulatory responses
in females that might also contribute to the incidence of hypoglycemia.173,207
There has been considerable evidence that various treatment modalities might result
in a higher propensity to suffer from hypoglycemia through various mechanisms like
increase in insulin sensitivity.208 In our study, we found that a higher number of
medications used by the patient increased the risk of hypoglycemia. This finding is
corroborated by other studies, which provided similar evidence regarding
polypharmacy.209,210 For example, Shorr et al in a study of 19,932 Tennessee
Medicaid enrollees, aged 65 years or older found that patients using drugs from 5 or
more therapeutic classes had a 30% increase in the likelihood of having a
hypoglycemic event.211 With respect to oral antidiabetic medications, we found a
significantly increased risk with insulin, sulfonlyureas and meglitinides. Even though
tight glycemic control Is being increasingly recommended in clinical practice, this has
shown to pre-dispose patients to an increased risk of hypoglycemia.208 For example, a
prospectively planned group-level meta-analysis of various largescale trials
demonstrated a two-fold increase in the risk of developing severe hypoglycemia in
patients who were underwent intensive glucose lowering therapy.212 Similarly, both
prospective trials and retrospective studies have consistently demonstrated the
higher risk of hypoglycemia events with insulin.169,199,213-215 This risk however varies
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with the patient’s medication regimen as well as the severity of the person’s
diabetes.190 However, fear of hypoglycemia is known to prolong the initiation of
insulin therapy in patients thereby seriously compromising the achievement of
glycemic goals.216 Similarly, sulfonylureas have also traditionally been associated with
an additional risk of hypoglycemia.169,190,215,217 For example, Bodmer et al. conducted
a nested case control study to compare the risk of lactic acidosis and hypoglycemia
among patients with type 2 diabetes using oral antidiabetic drugs and found that
sulfonylureas had a substantially higher risk of causing hypoglycemia (AOR 2.79 95%
CI 2.23–3.50).197 Literature suggests that meglitinides have a lower potential to cause
hypoglycemia as compared to insulin and sulfonylureas.94 Interestingly, we found no
significant association between the biguanide class of medications and incidence of
hypoglycemia. There has been prior evidence of these drugs having a reduced
hypoglycemic effect and hence are usually used as first line therapy. We did not find
any association between the use of non-diabetic medications like allopurinol,
warfarin, fibrates, NSAIDs, or B-blockers with severe hypoglycemia in multivariate
analyses. The use drugs have previously shown an increase the likelihood of
incidence of hypoglycemia.166,190,218
Moreover, incidence of hypoglycemia has been associated with significant health
care resource use as well as direct and indirect economic burden in previous
literature.184,208,219,220 Due to under reporting of hypoglycemia itself, these cost
estimates are often underestimated. In our study, hypoglycemia related visits were
accountable for 0.7% and 0.2% of the total costs for inpatient and outpatient visits
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respectively. Our results might differ from results described in other studies due to
variations in the methods to measure costs as well as definitions of hypoglycemia.
For example, we calculated the cost estimates based on total amount that was paid
for the services, which included the copay amounts. Heaton et al. in a study to
determine the incidence and economic cost of hypoglycemia in patients with
diabetes taking insulin found that mean cost per episode was $1,186 (range, $181$4,924) or $7.04 per patient per month.221 On the other hand, Quilliam et al. while
investigating the incidence rate and costs of hypoglycemia in patients with T2DM
estimated the mean costs per encounter for inpatient and outpatient visits for
hypoglycemia to be $17,564.25 and $ 393.64 respectively.184 Similarly, in a series of
studies conducted in three European countries, the average cost per hypoglycemic
event was found to be €537–688.222,223 It was interesting to note that most of the
hypoglycemia cost studies have been performed in patients who are being treated
with insulin with there being a scarcity of information on patients who are being
treated with non-insulin therapies.
Even though, the study provides valuable insights into the predictors and costs of
hypoglycemia in inpatient and outpatient settings, there are some inherent
limitations to our study. Since our data represents a regional health plan, the results
might not be generalizable to all patients with T2DM. Secondly, as with other studies,
our diagnoses of hypoglycemia only represents the most severe cases for which
medical assistance was necessary since only these may be considered as reliable
events.174,190,224 The true rates of hypoglycemia may be considerably higher than our
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estimates. Moreover, we could not elucidate the effects of certain clinical as
demographic aspects like blood glucose levels and race/ethnicity that are vital in the
progression of diabetes. Lastly, due to the cross sectional design of the study,
consideration of previous hypoglycemic events was beyond the scope of the study.
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3.5 Conclusions
Hypoglycemia is the principal and often underreported limiting factor in the
management of patients with T2DM. Considering the clinical and economic
implications of hypoglycemia, we conducted a cross sectional study to identify the
predictors and estimate the costs of a comprehensive definition of severe
hypoglycemia. Our study confirms that specific comorbidities as well as diabetic and
non-diabetic treatment modalities are significantly predictive of hypoglycemic
episodes. The cost estimates also provide evidence of the significant economic
burden associated with hypoglycemia. The inpatient episodes related to
hypoglycemia incur a much larger financial burden as compared to the outpatient
episodes of hypoglycemia. Considering the clinical burden of hypoglycemia, reducing
the incidence of this adverse event in diabetic patients will have a significant impact
on improvement of the quality of life of patients.
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Figure 3.1 : Final Patient Selection Flowchart
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Table 3.1: Demographic Characteristics of the study population Stratified by the
Hypoglycemia

Demographic
Characteristic
Agea
18 - 34
35 - 49
50 - 64
65 And Above
Gendera
Male
Female

Hypoglycemia
(n=1243)(%)

No Hypoglycemia
(n=28,128)(%)

Chi-Sq
Value

P Value

29 (2.33)
137 (11.02)
497 (37.38)
580 (46.66)

808 (2.87)
4,469 (15.89)
13,135 (46.70)
9,716 (34.54)

80.62

<0.001*

676 (54.38)
567 (45.62)

13,275 (47.19)
14,853 (52.81)

49.86

0.27

a: The Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
*: Significant at p value 0.05
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Table 3.2: Prevalence of Comorbidities as Measured by the Charlson Cormobidity
Index Stratified by the Presence of Serious Hypoglycemic Events

Demographic
Characteristic

Hypoglycemia
(n=1243)

No Hypoglycemia
(n=28,128)

Charlson’s Comorbidity Index (Categorical Variable)a
Cat 1 (0)+
250 (20.11)
12,690 (45.12)
Cat 2 (1)+
136 (10.94)
4,409 (15.67)
+
Cat 3 (2)
250 (20.11)
4,869 (17.31)
Cat 4 (3 and
607 (48.83)
6,160 (21.90)
above)+
Charlson’s Comorbidity Index (Continous Variable)b
Score
3.14 + (2.86)
1.50 + (2.03)

Test
Statistic
Value

P Value

529.82

<0.001*

36.22

<0.001

+: Category (Score).
a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
b: Mean + (Standard Deviation) & a paired t-test was used to compare continuous variables.
*: Significant at p value 0.05 as derived from Chi-square or T test.
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Table 3.3: Prevalence of Elixhauser Comorbidity Conditions Stratified by the
Presence of Serious Hypoglycemic Events
Chi-Sq.
Value

P Value

3 (0.24)
28 (2.25)
28 (2.25)
324 (26.07)
326 (26.23)
56 (4.51)
290 (23.33)
156 (12.55)
245 (19.71)
1,034 (83.19)
1,121 (90.19)
20 (1.61)
230 (18.50)
106 (8.53)
825 (66.37)
208 (16.73)
114 (9.17)
22 (1.77)
199 (16.01)
37 (2.98)
79 (6.36)
133 (10.70)
22 (1.77)

No
Hypoglycemia
(n = 28,128)
37 (0.13)
361 (1.28)
339 (1.21)
3,682 (13.09)
5,092 (18.10)
532 (1.89)
2253 (8.01)
1,607 (5.71)
3,853 (13.70)
6,317 (22.46)
25,172 (89.49)
230 (0.82)
1191 (6.79)
1190 (4.23)
17,341 (61.65)
3,764 (13.38)
1,732 (6.16)
271 (0.96)
2,979 (10.59)
391 ( 1.39)
1,388 (4.93)
1,059 (3.76)
124 (0.44)

1.05
8.55
10.58
170.15
52.22
41.45
353.31
98.62
35.84
2339.5
0.61
8.83
241.52
52.11
11.24
11.43
18.35
7.83
36.22
20.86
5.06
147.03
43.03

0.3043
0.0034*
0.0011*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
0.4343
0.0030*
<0.001*
<0.001*
0.0008*
0.0007*
<0.001*
0.0051*
<0.001*
<0.001*
0.0244*
<0.001*
<0.001*

19 (1.53)

211 (0.75)

9.28

0.0023*

346 (27.84)
70 (5.63)
65 (5.23)
199 (16.21)

3,272 (11.63)
469 (1.67)
700 (2.49)
1,224 (4.35)

289.36
103.84
35.24
350.93

<0.001*
<0.001*
<0.001*
<0.001*

Rheumatoid Arthritis/ Collagen
Vascular Diseases

87 (7.00)

1,284 (4.56)

15.85

<0.001*

Valvular Disease
Weight Loss

167 (13.44)
50 (4.02)

2,087 (7.42)
701 (2.49)

60.79
11.18

<0.001*
0.0008*

Elixhauser Comorbidity Indexa

Hypoglycemia
(n=1,243)

AIDS/HIV
Alcohol Abuse
Blood Loss Anemia
Cardiac Arrhythmias
Chronic Pulmonary Disease
Coagulopathy
Congestive Heart Failure
Deficiency Anemia
Depression
Diabetes Complicated
Diabetes Uncomplicated
Drug Abuse
Fluid And Electrolyte Disorders
Hypertension, Complicated
Hypertension, Uncomplicated
Hypothyroidism
Liver Disease
Lymphoma
Solid tumor without metastasis
Metastatic Cancer
Obesity
Other Neurological Disorders
Paralysis
Peptic Ulcer Disease Excluding
Bleeding
Peripheral Vascular Disorders
Psychoses
Pulmonary Circulation Disorders
Renal Failure

a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
*: Significant at p value 0.05 as derived from Chi-square
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Table 3.4: Prevalence of Micro and Macrovascular Diabetes Complications and
Other Contributing Diseases Stratified by the Presence of Serious Hypoglycemic
Events
Diabetes Complications

Arrhythmia
Congestive Heart Failure
Coronary Artery Disease
Peripheral Vascular
Disease
Stroke

Hypoglycemia
(n=1,243)

No
Hypoglycemia
(n=28,128)

Chi Sq.
Value

Macrovascular
196 (15.77)
262 (21.08)
411 (33.07)

2,016 (7.17)
1,911 (6.79)
5,269 (18.73)

126.45
354.51
156.77

<0.001*
<0.001*
<0.001*

451 (36.28)

4,334 (15.41)

380.37

<0.001*
<0.001*

171.89

<0.001*

7 (0.56)
66 (0.23)
5.18
3 (0.24)
12 (0.04)
9.24
71 (5.71)
574 (2.04)
74.70
259 (20.84) 3,861 (13.73)
49.90
339 (27.27)
1,508 (5.36)
969.82
Other Contributing Diseases
13 (1.05)
54 (0.19)
38.13
82 (6.60)
1,225 (4.36)
14.07
187 (15.04) 3,515 (12.50)
7.01

0.0228+
0.0024+
<0.001*
<0.001*
<0.001*

Acute Renal Failure
Amputation

195 (15.69)
9 (0.72)

765 (2.72)
98.32
Microvascular
919 (3.27)
503.27
61 (0.22)
12.87

Chronic Renal
Pathophysiology

131 (10.54)

951 (3.38)

Dialysis
End Stage Renal Disease
Diabetic Nephropathy
Diabetic Retinopathy
Ulcer
Addison's Disease
Liver Disease
Thyroid Disease

P value

94 (7.56)

a: n(%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
*: Significant at p value 0.05 as derived from Chi-square.
+: Significant at p value 0.05 as derived from Fischer’s Exact Test.
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<0.001*
0.0003+

<0.001*
0.0002*
0.0081*

Table 3.5: Concomitant Usage of Diabetic Medications Stratified by Exposure to
Hypoglycemia
Concomitant
Medicationsa

Hypoglycemia
(N = 1243)

No
Hypoglycemia
(N = 28,128)

Chi
Sq.

P value

Alpha Glucosidase
Inhibitors
Biguanides
Dipeptidyl Peptidase 4
Inhibitors

9 (0.72)

80 (0.28)

7.61

0.0058+

528 (42.48)

12,047 (42.83)

0.06

0.8065

120 (9.65)

2,338 (8.31)

2.79

0.0945*

Insulin

300 (24.14)

2,572 (9.14)

Other Injectable Agents
Meglitinides

32 (2.57)
29 (2.33)

504 (1.79)
232 (0.82)

Sulfonylureas

516 (41.51)

7,305 (25.97)

Thiazolidinediones

144 (11.58)

2,737 (9.73)

a: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
*: Significant at p value 0.05 as derived from Chi-square.
+: Significant at p value 0.05 as derived from Fischer’s Exact Test.
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303.2
4
4.06
30.74
147.1
7
4.62

<0.001*
0.0437*
<0.001*
<.001*
0.0315*

Table 3.6: Prevalence of Anti-diabetic Medications Stratified by Exposure to
Hypoglycemia
Hypoglycemia
(N = 1,243)
No Therapy
434 (34.92)
Monotherapy
Insulin
70 (5.63)
Sulfonylureas
102 (8.21)
Biguanides
112 (9.01)
Thiazolidinediones
6 (0.48)
Alphaglucosidase Inhibitors
3 (0.24)
Meglitinides
1 (0.08)
Dipeptidyl Peptidase – 4 Inhibitors
3 (0.24)
a,b
Combination Therapy
Insulin + Biguanides
49 (3.24)
Insulin + Sulfonylureas
28 (2.25)
Insulin + Thiazolidinediones
8 (0.64)
Biguanides +Sulfonylureas
146 (11.25)
Biguanides + Thiazolidinediones
9 (0.72)
Sulfonylureas + Thiazolidinediones
11 (0.88)
Insulin + Biguanides + Sulfonylureas
57 (4.59)
Biguanides + Sulfonylureas + Dipeptidyl
26 (2.09)
Peptidase – 4 Inhibitors
Biguanides +Sulfonylureas +
32 (2.57)
Thiazolidinediones
Others
137 (11.02)
Diabetes Medications

No Hypoglycemia
(N = 28,128)
13,175 (46.84)
600 (2.13)
1,192 (4.24)
4,641 (16.50)
233 (0.83)
10 (0.04)
21 (0.07)
90 (0.32)
474 (1.69)
138 (0.49)
58 (0.21)
2,871 (10.21)
513 (1.82)
188 (0.67)
498 (1.77)
659 (2.34)
651 (2.31)
2,116 (7.52)

a: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
b: Examples of combination therapy (use of more than one medication) might include Glipizide/Metformin
Hydrochloride, Glyburide/Metformin Hydrochloride, Pioglitazone Hydrochloride/Glimepiride, Pioglitazone
Hydrochloride/Metformin Hydrochloride, Repaglinide/Metformin Hydrochloride, Rosiglitazone
Maleate/Glimepiride, Rosiglitazone Maleate/Metformin Hydrochloride, Sitagliptin Phosphate/Metformin
Hydrochloride.
*: Significant at p value 0.05 as derived from Chi-square.
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Table 3.7: Concomitant Usage of Non –Diabetic Medications Stratified by Exposure
to Hypoglycemia
No
Hypoglycemia
(N = 28,128)
Overall Medication Frequencya
Number of Medications 15.34 + (12.21) 10.97 + (9.63)
Categorized Medication Frequencyb
Number of Medications
0-3
296 (23.81)
7881 (28.02)
4-7
62 (4.99)
3347 (11.90)
8 - 10
59 (4.75)
2255 (8.02)
More than 10
826 (66.45)
14645 (52.07)
Medication Classesb
ACE Inhibitors
549 (44.17)
10548 (37.50)
Allopurinol
70 (5.63)
1048 (3.73)
Angiotensin II Receptor
120 (9.65)
2419 (8.60)
Blockers
Benzodiazepines
262 (21.08)
4815 (17.12)
Beta-Adrenergic Blocking
484 (38.94)
7404 (26.32)
Agents
Fibrates
107 (8.61)
2146 (7.63)
Fluoroquinolones
411 (33.07)
6130 (21.79)
Nonsteroidal Anti344 (27.67)
8011 (28.48)
Inflammatory Drugs
Trimethoprim
4 (0.32)
92 (0.33)
Warfarin
158 (12.71)
1520 (5.40)
Concomitant
Medications

Hypoglycemia
(N = 1243)

Chi Sq.

<0.001*

119.48

<0.001*

22.51
11.80

<0.001*
0.0006*
0.1956*

1.67
13.05
96.44

0.0003*
<0.001*

1.61
87.37

0.2045*
<0.001*

0.37

0.5379

0.01
118.01

0.9746
<0.001*

a: Mean + (STD. DEV) & T test used for continuous variables.
b: n (%) & the Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
*: Significant at p value 0.05 as derived from Chi-square.
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P-Value

Table 3.8: Independent Predictors Of Serious Hypoglycemic Eventsa
Risk Factor

Crude OR

95% CI

Age Category
18 - 34
1.00
NA
35 - 49
0.85
0.56 – 1.28
50 - 64
1.05
0.72 – 1.54
65 And Above
1.66
1.13 – 2.43
Gender
Female
1.00
NA
Male
1.06
0.95 – 1.19
Charlson’s Comorbidity Index
CAT 1 (0)
1.00
NA
CAT 2 (1)
1.56
1.26 – 1.93
CAT 3 (2)
2.60
2.18 – 3.11
CAT 4 (3 Or More)
5.00
4.30 – 5.18
c
Congestive heart failure
3.49
3.04 – 4.01
c
Cardiac arrhythmia
2.34
2.05 – 2.67
c
Peripheral vascular disorders
2.93
2.57 – 3.33
c
Hypertension (uncomplicated)
1.22
1.08 – 1.38
c
Paralysis
4.10
2.59 – 6.48
c
Other Neurological Disorders
3.06
2.53 – 3.70
Hypothyroidismc
1.30
1.11 – 1.51
c
Renal failure
4.19
3.56 – 4.92
c
Obesity
1.30
1.03 – 1.65
c
Fluid and electrolyte disorders
3.11
2.68 – 3.62
c
Deficiency anemia
2.36
1.98 – 2.82
c
Psychoses
3.52
2.72 – 4.55
c
Chronic renal pathophysiology
3.36
2.77 – 4.08
c
Acute renal failure
5.50
4.66 – 6.50
Ulcerc
6.62
5.78 – 7.57
c
Amputation
3.35
1.66 – 6.77
c
Addison’s Disease
5.49
2.99 – 10.09
Number Of Medications
0-3
1.00
NA
4-7
0.49
0.37 – 0.65
8 - 10
0.69
0.52 – 0.92
More than 10
1.50
1.31 – 1.72
Insulinc
3.16
2.75 – 3.62
c
Sulfonylureas
2.02
1.80 – 2.27
c
Alphaglucosidase Inhibitors
2.55
1.28 – 5.10
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Adjusted
ORb

95% CI

1.00
0.78
0.76
0.71

NA
0.51 – 1.18
0.50 – 1.13
0.47 – 1.07

1.00
1.04

NA
0.92 – 1.14

1.00
1.38
2.05
2.12
1.24
1.21
1.19
0.84
1.67
1.52
1.13
1.19
1.30
1.31
1.37
1.60
1.23
1.79
4.07
2.73
3.17

NA
1.11 – 1.72
1.70 – 2.47
1.73 – 2.59
1.04 – 1.49
0.99 – 1.49
1.02 – 1.40
0.74 – 0.97
1.01 – 2.78
1.22 – 1.89
0.96 – 1.34
0.96 – 1.48
1.01 – 1.67
1.09 – 1.57
1.13 – 1.67
1.19 – 2.14
0.98 – 1.56
1.44 – 2.23
3.50 – 4.72
1.26 – 5.91
1.64 – 6.14

1.00
1.38
2.05
2.12
2.20
1.71
1.93

NA
1.11 – 1.72
1.70 – 2.47
1.73 – 2.59
1.88 – 2.56
1.49 – 1.97
0.92 – 4.06

Meglitinidesc

2.87

1.94 – 4.24

a: Independent predictors were identified using a conditional logistic regression model.
b: Adjusted for all factors listed in the table.
c: Dichotomized predictors; absence of factor is the referent group.
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1.75

1.14 – 2.70

Figure 3.2: Classification For Episodes Of Inpatient Claims
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Figure 3.3: Classification Of Episodes For Outpatient Claims
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Table 3.9: Cost Estimates of Hypoglycemic Events, Other Diabetes-Related Events,
and All Other Events Stratified by Setting.
Setting

Type Of Costa

Inpatient
Costs

Hypoglycemia
Other Diabetes
All Other

Outpatient
Costs

Hypoglycemia
Other Diabetes
All Other

Encounters

Mean cost per
encounter ($)
2,025
1,514.60
27,412
232.71
367,531
1,171.60
Total Inpatient Costs
2,851
142.91
206,671
89.93
1,229,828
182.63
Total Outpatient Costs

Total Costs ($)b
3,067,076
6,379,256
430,600,338
440,046,671c
407,456
18,587,620
224,610,691
243,605,766c

a: Cost category identified using ICD-9 codes associated with the claim and creating 3 mutually exclusive groups:
1) those identified as hypoglycemia (hypoglycemia costs).
2) those with primary ICD-9 code 250.XX (other diabetes costs).
3) others (all other costs).
b: Total costs rounded to nearest dollar.
c: Costs of hypoglycemic events, other diabetes-related events, and all other events may not sum to total costs due
to rounding.
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4.1 Sulfonylureas
Sulfonylureas (SUs) have been the widely prescribed medications in the management
of T2DM since the 1950s, with as many as 75 to 80% of patients initiated on one of
these agents.225,226 First-generation agents such as acetohexamide, chlorpropamide,
and tolbutamide were very popular in the 1960s.227 However, by the 1970s, many
safety concerns arose over the use of these drugs with many observational studies
clinical trials, most notably the UGDP (University Group Diabetes Program), providing
inconclusive evidence regarding the detrimental effects of this class of drugs.227 The
UGDP was intervention trial of 1027 newly diagnosed T2DM patients with the
objective of comparing the efficacy of oral anti hyperglycemic agents, insulin and diet
alone in the prevention of diabetes-related vascular complications. This study
demonstrated an annual rise of approximately 1% per year in the rate of
cardiovascular mortality of patients receiving tolbutamide (a sulfonylurea) compared
to diet alone. Subsequently, the safer second generation of SUs (e.g., glyburide,
glipizide, and glimepiride) emerged in the next few decades and has largely replaced
the first generation of SUs. Even though they differ from the first generation of SUs
with respect to their chemical composition, both groups were found to be equivalent
in their hypoglycemic effect.90
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4.1.1 Efficacy And Indications
Many retrospective and prospective have focused on the efficacy of SUs. Although
potency of effects can vary among patients, when used as a monotherapy in patients
who cannot achieve the glycemic goals by nonpharmacologic interventions, SUs tend
to lower A1C by 1.5 to 2.0 percentage points and fasting plasma glucose by 60 – 70
mg/dL, when used as monotherapy at maximal doses are used.90,228,229 SUs can be
used as the first line oral antidiabetic agents of choice in patients who fail to achieve
adequate glycemic control using nonpharmacological measures or may also be added
to a patients regimen if metformin monotherapy is contraindicated, not tolerated or
does not achieve the target A1C at 3-6 months of treatment. SUs can be combined
with other classes of OADs, excluding insulin secretagogues and combining daytime
SUs with bedtime insulin, an increasingly popular practice lacking scientific evidence
of potential advantages over insulin monotherapy, can help reduce can reduce
insulin doses by half. SUs are preferred in patients who are not obese or overweight
since weight gain is a major concern with this class of agents.227 Similarly these drugs
are used conservatively in the geriatric population as well as patients with impaired
renal and hepatic functions and belong to pregnancy category B or C. However,
according to the UKPDS, despite achieving the target achieved a A1C of <7 % in the
first 3 years, only 34 % of patients attained a HbA1c <7 % at 6 years, with this number
further declining to 24 % at 9 years.97,230
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4.1.2 Adverse Events With Sulfonylureas
This class of drugs has been historically accepted as being well tolerated with only
about 2 -5 % of patients reporting primary toxicities associated with it being
hypoglycemia, weight gain, B cell exhaustion and adverse cardiovascular
outcomes.231
Previous literature attributes initiation of SU therapy to a resulting increase in body
weight, which also accompanies many of agents, apart from metformin, that are
used for diabetes management.232 Typically, various studies report a weight gain of
approximately 1 – 4 kg.227,231-235 There have been concerns regarding the cardiac
safety of the sulfonylureas class of drugs especially after research on the
physiological effect of these drugs.99,236-238 SUs usually affect an initial increase in the
B cell function, which is followed by a gradual and linear reduction, which goes hand
in hand with the therapeutic failure of these drugs and the resulting progressive
worsening of glycemic control.217,239,240
4.1.3 Hypoglycemia with Sulfonylureas
Even though different SUs possess different pharmacotherapeutic profiles, the major,
most common, and potentially, the most worrisome adverse effect associated with
this class of drugs is hypoglycemia. The risk of development of hypoglycemia
episodes differs between different SUs with the likelihood of the prolonged
manifestation of this side effect being greater with longer-acting agents like
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chlorpropamide, glyburide, glibenclamide and longer acting glipizide as compared to
the newer second generation like glimepiride (150 vs 105 episodes for glibenclamide
and respectively).94,241,242 Similarly, other factors like timing of the drug, dose, and
potency of the specific agent are known to affect the risk of this adverse event.
Previous studies have attempted to characterize the risk factors for hypoglycemia in
patients with T2DM. Among the other patient related factors, advanced age, taking
multiple medications, inconsistent frequency of meals and physical activities as well
as impaired organ system functions are clearly known to increase the risk of
recurrent hypoglycemic effects of SUs.243 For example, Setzer et al., in a
comprehensive review of 1,418 cases of severe drug-induced hypoglycemia, found
that sulfonylurea ingestion was a factor in 65% of adult cases, 86% of cases were
older than 50 years, and the omission of 1 or more meals was implicated in 80% of
cases. Moreover these results should be viewed in light of the drawbacks of this
study including lack of a control group, inclusion of patients with and without
diabetes as well as intentional overdoses, and design flaws244. Similarly, Asplund et al
reported that more than 90% of the 57 type 2 diabetic patients experiencing
glibenclamide-associated hypoglycemia were older than 60 years and more than 70%
were older than 70 years.245
Bonds and colleagues, in a secondary analysis of the ACCORD clinical trial data, did
not find any association between sulfonylureas and severe hypoglycemia in both the
intensive [Hazard ratio 1.06, 95% CI 0.88–1.28] and the standard intervention group
[Hazard ratio 0.85, 95% CI 0.6–1.20].178 Similarly, Burge et al. in a prospective,
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randomized, double-blind clinical trial evaluated the hypoglycemic effects of
maximum doses of once-daily second-generation sulfonylureas in the elderly
patients. Each patient was assigned to either glyburide or glipizide therapy and took
part in three 23-hour fasting studies after undergoing sequential administration of 1
week of placebo and 1 week of 10 mg and 1 week of 20 mg of the assigned
sulfonylurea. It was observed that none of the 58 patients had and event of
hypoglycemia during the fasting period.246 Similarly, The GUIDE study which
randomized 845 T2DM patients to gliclazide modified release (MR) or glimepiride
monotherapy or in combination with other treatments to HbA1c and safety by
episodes of hypoglycemia, showed no hypoglycemia requiring external assistance for
similar HbA1c reduction in both groups, age notwithstanding.235
However, in contrast, many other clinical trials as well as observational studies
implicate pharmacological effect of the SUs as the principal cause. Data from several
clinical trials, though variable with respect to the rates of hypoglycemic events,
attribute hypoglycemia to SU therapy. In the UKPDS, the rates of hypoglycemia
varied from 11% to 17.7% depending on the specific agent used with the rates of
severe episodes being less than 1% with either chlorpropamide or glibenclamide. 97,232
However, failure to provide details of the diagnosis of the hypoglycemia episode and
considerable inter changing between agents were the principal drawbacks of this
study which made it difficult to define and associate the hypoglycemic episode to a
particular agent.97 However, in comparison to the Diabetes Control and
Complications Trial (DCCT), the relative risk of hypoglycemia was much lower in the
130

UKPDS. Both, Draeger et al. and Clarke et al. compared glyburide with other
sulfonylureas and found varying rates of hypoglycemia, with all the agents within the
class associated with a higher risk of hypoglycemia.242,247
Gangji et al. in a meta-analysis to glyburide with other secretagogues as well as
insulin with respect to the potency to cause hypoglycemia and cardiovascular events
found a 52% and 83% greater risk of hypoglycemic events associated with glyburide
in comparison to other secretagogues (Relative Risk (RR) 1.52 [95% CI 1.21-1.92]) and
other sulfonylureas respectively ( RR 1.83 [95% CI 1.35-2.49]).243 Hollander et al.
compared the effects of nateglinide, glyburide, and placebo on post meal glucose
excursions and insulin secretion in 152 patients and as one of the outcomes found
that nateglinide-treated patients had significantly fewer hypoglycemia events as
compared to those treated with glyburide but more events than placebo-treated
patients (12 vs. 53 vs. 2, respectively).248
Van Staa et al. assessed the risk of hypoglycemia in 33,243 patients treated with
sulfonylureas in 719 clinical practices in the UK and found that a diagnosis of
hypoglycemia during sulfonylurea therapy was recorded in 605 people over 34,052
person-years of sulfonylurea therapy thus amounting an annual risk of 1.8% 249,250
while in another review in Germany, the incidence rates for severe hypoglycemia was
0.86/1000 person- therapy years and 5.6/1000 person-years for glimepiride and
glibenclamide respectively.251
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Jennings et al. demonstrated that up to 20% of the patients taking SUs experience
symptoms consistent with hypoglycemia over a 6-month period with 6% of the
patients having hypoglycemic symptoms in a month.252,253 Shorr et al. while studying
the incidence and risk factors for developing serious hypoglycemia among older
persons using sulfonylureas or insulin in a population-based, retrospective cohort
study of 19932 Tennessee Medicaid enrollees, aged 65 years or older taking SUs or
insulin identified 586 persons with a first episode of serious hypoglycemia during
33,048 person-years of insulin or sulfonylurea use thereby giving crude rates of
1.23/100 person years for serious hypoglycemia (95% confidence interval [CI], 1.081.38) in users of sulfonylureas and 2.76100 person years (95% CI, 2.47-3.06) among
insulin users and 3.38/100 person years in patients using both. The adjusted relative
risk was 0.2 for tolbutamide, 0.6 for glipizide and tolazamide, and 1.0 for
glibenclamide in comparison to chlorpropamide. The authors also reported that that
recent hospitalization was the strongest predictor of hypoglycemia in the elderly
population211,252. Vickova et al. reported rates of 157.1 per 10 000 person-years in
nateglinide users and 203.2 per 10 000 person-years in repaglinide users.254,255
Thus, it can be seen from the literature that the incidence of hypoglycemia is
widespread in T2DM patients on SU therapy and that this has the potential to be the
limiting factor in the attainment of the target goals for glycemic control. Thus,
experts largely advice prudent setting of glycemic targets as well as careful selection
and dosing of the oral diabetic agents based on various patient and other
environmental factors.
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4.1.4 Persistence with Sulfonylureas
The relationship between persistence to SU therapy and health outcomes has been
previously explored in a number of studies. Boccuzzi et al. noted that in patients who
continuously refilled a prescription for their initial oral antidiabetic within 1.5 times
the days’ supply of the previous fill, the rate of discontinuation for sulfonylureas was
less than that for metformin (11.3% vs 11.9%).109 In contrast, Dailey et al. examined
drug use patterns among patients with T2DM to understand drug use patterns
among Medicaid recipients and assess their persistence to different antidiabetic
regimens. After following 37,431 patients for a year, the authors found that 85.3% of
the sample on monotherapy was taking a sulfonylurea among whom 15% of the
patients remained persistent in comparison to the 14% who were on metformin
monotherapy among whom 16% remained persistent.256 Jermendy et al. compared
the persistence of diabetic patients initiated on metformin or a SU to patients newly
prescribed statin or clopidogrel therapy and found that the 1-year persistence of
initial treatment with metformin, sulfonylureas or metformin/sulfonylureas
combination was 47.7%, 45.4% and 55.8%, respectively. This though higher than
statin therapy (26.3%), was still sub optimal.257 Similarly, Sclar et al. in a study of
Medicaid recipients in South Carolina exhibited low treatment persistence in SU
users, with only 39.4% of the study population obtaining atleast a 6 month supply. 258
Hertz and colleagues conducted a retrospective cohort study of 6090 newly treated
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patients aged 18-64 years to determine adherence with pharmacotherapy for T2DM
found that 9.7% of patients initiated on sulfonylureas were non-persistent at an early
stage while almost 34% of the patients were non-persistent at the end of a year.259
Grégoire et al. assessed persistence patterns with oral antidiabetic medications in a
population-based cohort study. They found that the likelihood of continuing the with
the initially prescribed oral antidiabetic medication over a 12 month period was 56%
for SUs, which was about 10% less than that for metformin. In another study,
Ligueros-Saylan and colleagues found that almost 44% of the patients on SUs
discontinued their therapy within one year of initiation.260 The risk of medication
discontinuation during the follow up period was significantly higher for patients who
were prescribed sulfonylureas as compared to metformin, the likelihood of (Adjusted
Hazard Ratio: 1.32; 95% CI 1.29–1.34) and probability of restarting the therapy after
discontinuation was less likely (Adjusted Hazard Ratio: 0.91; 95% CI 0.89–0.93).261
It is well understood from previous literature that persistence with medications is a
vital factor in achieving optimal glycemic control. A large body of literature also
points to the fact that treatment non persistence is a frequent issue related to oral
antidiabetic medications including sulfonylureas. Cramer et al., while reviewing
studies of patient compliance and persistence with cardiovascular or antidiabetic
medications, suggested that even though the overall persistence rate for oral
antidiabetics was comparable to other therapeutic classes of medications for various
diseases, noncompliance with antidiabetic medication was still a grave issue with the
results showing that the 12-month persistence of oral antidiabetics was 62% with
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almost 30% of days of therapy not covered by medication and only 59% of patients
having medication for more than 80% of their days on therapy in the year. 107 It has
also been shown in various studies that conforming to the medication regimen can
significantly decrease the utilization of medical resources. For example, Hepke et al.
conducted a study in a non-managed care setting and concluded that higher degree
of medication adherence was associated with reduced use of emergency department
and inpatient visits.262 Thus considering the association between medication
persistence and positive health outcomes including achievement of glycemic control
and reducing complications and hospitalizations as well as medical costs, it becomes
necessary to explore the association between medication persistence to SUs and
various patient related factors, one of them being hypoglycemic events.
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4.2 Rationale And Objectives Of The Study
Data suggests that intensive glycemic control, though beneficial in minimizing several
complications of diabetes may sometimes act as a precursor to incidence of
hypoglycemia.95,200,263 Recurrent hypoglycemia is associated with significant
morbidity and often leads to negative health outcomes with respect to ideal diabetes
management. Moreover, there is evidence that hypoglycemia may create a barrier to
medication adherence. For example, Walz et al. evaluated the impact of symptomatic
hypoglycemia on medication adherence, satisfaction with treatment, and glycemic
control in patients with T2DM and reported that patients who experienced moderate
or worse symptoms of hypoglycemia reported poorer adherence to medication (46%
versus 67%; p-value <0.01) and were more likely to report barriers such as “bothered
by medication side effects” (36% versus 14%; P-value <0.001) compared with
patients with no hypoglycemia or mild symptoms of hypoglycemia.264 Similarly, Lopez
et al. carried out a retrospective study in adults with T2DM taking antidiabetic agents
and found that 55.7% of the patients had at least one hypoglycemic event. Among
patients taking antidiabetic medications, 52% reported medium to low adherence
with their medications, with almost 60% of people with medium to low adherence
having experienced a recent episode of hypoglycemia.265 The RECAP-DM (Real-Life
Effectiveness and Care Patterns of Diabetes Management) study, a multicentre study
was conducted in seven countries, evaluated the association of patient-reported
hypoglycemic symptoms with treatment satisfaction and barriers to adherence. The
study focused on the addition of a sulfonylureas or a thiazolidinedione to ongoing
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metformin therapy. Nevertheless, 38% of patients reported hypoglycemic symptoms
during the previous year, patients with hypoglycemic symptoms were more likely to
report barriers to adherence.181
Although various aspects of medication adherence in diabetes therapy have been
investigated, studies which have focused on evaluating the impact of hypoglycemia
on the adherence and persistence to SU therapy have been scarce. Medication
persistence and treatment continuation could be altered in patients on SU therapy
who experience hypoglycemic events due to number of reasons including fear of
hypoglycemic events, impaired physical functioning as well as the impact on the
quality of life, social well-being and activities of daily living. Studies report
approximately 7% of patients on SU therapy experience one or more episodes of
severe hypoglycemia per year, with hypoglycemic episodes potentially affecting
decisions to discontinue treatment. It is essential to understand and describe
differences in medication persistence in patients taking SU therapy related to
hypoglycemia.213 Therefore, the aim of this study was quantify the effect of
hypoglycemia on persistence rates with oral SU therapy.

137

4.3 Methods
4.3.1 Datasource
For the purpose of our study, we used the Blue Cross and Blue Shield Of Rhode Island
(BCBSRI) administrative claims data for the years 2009 - 2012. BCBSRI is a non-profit
hospital service and medical service corporation covering more than 600,000
members. In the data extract used for our analyses, all the members had at least one
International Classification of Disease-9 (ICD-9) code for diabetes (ICD-9 250.XX)
between 2009 and 2012. To achieve the aims of our study, we utilized three
administrative files, including eligibility files, medical claims (inpatient and
outpatient) and pharmacy claims. The enrollment file included age, gender as well as
the start and end dates for enrollment in the health plan. Similarly, the outpatient
and inpatient files include diagnosis information (ICD-9 codes), Current Procedural
Terminology (CPT) codes, admit and discharge dates as well as cost and copayment
information. The medication claims dataset included prescription medications
dispensed during the study period and included the National Drug Codes (NDC), drug
product names, prescription quantity (number of units dispensed) and days supplied
at the time of dispensing (e.g. 30 day supply of medication). Due to the
comprehensive nature of the claims provided in the dataset, it can be assumed that
this dataset provides a near complete picture of an individual’s health care.
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4.3.2. Research Design And Study Population
Using the inpatient and outpatient medical claims, and prescription claims, we
conducted a retrospective cohort study using a new user design (Figure 4.1). 266 As
our focus was on patients taking SU therapy, we further identified patients in the
dataset who initiated treatment with a SU.

More specifically, we utilized the

following inclusion and exclusion criteria:
Inclusion Criteria:
•

At least 18 years of age. Patient age was calculated as of the date of first SU

fill.
•

At least 1 prescription claim for an SU Oral Antidiabetic Drug (OAD).

•

Continuous enrollment in the health plan for at least 12 months after the

initial SU fill date.
Exclusion Criteria:
•

At least one claim for type 1 diabetes (ICD-9 250.X1 or 250.X3) or gestational

diabetes (ICD-9-CM 648) within the baseline period.
Since we required a continous eliglibility period of 12 months following the cohort
entry for each patient, we constructed eligibility episodes for each unique patient by
considering the eligibility episode separate if there was a lag of 30 or more days
between the end date of the previous episode and the start date of the next episode.
We only considered the eligibility episode in which the first prescription was
recorded. Thus, after the initial identification of the patient cohort, we created the
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cohort entry date as an indicatior of the first date of fill for a SU. We further divided
the study period for each patient into two phases: the baseline period and the post
baseline period (Figure 4.2). The duration of the baseline phase was 3 months from
the date of the first SU fill. The length of the post baseline phase was 9 months from
the end date of baseline arm of the study. Thus, we followed each identified patient
for a total maximum duration of 12 months starting on the first date of SU fill. An
overview of study design is presented in Figure 4.2. Further, we assessed the
hypoglycemia exposure, demogrpahics, other diabetic medication exposure as well
as history of comorbid conditions within the baseline arm or the first 3 months of the
study after the first date of fill.
4.3.3 Exposure To The Medication Class Of Interest (SUs)
As mentioned earlier, the BCBSRI data includes information on the use of
prescription drugs by the patients in the health plan and can be linked to the
inpatient and outpatients medical claim files using a unque indentifier. Utilizing the
prescription claims data, we identified the use of medications in the patient
population by using a combination of NDC codes as well as generic and brand
product names. NDC codes are unique, three-segment numbers, usually 10 digits in
length, which act as a universal product identifier for drugs. Further, for verification
purposes, we used the Redbook 2008 to link the therapeutic groups and therapeutic
classes to the drug records in the dataset. Moreover, we excluded observations if
patient had day of supply less than or equal to 0 as well as those patients who had
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days of supply more than 180. Using the aforementioned methods, we identified all
the patients who received their first prescription for SU along the duration of the
study. It has been noted in literature that patients with T2DM are often treated with
a variety of concomittant medication. Based on previous evidence, we established
and outlined certain classes of drugs that were know to act as contributing factors to
risk of hypoglycemia.
Once we identified the eligible study population, we then evaluated exposure history
during the baseline period to create two exposure groups: 1) those with at least one
inpatient or outpatient claim for hypoglycemia during the baseline period; and 2)
those without any claims for hypoglycemia during the baseline period. Hypoglycemic
exposure was defined as the first hypoglycemic event within the baseline period
requiring medical attention in either the inpatient or outpatient setting. To identify
these hypoglycemic events we used the algorithm suggested by Ginde and
colleagues.187 This algorithm identifies an hypoglycemic event if any hospital and
clinic visits are indicative of hypoglycemia by using standard ICD-9 codes (ICD-9:
251.0, 251.1, 251.2, 270.3, 962.3).Further if there is absence of hypoglycmia but
presence of diabetes with other specified manifestations (ICD–9 : 250.8) without
other contributing diagnoses (ICD-9 : 259.8, 272.7, 681.XX, 682.XX, 686.9X, 707.1707.9, 709.3, 730.0-730.2 or 731.8), then such incidents are also termed as a
hypolgycemic event. This algorithm is well validated and demonstrated an 89%
positive predictive value (PPV) (95%CI,86–92) in accurately identifying hypoglycemia
visits and an exhibited an estimated 97% sensitivity and > 99 specificity. 187,263 It has
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been well documented that severe episodes of hypoglycemia are often followed in
quick succession by further hypoglycemic events. Hence, while characterizing the
subsequent events of hypoglycmia following the first incident, we counted the events
that occurred with a minimum gap of 7 days between them as separate event, else
the entire hypoglycemic episode was considered as a single event. Using this
information, we created two groups of indivuduals, those with at least one
hypoglycemic event during the baseline period and those without. As our interest
was in incident discontinuation following hypoglycemia, we excluded patients with
treatment discontinuation (n= 16) before an event of hypoglycemia within the
baseline period.
4.3.4 Outcome of interest : SU Treatment Discontinuation
We followed all persons in both exposure groups for SU medication discontinuation
until the end of the follow-up period. We defined discontinuation as a gap of > 30
days in SU prescription availability that occurred between consecutive prescriptions.
Usually, the gap period allowed in various retrospective studies varies from 30 to 90
days or 1.5x last days supply.267 Based on the clinical relevence to hypoglycemia and
the day’s supply limts, we chose a window of 30 days to be appropriate. This period
was considered as a period where the patients would not anticipate suboptimal or
negative health outcomes.267,268 If another refill of the SU was filled within the
specified window from the end date of the preceeding prescription’s days of supply,
the patient was considered persistent.
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The persistence in terms of days to

discontinuation was calculated for the entire SU drug class, allowing for switches
within the same class (i.e. patients switched from one SU agent to another). We
followed all patients to the first of three endpoints: 1) time to discontinuation; 2) a
subsequent hypoglycemic episode; or 3) the end of the study period. An overview of
outcome identification is presented in Figure 2.
4.3.5 Demographics and Comorbidities
We compared the demographic as well as clinical characteristics between the
hypoglycemia exposed and the hypoglycemia non exposed cohorts during the initial
baseline period of the study. This process was carried out to characterize the
potential confouding effects of certain patient related factors of interest like age and
gender on the the risk of discontinuing the SU therapy. Since age was recorded as the
age at the end of the enrollement period, we re-calculated the age at the date of the
first fill of SU for all the patients in the study.
We used the inpatient as well as outpatient claims records for characterising rhe
presence of comorbidities in patients. We identified the ICD-9 codes in these files to
ascertain the presence of certain macro- and microvascular complications of diabetes
as well as other conditions like Addison’s disease and hypothyroidism which are
associated with diabetes by employing methodologies that have been applied in
other studies. We calculated a overall point estimate of comorbidity by application of
the Deyo adaptation of the Charlson’s Comorbidity Index.263,269 As a part of this
comorbidity index, scores from a minimum of 1 to a maximum of 6 were assigned
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with different weights, to each of the 19 selected medical conditions based on their
adjusted relative risks and were then summed into a composite score for each
individual patient. In addition to the overall comorbidity score, we also evaluated the
individual comorbidities that might have an association with hypoglycemia. This was
done by using the Quan H. ‘s enhanced ICD-9 codes of the Deyo’s adaptation of the
Elixhauser Comorbidity Index. The performance and validity of the Charlson and
Elixhauser comorbdity indices in predicting health outcomes has been previously
evaluated in a vareity of population studies where they have been consistent as
prognostic measures of outcomes.270 The presence of each comorbidity were
recorded as a categorical dichotomous variable.
Similar to the SU identification, we also characterized the use of other medications in
the baseline arm of the study by using a combination of NDC codes, product names
as well the threpautic classes and groups. The specific classes of drugs that we were
interested in evaluating were angiotensin converting enzyme (ACE) inhibitors,
angiotensin 2 receptor blockers (ARB), allopurinol, benzodiazepines, beta-blockers,
fibrates,

fluoroquinolones,

non-steroidal

anti-inflammatory

drugs

(NSAIDs),

trimethoprim and warfarin.190,208 The presence of each drug class were recorded as a
categorical dichotomous variable. We also created a continous variable to identify
the total number of unique medications that were used by each patient since it is a
known factor affecting medication persistence.

144

4.3.6 Statistical Analyses
In our initial phase of analyses, we compared demographic and clinical characteristics
between the two exposure groups to determine group comparability. Differences
between exposure and non exposure group were assessed using the Pearson's chisquare test or Fisher exact test in case of the categorical variables and Student t-test
or Mann Whitney U test for the continous variables. We also conducted a descriptive
analysis of the outcome variable and computed the total time to discontinuation SU
therapy by hypoglycemia exposure status thereby reporting the mean time to
discontinuation in both groups.
Since there would be a certain lag between the first prescription of SU to the first
instance of hypoglycemia in the hypoglycemia exposed cohort, a certain degree of
immortal time bias was introduced due to the fact that hypoglycemia exposed cohort
would not experience the discontinuation outcome prior to exposure (Appendix
4.12). To account for this phenomena, we adjusted for during immortal time in the
exposed group during our statistical analysis.271-273 The schematic representation of
immortal time bias is shown in Figure 3. We adjusted for this immortal time bias in
our statistical analyses by moving the start of follow-up or exposed time to the end of
the immortal period while accounting for the time between cohort entry and
exposure date as unexposed time.
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At this stage we had outlined the individual variables which were identified as
potential confounders during bivariate analyses based on either their clinical
relevence or their independent bivariate association with hypoglycemic exposure. To
identify the impact of the hypoglycemia exposure on the persistence of SU therapy in
terms of time to discontinuation, we developed a time varying Cox proportionalhazards model that was based upon the estimates of the descriptive bivariate
analyses in the first phase of analytical process. The anti-log transformation of
coefficients derived from this model were utilized to calculate Hazard Ratios (HR)
comparing the relative hazard of discontinuing medication in the hypoglycemia
exposure group compared to the hypoglycemia non-exposure group while adjusting
for the immortal time bias in the hypoglycemia exposed group. In the general form of
the time-varying Cox-Proportional Hazards model is274
h(t|X) = h(t) exp(X1β1 + • • • + Xp βp).
The dependent variable in our model was the time from the first date of SU
precription to the date of discontinuation of the therapy which was the date on
which the days of supply of the last prescription ended. The independent variable of
interest was hypoglycemia exposure, and operationalized as time varying
(1=hypoglycemia exposure, 0=Hypoglycemia Unexposure). We used the method
suggested by Suissa et al. in order to define the time varying nature of the
hypoglycemia exposure. The status of a patient was considered unexposed from the
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date of the cohort entry until the date of the hypoglycemic event and thereafter
exposed until the end of follow-up.271,273
Other confoudning variables that were found significantly associated with
hypoglycemic were eligible for entry into the model if they had atleast a 10%
difference between the hypoglycemia exposed and hypoglycemia unexposed groups
during bivariate anlyses. We then fitted sequential models in a nested manner by
means of a manual non-computer generated forward stepwise approach. We
assessed the B-coefficient for the hypoglycemia exposure group from the model at
each step when the confounding factor was added. If there was a 10% change in the
B-coefficient for hypoglycemia exposure in the model in comparison to the model
without the added confounding factor then it warranted the inclusion of the
confounding factor and it was retained in the model. These stepwise iterations were
continued until the most parsimonious model was fitted according to the proposed
criteria.
Once the preliminary model was fitted, we assessed the mulitcollinearity in the
retained variables using variance inflation factor (VIF) and the Condition Index (CX).
If the value of VIF exceeded 5, we considered that there was a high degree of
multicollinearity between two covariates and warranted one to be removed from the
model based on the p-value and clinical importance. We further evaluated two-way
interactions between biologically and clinically plausible variables that were retained
in the preliminary model. The interaction terms were sequentially added and the
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model with the interaction term was compared to the model without the interaction
term by means of likelihood ratio tests. Lastly, we also examined the model for any
violations of the proportional hazards assumption by visual inspection of the survival
curves.152,153 We used Akaike Information Criterion (AIC) at all steps of building the
final model, since AIC is asymptotically equivalent to cross-validation and the
bootstrap, two most popular validation methods. Also a likelihood test was
conducted to evaluate the final model. We estimated and reported crude and
adjusted hazard ratios (HR) and 95% confidence intervals (CI) from the crude and
final models.
We also performed a power and sample size calculation based on the rate of
medication discontinuation. We considered two-sided alpha level constant at 0.05
and based on our analyses, set the rate of medication discontinuation at 0.60. We
considered a that a 5% change in the rate of medication discontinuations between
groups is a clinically meaningful difference thereby setting the regression coefficient
at 0.05. Since there are no sample size estimations available that take into account
for the time-varying nature of the exposure for a Cox proportional-hazards model, we
estimated the power of our study based on time fixed methods.
All statistical tests were conducted with a two-tailed alpha level of 0.05, and all
statistical analyses in this study were performed using SAS software (SAS Institute
Inc., Cary, NC, Version 9.3). Sample size calculations were conducted using using PASS
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software (2014 version; NCSS, Kaysville,UT). This study was reviewed and approved
as exempt by the University of Rhode Island’s Institutional Review Board.

149

4.4 Results
Cohort Identififcation
The study sample was comprised of 36,954 individuals. Figures 4.3 and 4.4 give an
detialed explanation of the patient selection process. During the study period, 9,686
patients were initiated on SU therapy. Among SU users, 8,229 (85.0%) patients were
given a 30 day supply of medication while 1,153 patients were given a 90 day supply
(11.9%). Out of the study sample taking SUs, a total of 5,390 (55.7%) patients
recorded only one episode of SU drug use which might indicate complete persistence
or discontinuation after a single episode of SU use. In contrast about 4.9% of the
patients on SU therapy recorded more than 5 drug use episodes over the course of
the study. In this eligible sample of patients, 5,442 (56.2%) patients did not persist to
their medication and discontinued it at some point during the study follow up period.
The incidence of discontinuation is presented in Table 4.1. Overall, 2,016 patients
(34.0%) discontinued their medication. Within the unexposed cohort, 1,996 patients
(34.0%) discontinued their SU therapy at some point during the post baseline period,
while 20 patients (36.4%) of the exposed cohort discontinued their medication
(Χ2=0.14,; p-value: 0.70).
According to inpatient records in the dataset, a total of 1,295 patients had an
inpatient hypoglycemic events requiring medical attention occured and 2,368
patients had an outpatient visits for hypoglycemia occured. Within the baseline
period, 139 had a hypoglycemic episode for an overall risk of 0.37% over 3 months.
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Table 4.2 presents the basic demographic characteristics of the final study sample.
Age was comparable in the two exposure groups with a mean age (SD) at the index
date of first SU prescription of 64.9 years [11.21] and 64.5 [12.48] in the
hypoglycemia group and unexposed group, respectively. Gender distribution was
similar across the two cohorts with 56.4% of the hypoglycemia-exposed cohort (31
patients) and 57.2% (3,363 patients) of the patients in the exposed and unexposed
cohorts respectively being female (Χ2=0.01; p-value: 0.90). Nine patients (16.4%) in
the exposed cohort were using insulin in the baseline period in contrast to the 533
patients in the unexposed cohort (9.1%; Χ2=3.49; p-value: 0.06).
The prevalence of the comorbidities stratified by hypoglycemic exposure is
summarized in Table 4.3. The average Charlson’s comorbodity scores (SD) were
observed to be higher in the hypoglycemic cohort (3.78 [2.82]) as compared to the
hypoglycemia unexposed cohort (2.45 [2.43]; p value 0.001). Prevalence of all these
conditions was observed to be notably higher in the hypoglycemia exposed group.
Chronic pulmonary disease was diagnosed in 14.6% of patients with hypoglycemia in
contrast to the 4.5% in patients who did not experience hypoglycemia (Χ2=12.68; p
value=0.0004). Similarly, congestive heart failure was seen 9.1% of the hypoglycemia
exposed cohort and 3.6% of the hypoglycemia unexposed cohort (Χ2=4.75; p value:
0.02). Moreover, in the hypoglycemia group, 80% had a diagnosis of uncomplicated
diabetes and 72.7% were diagnosed with complicated diabetes (Χ2: 3.51, p value:
0.06). As opposed to the exposed cohort, the unexposed cohort had a lower
frequency of both diabetes with and without complications (896, 15.24% and 3545,
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60.30% respectively) (Χ2: 171.41, p value: <0.001). Other factors are presented in
Table 3 and were consistently higher in the hypoglycemia group versus the nonexposed group.
The overview of the microvascular and macrovascular complications associated with
diabetes is displayed in Table 4.4. Congestive heart failure was much more prevalent
in the diabetic patients who had an event of hypoglycemia with 9.1% being
diagnosed with this disorder compared to the 2.7% in the unexposed cohort (Χ2=8.55
p value: 0.003). Similarly, the patients in the exposed cohort had a higher prevalence
of coronary artery disease (16.1% vs 10.3%; Χ2=2.33 p-value=0.12). Patients with
hypoglycemia events had a higher prevalence of diabetic retinopathy (10.9% vs 5.0%,
Χ2= 29.22; p value=0.04) ulcer (7.3% vs 1.8%; Χ2= 76.89; p value=0.002) and thyroid
disease (7.3% vs 2.8%; Χ2= 90.17; p value=0.02) in contrast to those who did not
experience any hypoglycemia events.
Table 4.5 outlines a brief overview of the other medications that were concomitantly
used during the baseline period. Of those who exposed an event of hypoglycemia,
the average number of unique medications used was (8.63 +/- 3.84) which was
higher than drug use by the patients who did not experience an event of
hypoglycemia (7.16 +/- 3.67) during the baseline period. Notably, the use of
benzodiazepines were higher in the hypoglycemia group (14.6%) than in the
unexposed group (9.0%; Χ2=2.03; p value=0.1535). With respect to other
medications that were considered for analyses, the unexposed group was found to
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be using these medications to a higher degree. For example, with in case of warfarin,
5.9% in the unexposed group and 3.6% in the hypoglycemia group were using this
medication (Χ2=0.51; p-value=0.47).
Table 4.6 summarizes the use of other oral antidiabetic medications by the patients
during the baseline period. 37 patients (67.27%) within the exposed cohort were
using the biguanide class of oral antidiabetic medications simultaneously during the
baseline period as compared to 3639 patients (61.90%) in the hypoglycemia
unexposed group (Χ2= 0.66, p value= 0.41). Similarly, the frequency of use of TZDs
was higher in the hypoglycemia exposed group with 11 patients (20%) using these
medications as opposed to the 950 patients (11.11%) in the hypoglycemia unexposed
group (Χ2=0.59, p value=0.44). The use of alpha glucosidase inhibitors and
meglitinides was also higher in the hypoglycemia exposed group as compared to the
hypoglycemia unexposed group (1.82% vs 0.27%, 1.82% vs 0.19% respectively)( Χ2
4.55, p value=0.03 and Χ2= 7,18, p value= 0.0074 respectively). The frequency of
using DPP 4 inhibitors was identical in both cohorts with 5 and 505 patients (9.09%
and 8.59% respectively) in the exposed and unexposed cohort using this medication (
Χ2 =0.01, p value= 0.89).
Estimates for the accrued person time by both the study cohorts as well as the crude
and adjusted hazards ratios are presented in Table 4.7. Patients in the hypoglycemia
exposed cohort accrued 12,908 person days of follow up (Mean=234.69) during the
course of the study period while patients in the hypoglycemia unexposed cohort

153

accrued 1,789,222 days of follow up (Mean=304.31). The misclassified immortal time
contributed by the patients from the exposed cohort that had to be accounted for as
unexposed time was estimated to be 2,250 person days of follow-up.
The results of the Cox Proportional Hazards model are presented in Table 4.7. Age
and gender were included in the model irrespective of their significance during
bivariate analyses because of their biological importance. The crude HR for
discontinuation of SU medication was 1.47 (95% CI: 0.94 – 2.28). After adjusting for
effects of all the covariates under consideration, the HR for discontinuation of SU
medication was 1.32 (95% CI: 0.82 – 2.11). Thus, in both unadjusted analyses and
analyses that adjusted for relevant confounding variables, it could be seen that there
was a 47% and 32% elevation in the rate of medication discontinuation. Based on our
sample size, our study had approximately 82% power to detect a hazard ratio of 1.05.
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4.5 Discussion
Our current study sought to determine the impact of severe hypoglycemic episodes
requiring medical intervention on the persistence of the oral SU therapy. According
to our findings, though the patients who experience an event of hypoglycemia in the
baseline period are approximately 30% more likely to discontinue their medication,
this association was not statistically significant. To our knowledge, there have been
no previous studies that have specifically evaluated the impact of hypoglycemia on
the time to discontinuation of SU medications following hypoglycemic exposure using
a new user design.
We utilized an incident user design while conducting this study. This design was
preferred since it enabled us to capture all the hypoglycemia events that occurred
soon after initiation of the SU therapy. Ray et al. while reviewing the new user
designs, clearly state that even with medications, rate of outcomes, both beneficial
as well as adverse, varies with time since the initiation of therapy with the probability
of the outcome being the maximum immediately after the start of the medication
regimen.266 Hence using this design ensured that we accounted for even those
patients that were more susceptible to hypoglycemic effects of this medication
regimen as opposed to other designs that might have been incapable of selecting
these patients.275 For example, in a study to assess the risk of venous
thromboembolism (VTE), associated with newer oral contraceptives, Suissa et al. did
not distinguish between new users, repeaters and switchers and thereby found an
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excess risk of VTE associated with the use of third generation oral contraceptives. The
authors recognized the bias in this study and attributed it to the non-differentiation
between the three different user groups.276 In addition, this type of study design also
helps alleviate the need to methodically adjust for covariates that lie in the casual
pathway.266,277
Though the risk of hypoglycemia is widely recognized in the treatment of Type 1
Diabetes, there is increasing recognition of this issue in T2DM. Seaquist and
Associates reported that many trials like the ACCORD and ADVANCE have suggested
that T2DM patients might be at a greater risk of adverse events associated with
instances of hypoglycemia, including mortality.278 Mitchell et al. in an online survey of
1,329 T2D patients in United Kingdom (UK), found that 23% of patients who used oral
glucose lowering medications in absence of insulin experienced hypoglycemic
events.279 Leckie and colleagues conducted a prospective 12-month survey of 243
employed people to examine the frequency and consequences of hypoglycemia.
They found the rate of severe hypoglycemic events to be 0.14 episodes per person
per year and concluded that this rate was lower than the rates of 1.1–1.7 episodes
per patient per year that have been reported in previous Northern European
studies.224
Our decision to choose the SUs as the drug class of interest was based on the fact
that it has been traditionally established in various propective and retrospective
studies that among all the oral antidiabetic medications, SUs are associated with a
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higher propensity to cause hypoglycemic episodes. In our study we found that among
the 26.2% of patients who were initiated on an oral SU regimen, 3.9% of the patients
had at least one event of hypoglycemia. In our final study sample, 0.9% of patients
experienced a hypoglycemic event. Our study indicated a clear evidence of
recurrence

of

hypoglycemic

events,

with

patients

experiencing

multiple

hypoglycemic incidents requiring medical attention.
Other studies have reported varying rates for the incidence of hypoglycemic episodes
with SUs. For example, In the UKPDS, the mean rate of severe hypoglycemic events
was 18% at the end of 10 years of follow-up. In a study conducted by the UK
Hypoglycemia Study Group, 39% of the patients on SU medication reported severe
hypoglycemic events.213 Miller et al. evaluated the prevalence and risk factors for
hypoglycemic in 1055 patients with T2DM and found that only 5 patients (0.5%)
suffered from severe hypoglycemia and that all these patients were insulin users.195
Van Staa et al., using the UK General Practice Research Database, reported that 1.8%
users of SUs suffered from an incident of hypoglycemia with patients using
glibenclamide being at the highest risk.249 Jennings et al. investigated the prevalence
of hypoglycemia in patients treated with oral hypoglycemic agents and reported that
20% of patients treated with sulfonylureas had symptoms of hypoglycemia during the
previous 6 months.253 Bodmer et al. in a case control study to compare the risk of
lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral
antidiabetic drugs found the rate of mild/moderate or severe hypoglycemia was 60
per 100,000 person years for sulfonylureas.197 Thus, in the context of the pertinent
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issue, the rates that were found in our study are clinical significant findings
considering the number of patients that receive SU, either alone or as part of
combination therapy every year even though previous literature has documented a
relatively low risk of severe hypoglycemia in patients with T2DM. In addition, our
results could not be satisfactorily compared to these previous studies owing to the
differences in make-up of the study population, study designs, and definitions of the
hypoglycemic events.
We observed the persistence rates to oral SU medications from the cohort entry date
to the end of follow up period, which was a time span of 1 year. We observed that
the rate of medication discontinuation in our study was about 34.0%, with almost
one third of the patients in the exposed cohort discontinuing their medication within
the 9 month follow-up period. The principal finding of our study indicates that the
after adjusting for all relevant covariates, patients who are exposed to hypoglycemic
episodes are approximately 30% more likely to discontinue their medication regimen
than those who do not experience hypoglycemia, although this finding does not
attain statistical significance.
Cramer et al., in their review of literature, reported that the overall average
persistence rate for oral antihyperglycemic agents was 62.3% with the rate dropping
to 51.1% for studies conducted in the US.107 It has to be noted however that the
review failed to take into consideration the potential misclassification of studies as
well as the class differences in the medications under consideration. In another
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review investigating adherence to diabetic medications, Cramer et al. noted that the
rate of people continuing with their medications varied from 16% to 80% during a
treatment time of 6–24 months while the time to discontinuation of medications was
83–300 days.108 Similarly, Grégoire et al. found the persistence rates in newly
initiated SU therapy to be 56% and concluded that in comparison to metformin, SUs
displayed a poorer persistence profile. However, it was unclear in this study whether
the discontinuation was due to lack of clinical efficacy, adverse events, or any other
causes.261 Similarly, Sclar et al., Skaer et al, and Bocuzzi et al. demonstrated rates of
44%, 58% and 60% respectively for SU therapy during the first year.109,258,280
Rathmann and colleagues, in a study to investigate therapy persistence and other
factors in DPP-4 inhibitors and SUs, found the rate of discontinuation with the SUs to
be 49%, which was 10% higher than that for DPP-4 inhibitors.281 Moreover, it should
be seen that this study did not take into account the validity of the type of diabetes
the patients were suffering from as well as the prescribed daily dosages of the
medications281. In another European study, Jeremendy et al. found that the rate of
SU persistence was only about 49%.257
Our estimates should be viewed in light of some important differences with other
studies. A variety of definitions of persistence have been used in various studies.
Similarly, it is vital to understand that simply refilling the drug doesn’t necessarily
indicate persistence and that there are very few suitable means to evaluate the
actual medication taking behavior of people. Further, in studies of medication
compliance, it can be seen that the follow up times as well as the defined gap in
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medication refill in terms number of days can vary largely. In contrast to other
studies, we regarded a switch to other oral medications as a discontinuation of SU
therapy, potentially accounting for variation in rates between our study and
previously published studies.
While our study was intended to principally analyze the impact of hypoglycemia on
medication discontinuation, we found some other factors that were significantly
associated with discontinuation of medication namely age, number of concomitant
medications as well as use of insulin in the baseline period. It could be seen that the
increase in age was significantly associated with better persistence to medications.
This is in agreement with previous studies that have investigated the relationship of
age and persistence. For instance, Guénette et al. reported that patients aged 54
years or above were more likely to be persistent to their antidiabetic medications as
compared with those aged from 18 to 53 with people over the age of 75 being more
than 44% more likely to persist with their meducations.110 Similarly, Hertz et al.
demonstrated that younger age was significantly associated with discontinuation of
medication with patients between ages 17 – 24 being much more likely to have
discontinued therapy (HR=2.44, 95% CI 1.89 – 3.15) as compared to patients between
ages 50 and 64.259 One possible explanation for this finding would be greater
realization of the dependency of their health on therapy as compared to people who
are younger. Our finding that treatment with insulin was associated with higher
likelihood of medication discontinuation is supported by previous studies. Catalan et
al. reported that elderly patients with previous insulin use were 1.59 times less likely
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to persist with acarbose drug regimen as compared to those who had not received
insulin.282 Moreover, addition of insulin to SU might exacerbate the risk of having a
hypoglycemic event thereby increasing the risk of discontinuation. In context of the
progression of diabetes, poly-pharmacy to meet treatment goals is unavoidable.
Hence, an interesting finding in our study was an increase in likelihood of continuing
with therapy when the number of concomitant medications increased. There have
been contrasting results with respect to polypharmacy and hence treatment
complexity potentially being a cause of decreased therapy persistence with
medications. For example, Dailey et al., Donnan et al., and Venturini et al. reported
decreased compliance with increase in the number of medications.256,283,284 On the
other hand, Guénette et al. and Hertz et al. reported an increase in the persistence
rate with higher number of concomitant medications.110,259 Grant el at. found no
association between multiple medications and sub optimal treatment adherence but
suggested

rather that side effects of certain drugs caused the non-adherent

behavior.285
There is a plethora of literature that provides evidence that complex multifactorial
relationship between achievement of glycemic objectives, medication compliance,
and adverse events like hypoglycemia that might in turn affect them. There might be
a range of clinical and behavioral aspects like adverse events, severity of illness and
frequency of dosing that might be responsible for a person to adhere to the
medication

regimen.

Moreover,

with

the

oral

antidiabetic

medications,

hypoglycemia, and fear of hypoglycemia are known limiting factors affecting the
161

rates of medication compliance. Medication tolerability issues like hypoglycemia
might in turn affect an individual’s perception to perform certain self-care behaviors
that are essential in the management of diabetes, adhering to medications being one
of them265. Certain studies have demonstrated that the additional burden placed on
the patients as a consequence of the physical and psychological distress that is
associated with incidence of hypoglycemia and its management might prompt them
to make decisions in order to balance the unpleasant effects with achievement of
glycemic goals.190 In many cases it has been observed that blood glucose levels are
eventually compromised in this process.286 Shui et al. in a cross sectional study to
investigate the fear of hypoglycaemia among 120 insulin-treated patients noted that
15% of respondents reported high fear with 19.2% of the patients compromised on
their blood glucose levels.287,288 Leiter and colleagues conducted a study to assess the
influence of hypoglycemia and fear of future hypoglycemic episodes on patients with
type 1 or insulin-treated type 2 diabetes. The authors found that among the 133
insulin-treated type 2 diabetes patients, 29.9% and 84.2% patients reported an
increased fear of future hypoglycemia following a mild and severe episode of
hypoglycemia respectively. The authors also suggested that this subsequently
changed the patient’s willingness to continue with therapy. in a Swedish study of 309
patients above the age of 35, Lundkvist et al. found that in patients who had
incidents of hypoglycemia there was lower control of diabetes, worse general health
and that these patients were more anxious about future hypoglycemic events than
those without hypoglycemia. The authors concluded such patients exhibited a
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greater degree of avoidance behavior289. Severity of the hypoglycemic episode often
leads to reduced satisfaction to diabetes medication regimen, which in turn might
result in a greater degree of medication discontinuation.290 Although not all the
aspects of the relationship between fear of hypoglycemia and compliance with the
medication regimen are entirely clear, it is plausible that it acts as a major barrier to
patient’s medication taking behavior and thus the management of diabetes.
.However, since this was a retrospective cohort study using a medical claims
database, some inherent limitations need to be taken into consideration. With
respect to the diagnosis of hypoglycemia, it vital to understand that many of the
hypoglycemia episodes resolve by themselves or get treated without a visit to any
medical facility. Hence, our estimates of hypoglycemia might represent only a
fraction of the true extent of this adverse event associated with diabetes therapy.
Secondly, due to the nature of the datasource, examination of the clinical measures
of glycemic control and disease severity were not possible and hence the impact of
these measures on the likelihood of medication discontinuation could not be
ascertained. Moreover, since the patients might have been on SU medications while
in other insurance plans, using the incident user design does not necessarily
guarantee that all the patients in the final sample are newly prescribed SU therapy.
Our analysis was primarily based on the data from pharmacy drug dispensing. Hence,
even though we considered failure of the patients to refill their medications as being
a marker of discontinuation of therapy, in reality, there are no plausible methods to
understand if this reflected the true use of medications, which might be
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overestimated in case of patients who filled their prescriptions but did not take their
medications. Also, extending our selection of a 3 month period as a baseline period,
might have added to the capability to examine a higher number of hypoglycemia
events. However, it has been seen in previous studies of chronic disease medication
persistence that majority of events occur within the initial period of medication
initiation. In addition to this consideration, the nature of hypoglycemia episodes in
patients as well as the issue of repeated hypoglycemia events was instrumental in
choosing a baseline period of 3 months.
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4.6 Conclusions
Hypoglycemia is a known barrier to optimal use of oral antidiabetic medications,
especially SUs. Even though we found no statistical association between the
incidence of hypoglycemia and subsequent persistence to SUs, it is important to take
into account the implications of hypoglycemic episodes on medication adherence.
Optimal diabetes management requires timely examination of blood glucose levels
and reduction in the risk of side effects like hypoglycemia when on therapy. This
might be beneficial in the long-term well-being as well as the improvement in the
Quality of Life (QOL) of patients. Further research must be directed towards
exploring the association between hypoglycemia and other risk factors that might
have an impact on medication adherence and persistence. This might provide
invaluable insights into selection of an appropriate medication regimen that would
provide effective glycemic control and reduction in the risk of sub optimal health
outcomes.
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Figure 4.1 Overview of Cohort Study Design: Exposure To Severe Hypoglycemia With An
Outcome Of Medication Discontinuation
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Figure 4.2: Detailed Overview Of Study Timeline
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Figure 4.3: Detailed Cohort Selection of BCBSRI Enrollees
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Figure 4.4: Characterization Of The Association Between A Hypoglycemia Event
And Medication Discontinuation
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Table 4.1: Frequency Of Patients Who Were Persistent/Non-Persistent with Sulfonylurea
Therapy Stratified By Exposure To Hypoglycemia
Hypoglycemia
Outcome
No Hypoglycemia
Hypoglycemia
TOTAL

Non Discontinued

Discontinueda

Total (%)

3,883
35
3,918

1,996
20
2,016

5,879 (99.08)
55 (0.92)
5,934

a: Discontinuation: Defined as a gap of > 30 days between the end of day’s pf supply of the preceding prescription
and refill of the next prescription.
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Table 4.2: Demographics Stratified by Exposure to Hypoglycemia
Demographic
Characteristics
Age (Years)a
Genderb
Male
Female

Hypoglycemia
No Hypoglycemia
(N = 55)
(N = 5879)
Mean +/- STD.DEV
64.87 +/- 11.21
64.46 +/- 12.48
N (%)
31 (56.36)
24 (43.64)

3363 (57.20%)
2516 (42.80%)

a: Mean + Std. Dev & the T Test were used to compare continuous variables.
*: Significance at p value 0.05 as derived from T Test.
b: n (%) & Cochran-Mantel-Haenszel statistic was used to compare categorical variables.
+:Significance at p value 0.05 as derived from Fischer’s Exact Test.
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P Value

<0.001*

0.900

Table 4.3: Prevalence of Comorbidities Stratified by Exposure to Hypoglycemia
No
Hypoglycemia
(n=5879)

P-Value

3.78 +/- 2.82

2.45 +/- 2.43

<0.001

Elixhauser Comorbidity Indexb
AIDS/HIV
0 (0.00)
Alcohol Abuse
0 (0.00)
Blood Loss Anemia
0 (0.00)
Cardiac Arrhythmias
1 (1.82)
Chronic Pulmonary Disease
8 (14.55)
Coagulopathy
1 (1.82)
Congestive Heart Failure
5 (9.09)
Deficiency Anemia
2 (3.64)
Depression
3 (5.45)
Diabetes Complicated
44 (80.00)
Diabetes Uncomplicated
40 (72.73)
Drug Abuse
0 (0.00)
Fluid And Electrolyte Disorders
1 (1.82)
Hypertension, Complicated
1 (1.82)
Hypertension, Uncomplicated
9 (16.36)
Hypothyroidism
4 (7.27)
Liver Disease
2 (3.64)
Lymphoma
0 (0.00)
Solid tumor without metastasis
3 (5.45)
Metastatic Cancer
0 (0.00)
Obesity
0 (0.00)
Other Neurological Disorders
1 (1.82)
Paralysis
0 (0.00)
Peptic Ulcer Disease Excluding Bleeding
0 (0.00)
Peripheral Vascular Disorders
6 (10.91)
Psychoses
0 (0.00)
Pulmonary Circulation Disorders
1 (1.82)
Renal Failure
5 (9.09)

4 (0.07)
12 (0.20)
21 (0.36)
364 (6.19)
263 (4.47)
18 (0.31)
210 (3.57)
95 (1.62)
235 (4.00)
896 (15.24)
3,545 (60.30)
11 (0.19)
58 (0.99)
60 (1.02)
1,248 (21.23)
155 (2.64)
71 (1.21)
24 (0.41)
276 (4.69)
10 (0.17)
30 (0.51)
40 (0.68)
6 (0.10)
2 (0.03)
247 (4.20)
24 (0.41)
29 (0.49)
110 (1.87)

0.8466
0.7373
0.6570
0.1791+
0.0004+
0.0482+
0.0292+
0.2395+
0.5835
<0.001*
0.0607*
0.7481
0.5361
0.5594
0.3795
0.0341+
0.1039+
0.6349
0.7910
0.7595
0.5953
0.3106
0.8126
0.8912
0.0143+
0.6349
0.1679+
0.0001+

Hypoglycemia
(n=55)

Comorbidity

Charlson’s Comorbidity Index
Charlson’s Comorbidity Scorea

^

Rheumatoid Arthritis/ Collagen Vascular
Diseases

1 (1.82)

77 (1.31)

0.7418

Valvular Disease
Weight Loss

0 (0.00)
0 (0.00)

104 (1.77)
8 (0.14)

0.3197
0.7843

a: Mean + (Std. Dev) & the T test was used to compare overall Charlson’s Index.
^: Significance at p value 0.05 as derived from T Test.
b: n (%) & the Cochran-Mantel-Haenszel statistic / Fischer’s Exact Test were used to compare categorical variables.
*: Significance at p value 0.05 as derived from Chi-square.
+: Significance at p value 0.05 as derived from Fischer’s Exact Test due to smaller sample sizes.
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Table 4.4: Prevalence of Micro and Macrovascular Diabetes Complications, Other
Contributing Diseases Stratified by Exposure to Hypoglycemia
Hypoglycemia
No Hypoglycemia
(n=55)
(n=5879)
a
Macrovascular
Arrhythmia
1 (1.82)
259 (4.41)
Congestive Heart Failure
5 (9.09)
159 (2.70)
Coronary Artery Disease
9 (16.13)
603 (10.26)
Peripheral Vascular Disease
7 (12.73)
725 (12.33)
Stroke
0 (0.00)
27 (0.46)
a
Microvascular
Acute Renal Failure
1 (1.82)
39 (0.66)
Amputation
0 (0.00)
2 (0.03)
Chronic Renal Pathophysiology
1 (1.82)
33 (0.56)
Dialysis
0 (0.00)
9 (0.15)
End Stage Renal Disease
0 (0.00)
0 (0.00)
Diabetic Nephropathy
0 (0.00)
41 (0.70)
Diabetic Retinopathy
6 (10.91)
293 (4.98)
Ulcer
4 (7.27)
104 (1.77)
a
Other Contributing Diseases
Addison's Disease
0 (0.00)
2 (0.03)
Liver Disease
1 (1.82)
52 (0.88)
Thyroid Disease
4 (7.27)
146 (2.78)
Diabetes Complications

a: n (%) & the Fischer’s Exact Test were used to compare categorical variables due to smaller sample sizes.
+: Significance at p value 0.05 as derived from Fischer’s Exact Test.
^: No p value calculated due to 0 sample size.
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P-Value
0.3508
0.0034+
0.1383+
0.9293
0.6144
0.2975
0.8912
0.2190
0.7755
NA^
0.5343
0.0455+
0.0024+
0.8912
0.4638
0.0243+

Table 4.5: Concomitant Usage of Non-Diabetic Medications Stratified by Exposure to
Hypoglycemia
Hypoglycemia
No Hypoglycemia
P-Value
(N = 55)
(N = 5879)
Overall Medication Usea
Number Of Medications
8.63 +/- 3.84
7.16 +/- 3.37 <0.001*
Use Of Other Non-Diabetic Medication Classesb
ACE Inhibitors
25 (45.45)
2958 (50.31) 0.4730
Allopurinol
3 (5.45)
222 (3.78) 0.5165
Angiotensin II Receptor Blockers
1 (1.82)
174 (2.96) 0.6184
(ARBs)
Benzodiazepines
8 (14.55)
529 (9.00) 0.1535+
Beta-Adrenergic Blocking
22 (40.00)
2149 (36.40) 0.5809
Agents
Fibrates
9 (16.36)
608 (10.34) 0.1453+
Fluoroquinolones
6 (10.91)
320 (5.44) 0.0766+
Nonsteroidal Anti-Inflammatory
8 (14.54)
624 (10.61) 0.3468
Drugs
Trimethoprim
0 (0.00)
3 (0.05)
NA^
Warfarin
2 (3.64)
348 (5.92) 0.4744
Medications

a: Mean + Std. Dev & the T Test was used to compare continuous variables.
*: Significance at p value 0.05 as derived from T Test.
b: n (%) & the Fischer’s Exact Test were used to compare categorical variables.
+: Significance at p value 0.05 as derived from Fischer’s Exact Test.
^: No P value calculated due to 0 sample size in hypoglycemia group.
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Table 4.6: Usage of Other Oral Diabetic Medications Stratified by Exposure to
Hypoglycemia
Concomitant Medicationsa
Insulin
Biguanides
Thiazolidinediones
Alpha Glucosidase Inhibitors
Meglitinides
Dipeptidyl Peptidase 4 Inhibitors

Hypoglycemia
(N = 55)
9 (16.36)
37 (67.67)
11 (20.00)
1 (1.82)
1 (1.82)
505 (8.50)

a: n (%) & the Fischer’s Exact Test were used to compare categorical variables.
+:Significance at p value 0.05 as derived from Fischer’s Exact Test.
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No Hypoglycemia
(N = 5879)
533 (9.07)
3639 (61.90)
950 (16.16)
16 (0.27)
11 (0.19)
5 (9.09)

P-Value
0.0060+
0.4139
0.4415
0.0327+
0.0074+
0.8950

Table 4.7: Descriptive Statistics Of Follow-Up Time, Stratified By Exposure To Hypoglycemia
And The Effect Of Hypoglycemia On Sulfonylurea Medication Discontinuation

Hypoglycemia
Status

S.
Size

Person
Days Of
Follow Up

Discont’d
Patients

Crude HR
(95% CI)

Adjusted HR
(95% CI)

1.00 (REF)

1.00 (REF)

1.47

1.32

No
Hypoglycemia

5,879

1789147*

1996

Hypoglycemia

55

12908**

20

+

(0.94 2.11)

++

(0.82 1.88)

*Includes Time From Cohort Entry To Sooner Of Date Of Discontinuation, Date Of Hypoglycemia Or End
Of Study Period.
**Includes Time From Cohort Entry To Date Of Hypoglycemia Exposure.
+ Derived From A Time-dependent Exposure Cox Proportional-hazards Model With SU Medication
Discontinuation As The Outcome Variable And Exposure Status As The Time-dependent Independent
Variable.
++Derived From A Time-dependent Exposure Cox Proportional-hazards Model Adjusted For Age, Gender,
Number Of Medications, Insulin Use, Congestive Heart Failure, Cardiac Arrthymia, Pulmonary Circulation
Disorder, Peripheral Vascular Disorder, Diabetes (Complicated And Uncomplicated), Hypothyroidism,
Renal Failure, Liver Disease, Coagulopathy, Deficiency Anemia, Depression, Retinopathy, Ulcer,
Fluoroquinolones, Fibrates , Benzodiazepines, Biguanides, Tzd, Alphaglucosidase Inhibitors, Meglitinides.
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Appendix 1: Population Characteristics Of The Respondents With Diabetes Within
The MEPS 2008-2011
Variables

Unwtd Freq
(4668)

Wtd %

Age
18-34
35-49
50-64
65 And Above
Missing

204
816
1777
1631
240

4.37
17.48
38.07
34.94
5.14

Gender
Male
Female

2065
2603

44.24
55.76

Marital Status
Married
Widowed/Divorced/Separated
Never Married

2619
1535
514

56.11
32.88
11.01

Income Level
Poor/Near Poor
Low Income
Middle Income
High Income

1170
782
1413
1303

25.06
16.75
30.27
27.91

Education Level
Less Than High School
High School
Advanced Education
Others
Missing

1381
2068
831
370
18

29.58
44.30
17.80
7.93
0.39

Race/Ethnicity
Hispanic
White Non Hispanic
Black Non Hispanic
Others

1042
2221
1026
379

22.32
47.58
21.98
8.12

Percieved Health Status
182

Excellent/Very Good
Good
Fair/Poor

1133
1839
1696

24.27
39.40
36.33

Insurance Coverage
Any Private
Public Only
Uninsured

2624
1562
482

56.21
33.46
10.33

Insulin Use
Yes
No
Missing

1363
770
4

29.20
70.44
0.36

MSA Status
NON MSA
MSA

833
3835

17.84
82.16

Employment Status
Employed
Not Employed
Missing

2065
2599
4

44.24
55.68
0.09

BMI Status
Under /Normal
Over
Missing

646
3923
99

13.84
84.04
2.12

Smoking Status
Yes
No
Missing

647
3930
91

13.86
84.19
1.95

Primary Care Provider
Yes
No
Missing

4299
342
27

92.10
7.33
0.58
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Appendix 2 : Sample Panel Design For MEPS

Quality AfHRa. Medical Expenditure Panel Survey, Household Component, MEPS-HC Panel Design and Data Collection
Process. 2013; http://meps.ahrq.gov/mepsweb/survey_comp/hc_data_collection.jsp. Accessed 01 September, 2014.
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Appendix 3: List of Product Names For Sulfonylurea Medications
AMARYL
AVANDARYL
CHLORAL HYDR
CHLORAMPHEN
CHLORPROMAZ
CHLORPROPAM
DIABETA
GLIMEPIRIDE
GLIPIZIDE
GLIPIZIDE ER
GLIPIZIDE XL
GLUCOTROL
GLUCOTROL XL
GLUCOVANCE
GLYBURID MCR
GLYBURIDE
METAGLIP
TOLBUTAMID
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Appendix 4: Frequency OF Drug Episodes For The Study Population
Number of Drug Episodesa
1
2
3
4
5
6
7
8
9
10
11
12
13
15

Frequency
5408
2107
953
467
297
172
114
75
51
25
17
11
5
2

Percentage(%)
55.72
21.71
9.82
4.81
3.06
1.77
1.17
0.77
0.52
0.25
0.17
0.11
0.05
0.02

a: Separate episodes are defined by a gap of > 30 days between the end of days pf supply of the
preceding prescription and refill of the next prescription
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Appendix 5: Ginde and Colleagues‐Algorithm to Identify Cases of Hypoglycemia

Ginde AA, Blanc PG, Lieberman RM et al. Validation of ICD-9-CM coding algorithm for
improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4
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Appendix 6: Total Number Of Patients With First Episodes Of Hypoglycemia Within The Study
Period Stratified By The Baseline And Post Baseline Timeline

Study Timeline period
Baseline Perioda
Post-Baseline Periodb

Hypoglycemia Frequency
139
240

Percentage(%)
36.68
63.32

a: Baseline Period : 90 days starting from the first prescription of a sulfonylurea.
b: Post baseline period : 9 months starting from the end of baseline period until the end of study period.

Appendix 7: Frequency For Discontinuation Of Sulfonylurea Medication In The Eligible
Sample Population
Discontinuation Outcome
Discontinuationa
No Discontinuation

Frequency
5442
4262

Percentage(%)
56.08
43.92

a: Discontinuation : Defined as a gap of > 30 days between the end of days pf supply of the preceding prescription
and refill of the next prescription

Appendix 8: Frequency For Outcomes During The Study Timeline In The Eligible Sample
Population
Outcome
Discontinuationa
Censoredb
End Of Study Periodc

Frequency
5442
184
4078

Percentage(%)
56.08
1.89
42.03

a: Discontinuation : Defined as a gap of > 30 days between the end of days pf supply of the preceding prescription
and refill of the next prescription
b: Censored : Defined as an event of hypoglycemia occurring in the post baseline period.
c: End of study period : Patients who were followed till the end of study period were free of the outcome of
discontinuation or exposure to hypoglycemia within the post baseline period.
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Appendix 9: Charlson’s Comorbidity Index
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining Comorbidities in ICD9-CM and ICD-10 administrative data. Med Care. 2005 Nov; 43(11): 1130-9.

Myocardial Infarction: 410.X, 412.X
Congestive Heart Failure: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4-425.9, 428.X
Peripheral Vascular Disease: 093.0, 437.3, 440.X, 441.X, 443.1--443.9, 447.1, 557.1, 557.9, V43.4
Cerebrovascular Disease: 362.34, 430.X--438.X
Dementia: 290.X, 294.1, 331.2
Chronic Pulmonary Disease: 416.8, 416.9, 490.X--505.X, 506.4, 508.1, 508.8
Rheumatic Disease: 446.5, 710.0--710.4, 714.0--714.2, 714.8, 725.X
Peptic Ulcer Disease: 531.X--534.X
Mild Liver Disease: 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 570.X, 571.X, 573.3, 573.4,
573.8, 573.9, V42.7
Hemiplegia Or Paraplegia : 334.1, 342.X, 343.X, 344.0--344.6, 344.9
Renal Disease: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582.X, 583.0--583.7,
585.X, 586.X, 588.0, V42.0, V45.1, V56.X
Any Malignancy, Including Lymphoma And Leukemia, Except Malignant Neoplasm Of Skin: 140.X--172.X, 174.X-195.8, 200.X--208.X, 238.6
Moderate Or Severe Liver Disease: 456.0--456.2, 572.2--572.8
Metastatic Solid Tumor: 196.X--199.X
AIDS/HIV : 042.X--044.X
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Appendix 10: Elixhauser Comorbidity Index
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining Comorbidities in ICD-9-CM and
ICD-10 administrative data. Med Care. 2005 Nov; 43(11): 1130-9.
Peptic Ulcer Disease Excluding Bleeding: 531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9
AIDS/H1V: 042.x‐‐044.x
Lymphoma: 200.x‐‐202.x, 203.0, 238.6
Metastatic Cancer: 196.x‐‐199.x
Solid Tumor without Metastasis: 140.x‐‐172.x, 174.x‐‐195.x
Rheumatoid Arthritis/Collagen Vascular Diseases: 446.x, 701.0, 710.0‐‐710.4, 710.8, 710.9, 711.2,
714.x, 719.3, 720.x, 725.x, 728.5, 728.89, 729.30
Coagulopathy: 286.x, 287.1, 287.3‐‐287.5
Obesity: 278.0
Weight loss: 260.x‐‐263.x, 783.2, 799.4
Fluid and Electrolyte Disorders: 253.6, 276.x
Blood Loss Anemia: 280.0
Deficiency Anemia : 280.1‐‐280.9, 281.x
Alcohol Abuse: 265.2, 291.1‐‐291.3, 291.5, 291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0‐‐
571.3, 980.x, V11.3
Drug Abuse: 292.x, 304.x, 305.2‐‐305.9., V65.42
Psychoses: 293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x
Depression: 296.2, 296.3, 296.5, 300.4, 309.x, 311
Congestive Heart Failure: 398.91, 402.01, 402.11. 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, 425.4-425.9, 428.x
Cardiac Arrhythmias: 426.0, 426.13, 426.7, 426.9, 426.10, 426.12, 427.0-427.4, 427.6-427.9, 785.0,
996.01, 996.04, V45.0, V53.3
Valvular Disease: 093.2, 394.x-397.x, 424.x, 746.3-746.6, V42.2, V43.3
Pulmonary Circulation Disorders: 415.0, 415.1, 416.x, 417.0, 417.8, 417.9
Peripheral Vascular Disorders: 440.x, 441.2, 441.4, 441.7, 441.9, 443.1, 443.9, 447.1, 557.1, 557.9,
V43.4
Hypertension, Uncomplicated: 401.x
Hypertension, Complicated: 402.x-405.x
Paralysis: 334.1, 342.x, 343.x, 344.0 344.6, 344.9
Other Neurological Disorders: 331.9, 332.0, 332.1, 333.4, 333.5, 333.92, 334.x-335.x, 336.2, 340.x,
341.x, 345.x, 348.1, 348.3, 780.3, 784.3
Chronic Pulmonary Ddisease: 416.8, 416.9, 490.x-505.x, 506.4, 508. 1, 508.8
Hypothyroidism: 240.9, 243.x, 244.x, 246.1, 246.8
Renal Failure: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.x, 586.x,
588.0, V42.0, V45.1, V56.x
Liver Disease: 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 456.0-456.2, 570.x,
571.x, 572.2-572.8, 573.3, 573.4, 573.8, 573.9, V42.7
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Appendix 11: Diabetes Complications
Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity:
implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22
Suppl 3:408-18. PMCID: 2150612.
Diabetes-related complexity
Macrovascular complications
Coronary artery disease: 410, 410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11, 410.12, 410.2,
410.20, 410.21, 410.22, 410.3, 410.30, 410.31, 410.32, 410.4, 410.40, 410.41, 410.42, 410.5, 410.50,
410.51, 410.52, 410.6, 410.60, 410.61, 410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81,
410.82, 410.9, 410.90, 410.91, 410.92, 411.0, 411.1, 411.8, 411.81, 411.89, 412, 413, 413.0, 413.1,
413.9, 414, 414.0, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.1, 414.10, 414.11, 414.19,
414.8, 414.9
Congestive heart failure: 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428, 428.0, 428.1, 428.9
Arrhythmia 423, 423.0, 423.1, 423.2, 423.8, 423.9, 427.31
Stroke 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91
Peripheral vascular disease: 250.7, 250.70, 250.71, 250.72, 250.73, 440.2, 440.20, 440.21, 440.22,
440.23, 440.24, 440.29, 440.8, 440.9, 442.2, 442.3, 443, 443.0, 443.1, 443.8, 4438.1, 443.89, 443.9,
444.22, 444.81
Microvascular complications
Chronic renal pathophysiology: 274.1, 274.10, 274.11, 274.19, 403.10, 403.90, 404.10, 404.11, 404.90,
404.91, 581, 581.0, 581.1, 581.2, 581.3, 581.8, 581.9, 582, 582.0, 582.1, 582.2, 582.4, 582.8, 582.81,
582.89, 582.9, 583, 583.0, 583.1, 583.2, 583.4, 583.6, 583.7, 583.8, 583.81, 583.89, 583.9, 583, 583.0,
583.1, 583.2, 583.4, 583.6, 583.7, 583.8, 583.81, 583.89, 583.9, 590.0, 590.00, 590.01, 593.6, 593.9,
753.12, 753.13, 753.14
Diabetic nephropathy: 250.4, 250.40, 250.41, 250.42, 250.43
Acute renal failure: 403.00, 403.01, 404.00, 404.01, 404.02, 404.03, 405.01, 453.3, 584, 584.5, 584.6,
584.7, 584.8, 584.9, 580, 580.0, 580.4, 580.8, 580.81, 580.89, 580.9, 590.1, 590.10, 590.11, 590.2,
590.3, 590.8, 590.80, 590.81, 593.81, 866, 866.0, 866.00, 866.01, 866.02, 866.03, 866.1, 866.10,
866.11, 866.12, 866.13
End-stage renal disease: V56.xx, 458.21, E87.91, V45.1
Dialysis: 389.5, 392.7, 394.2, 394.3, 399.5, 549.8
Diabetic retinopathy: 362.0, 362.01, 362.02, 250.50, 250.51, 250.52, 250.53
Ulcer: 700, 681.10, 681.11, 682.7, 707.1, 730.76, 730.77
Amputation: 841.1, 841.2, 841.3, 841.4, 841.5, 841.6, 841.7, 841.8, 841.9
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Appendix 12: Testing the Proportionality Assumption

In the above figure, the curves do not cross each other thereby indicating that the
assumption of proportionality is not violated. A time varying exposure variable was created
in order to confirm this assumption and it could be seen that it reiterated the satisfaction of
this assumption since it was insignificant.(a significant variable would indicate violation).
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Appendix 13: Observed Scenarios For Medication Refill And Persistence Patterns
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Appendix 14: Description Of Hypoglycemia Exposed And Unexposed Patients As An Example
Of Classifying Immortal Time Bias As Unexposed Time.
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